<<<<<<< HEAD
element_id,text,page_number,filename,chunk_id,relevant
38dc4ba7c2bf7ed7323042c35312ad5f,Article,1,ALD patent background + target paper.pdf,1,False
26e2ffa12765874ed647b25892f5742c,Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease,1,ALD patent background + target paper.pdf,2,True
c63fdce5cb4625e212fa4efac8896883,"https://doi.org/10.1038/s41586-019-1742-x Received: 9 April 2019 Accepted: 2 October 2019 Published online: 13 November 2019

https://doi.org/10.1038/s41586-019-1742-x",1,ALD patent background + target paper.pdf,3,False
d0c8e114f7b68a282cb37bd9079e3521,"Received: 9 April 2019

Accepted: 2 October 2019

Published online: 13 November 2019",1,ALD patent background + target paper.pdf,4,False
c6459af67a5b5bcbc573101561e95a20,"Yi Duan1,2,29, Cristina Llorente1,2,29, Sonja Lang1, Katharina Brandl3, Huikuan Chu1, Lu Jiang1,2, Richard C. White4, Thomas H. Clarke4, Kevin Nguyen4, Manolito Torralba5, Yan Shao6, Jinyuan Liu7, Adriana Hernandez-Morales8, Lauren Lessor9, Imran R. Rahman10, Yukiko Miyamoto1, Melissa Ly11, Bei Gao1, Weizhong Sun1, Roman Kiesel1, Felix Hutmacher1, Suhan Lee1, Meritxell Ventura-Cots12, Francisco Bosques-Padilla13, Elizabeth C. Verna14, Juan G. Abraldes15, Robert S. Brown Jr16, Victor Vargas17,18,",1,ALD patent background + target paper.pdf,5,False
ce9eb7d75f558f48a95a559ddca7a40c,"Jose Altamirano17, Juan Caballería18,19, Debbie L. Shawcross20, Samuel B. Ho1,2, Alexandre Louvet21, Michael R. Lucey22, Philippe Mathurin21, Guadalupe Garcia-Tsao23,24, Ramon Bataller12, Xin M. Tu7, Lars Eckmann1, Wilfred A. van der Donk10,25,26, Ry Young8,9, Trevor D. Lawley6, Peter Stärkel27, David Pride1,11,28, Derrick E. Fouts4 & Bernd Schnabl1,2,28*",1,ALD patent background + target paper.pdf,6,False
a97990c757688b2ad9f9547223e628af,"Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol- induced liver disease in mice4, but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin—a two-subunit exotoxin that is secreted by Enterococcus faecalis5,6—as a cause of hepatocyte death",1,ALD patent background + target paper.pdf,7,True
7700e213119d995bb900c028b2058ba8,"and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of",1,ALD patent background + target paper.pdf,8,True
55628f8d8fcd11065a2f49008a2a0a12,"bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort",1,ALD patent background + target paper.pdf,9,True
c89b81b155163e63a1fc1b3046eaa555,"is required to validate the relevance of our findings in humans, and to test whether this therapeutic approach is effective for patients with alcoholic hepatitis.",1,ALD patent background + target paper.pdf,10,False
4d0808dcc0de15622ab920197f3e824e,"The most severe form of alcohol-related liver disease is alcoholic hepa- titis; mortality ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a diagnosis of severe alcoholic hepatitis7–9. Therapy with corticosteroids is only marginally effective9. Early liver transplantation is the only curative therapy, but is offered only at select centres and to a limited group of patients10.",1,ALD patent background + target paper.pdf,11,True
06eaaa92b96ca86c0147a2adb438eadb,Alcohol-related liver disease can be transmitted via faecal micro- biota4. We investigated the microorganisms and microbial factors that are responsible for this transmissible phenotype and for progression of alcohol-related liver disease.,1,ALD patent background + target paper.pdf,12,True
4d2733e4cdaa6f457e875d11f778b79d,Cytolysin linked to increased mortality,1,ALD patent background + target paper.pdf,13,False
06099ce696361c3be7c57600551dbda6,We performed 16S ribosomal RNA (rRNA) gene sequencing to deter- mine whether chronic alcohol use and alcoholic hepatitis are associated,1,ALD patent background + target paper.pdf,14,False
3c75a20ca0d5bdc385ad95ad226bec3e,A list of affiliations appears at the end of the paper.,1,ALD patent background + target paper.pdf,15,False
7d4f7d11058fefb73c25d74168a266b2,"with an altered composition of the faecal microbiota. Differences in faecal microbiota composition were noted in patients with alcohol-use disorder and alcoholic hepatitis, compared to subjects without alcohol- use disorder (controls) (Fig. 1a, Extended Data Fig. 1a, b, Supplementary Tables 1, 2). One substantial difference that we observed was an increase in the proportion of Enterococcus spp. in patients with alcoholic hepa- titis: in these patients, 5.59% of faecal bacteria were Enterococcus",1,ALD patent background + target paper.pdf,16,True
5d8c1ebe16d59c1d317dffc791695a29,"spp. compared with almost none in controls (0.023%; for comparison, 0.004% of all reads were Enterococcus spp. in the Human Microbiome Project) or patients with alcohol-use disorder (0.024%). Faecal sam- ples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls, as measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), which is consistent with the 16S rRNA sequencing results. About 80% of patients with alcoholic hepatitis are positive for",1,ALD patent background + target paper.pdf,17,True
23eb93f6a5a4adf3124516a9c68c369f,E. faecalis in their faeces (Extended Data Fig. 1d).,1,ALD patent background + target paper.pdf,18,False
1b56a72a75d88bec0d17852044764348,"Nature | www.nature.com | 1

1",1,ALD patent background + target paper.pdf,19,False
73c263972496be4b420d04d0716712e2,Article,2,ALD patent background + target paper.pdf,20,False
76d6ee0795bc5c05a1c1e0cd1dc54a55,Controls 0.2 Alcohol-use disorder Alcoholic hepatitis ) % 5 7 . 7 1 ( 2 C P 0.1 0 −0.1 –0.2 –0.1 0 0.1 0.2 PC1 (29.25%),2,ALD patent background + target paper.pdf,21,False
1ee3a58fce339219f39ea9c5f9837725,"m

b",2,ALD patent background + target paper.pdf,22,False
735a5be842bab422a9a4f67f034f1160,100 Cytolysin-negative Cytolysin-positive ) % ( s t c e j b u S 80 60 40 20 0 Controls AUD Alcoholic,2,ALD patent background + target paper.pdf,23,False
a75eeac34e5709b9036e011db140cfe9,"m

=",2,ALD patent background + target paper.pdf,24,False
113d2dbdac5ce846a979532264d47059,) % ( l a v i v r u S 100 75 50 25 0 0 30 Cytolysin-negative Cytolysin-positive 60 90 120 150 180 Time (d),2,ALD patent background + target paper.pdf,25,False
98d5cb71dc3bd8a7ac9d5bdee0ce3872,d,2,ALD patent background + target paper.pdf,26,False
124ad639f11e561ec410ed0d94906c5c,0.15 Cytolysin-negative Cytolysin-positive,2,ALD patent background + target paper.pdf,27,False
712a9a756bc344c83b2da17daab96e2d,"@

@",2,ALD patent background + target paper.pdf,28,False
2fa8aa848b6439279c98de0fa1e9d8cd,"Fig. 1 | E. faecalis cytolysin is associated with mortality in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n = 75). We use principal coordinate analysis (PCoA) based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between each group (P < 0.01). b, Percentage of subjects",2,ALD patent background + target paper.pdf,29,False
2a0fa3f8a748f185786faa503f15c12e,"with faecal samples that were positive for both cylLL and cylLS DNA sequences (cytolysin-positive), in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. Statistically significant differences were detected between controls and patients with alcoholic hepatitis (P < 0.01), and between patients with alcohol- use disorder and patients with alcoholic hepatitis (P < 0.001). c, Kaplan–Meier curve of survival of patients with alcoholic",2,ALD patent background + target paper.pdf,30,True
c0cb33fc914a181a931f63d3f064994f,"hepatitis whose faecal samples were cytolysin-positive (n = 25) or cytolysin-negative (n = 54) (P < 0.0001). d, Core genome single-nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis (n = 93 strains, from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. faecalis. Genomically identical isolates from the same patient were combined, and are shown as a single dot. Scale bar represents the nucleotide substitutions per",2,ALD patent background + target paper.pdf,31,True
5f83e60c4dddb2f0280d1a7e278bce89,"SNP site. P values are determined by permutational multivariate analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR procedures (b) or two-sided log- rank (Mantel–Cox) test (c). The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",2,ALD patent background + target paper.pdf,32,True
561904fc909fe66441a85e2fd6b522a7,"The colonization of mice with E. faecalis induces mild hepatic stea- tosis and exacerbates ethanol-induced liver disease11, by mechanisms that are unclear. Cytolysin is a bacterial exotoxin (or bacteriocin) that is produced by E. faecalis12, and which contains two post-translationally modified peptides (CylLL′′ and CylLS′′) in its bioactive form6. The two peptides are encoded by two separate genes: cylLL and cylLS, respec- tively12. Cytolysin has lytic activity against not only Gram-positive",2,ALD patent background + target paper.pdf,33,True
611eb13b2d6e50c5fddc28b53f5e5681,"bacte- ria, but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA (cytolysin-positive) in faecal samples from 30% of patients with alco- holic hepatitis; none of the faecal samples from controls and only one sample from a patient with alcohol-use disorder was cytolysin-positive, as detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-positive patients with alcoholic hepatitis died within 180 days of admission, compared to only 3.8% of cytolysin-negative patients (P < 0.0001)",2,ALD patent background + target paper.pdf,34,True
143566463ffffbf593619724e143bd32,"(Fig. 1c). Among the cytolysin-positive patients, 72.2% (13 out of 18) died owing to liver failure (including complications related to liver",2,ALD patent background + target paper.pdf,35,True
df50d5c1f7816dd69d7ccb9fe933280b,2 | Nature | www.nature.com,2,ALD patent background + target paper.pdf,36,False
caa8512566105619e699d5975503c375,"failure, such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not associated with 30-day, 90-day or 180-day mortality (P = 0.403, 0.234 or 0.098) in patients with alcoholic hepatitis.",2,ALD patent background + target paper.pdf,37,True
79535293be1afc815d786a3f02a7f4b1,"Our univariate logistic and Cox regression of laboratory and clinical parameters found an association between the detection of cytolysin- encoding genes in faeces and the international normalized ratio (INR), platelet count, the model for end-stage liver disease (MELD) score, the sodium MELD score, the age, serum bilirubin, INR and serum creatinine (ABIC) score and death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding genes in faeces was associated with",2,ALD patent background + target paper.pdf,38,True
e6d629f4b1c9cb4dc395249f617132df,"90-day (P = 0.004) and with 180-day mortality (P = 0.001) (Supple- mentary Table 3), even after we adjusted for the geographical origin of the patient, antibiotic treatment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. We found no multicollinear- ity between the detection of faecal cytolysin-encoding genes and these cofactors (variance inflation factor < 1.6), which indicates that cytolysin is an independent predictor of mortality in patients with alcoholic",2,ALD patent background + target paper.pdf,39,True
94cde9ce9ef95ccd106fb02ae05cfb3e,"hepatitis. When we performed receiver-operating-characteristic curve analysis for 90-day mortality, cytolysin had an area under the curve of 0.81, which was superior to other widely used predictors for mortality in clinical practice (Extended Data Fig. 1e). On the basis of our findings, we propose that the detection of cytolysin may be a prognostic factor for more severe liver- related outcomes and increased risk of death, and a stronger predictor of mortality than MELD, ABIC and the",2,ALD patent background + target paper.pdf,40,True
1d4eff578119b5aee479d42cbd917a44,discriminant function score.,2,ALD patent background + target paper.pdf,41,False
902cf4996a4515d0de2f125dc02eddb3,"To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed targeted culturing from stool samples. Whole- genome sequencing of 93 E. faecalis isolates revealed a broad phylo- genetic diversity of cytolysin-positive E. faecalis from patients with alcoholic hepatitis (Fig. 1d), which indicates that cytolysin production is a variable trait among E. faecalis isolates and that cytolysin is car- ried in mobile genetic elements, which include both chromosomally encoded",2,ALD patent background + target paper.pdf,42,True
ebbb35022ddcef9c9c90ac7e6187c74d,pathogenicity islands and plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Table 4).,2,ALD patent background + target paper.pdf,43,True
4715251334e04eee26610aa45866c63d,"The total amount of faecal E. faecalis, or faecal E. faecalis positivity, did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5, 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar amounts of faecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the composition of the gut microbiota in patients with alcoholic hepatitis from different geographical regions (Extended Data",2,ALD patent background + target paper.pdf,44,True
f6ecdb28a54e5d4d94f4a14a103736db,"Fig. 1g), the proportion of cytolysin-positive patients, total amount of faecal E. faecalis, faecal E. faecalis positivity (Extended Data Fig. 1h–j), treatment and clinical outcomes (30-day and 90-day mortality) did not differ significantly among the regions or centres (Supplemen- tary Table 7). In addition, cirrhosis was not associated with cytolysin positivity, the total amount of faecal E. faecalis or faecal E. faecalis positivity in patients with alcoholic hepatitis (Extended Data Fig. 1k–m,",2,ALD patent background + target paper.pdf,45,True
e6db8bdc4405a6e2124134e9bb1b881b,Supplementary Tables 4–6). These results confirm our findings that the presence of cytolysin-producing E. faecalis rather than the total amount or presence of E. faecalis per se determines the severity of alcoholic hepatitis and mortality.,2,ALD patent background + target paper.pdf,46,True
a9175ffd6b2a8c9d9369c88800c62de5,Cytolysin and ethanol-induced liver disease,2,ALD patent background + target paper.pdf,47,False
4394ea43077688af40457154fcf3fe86,"To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we gavaged mice with a cytolytic E. faecalis strain (FA2- 2(pAM714)) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol diet15. Compared to mice gavaged with phosphate-buffered saline (PBS), mice fed with ethanol after they were gavaged with cytolytic E. faecalis developed more severe liver injury as indicated by a higher level of alanine amino-",2,ALD patent background + target paper.pdf,48,True
fd11f9ad465e4f18bbedd2fd7a5c22b7,"transferase (ALT) (Extended Data Fig. 2a) and increased hepatic stea- tosis (Extended Data Fig. 2b, c). Mice that were fed ethanol after they",2,ALD patent background + target paper.pdf,49,False
95f53b61b8996663894a1aaf9ef13479,") 1 – l U ( T L A f o 400 300 200 100 0 * *** *** ** Control Ethanol

b e d i r e c y l g i r t c i t a p e H ) r e v i l g r e p g m ( t n e t n o 50 40 30 20 10 0 **** **** *** * c",3,ALD patent background + target paper.pdf,50,False
f783712950b6a6e589e7a209e225ac81,c Control Ethanol Alcoholic hepatitis cytolysin-positive Alcoholic hepatitis cytolysin-positive Alcoholic hepatitis cytolysin-negative Alcoholic hepatitis cytolysin-negative no. 1 no. 2 no. 3 no. 4,3,ALD patent background + target paper.pdf,51,False
7d5351f64a8e7cbe13a79113871b1981,e,3,ALD patent background + target paper.pdf,52,False
190a75bfdec6ebfed3223da5fdc372e7,Cxcl1 e g n a h c d l o F 8 6 4 2 ** ** ** ** 0 Control Ethanol,3,ALD patent background + target paper.pdf,53,False
8f0e8eb8f52f9d1bc2c7b5fdef895f67,f,3,ALD patent background + target paper.pdf,54,False
75ec8a01e024eaadee39774b53737e37,Col1a1,3,ALD patent background + target paper.pdf,55,False
82b39a7f876867084f29cff5f9ea31bd,20 15 10 5 ** *** * * 0,3,ALD patent background + target paper.pdf,56,False
1df93d55e9f82344369a97e9ba92c93c,"h

LDH",3,ALD patent background + target paper.pdf,57,False
57573269094a7f78415d8f85eb3319d4,) % 40 * * ** ** ( y t i c i x o 30 20 t o t 10 y C 0 0 0 0 200 0 400 200 200 400 400 0 0 0 200 0 400 200 200 400 400 CylLS″ (nM) CylLL″ (nM) – + Ethanol,3,ALD patent background + target paper.pdf,58,False
dc7c1afebf70597a5de085db44d80dda,B,3,ALD patent background + target paper.pdf,59,False
e810dd71da3b6a70eb0070087726cf23,Alcoholic hepatitis cytolysin-positive no. 1,3,ALD patent background + target paper.pdf,60,False
f128b6cff45e0fde3b9b4273a97874b4,B,3,ALD patent background + target paper.pdf,61,False
c10c304c517e30fcf8ca5d265da88077,Alcoholic hepatitis cytolysin-positive no. 2,3,ALD patent background + target paper.pdf,62,False
bc91e1614e9736869b124fd97b938a92,B,3,ALD patent background + target paper.pdf,63,False
1fc4a1351455f6b45915414aef592df2,Alcoholic hepatitis cytolysin-negative no. 3,3,ALD patent background + target paper.pdf,64,False
fa39277d6ecdc7cb47baff17b520ec0e,B,3,ALD patent background + target paper.pdf,65,False
13642507312e158b14bd814c07aadd42,"Alcoholic hepatitis cytolysin-negative no. 4

e g n 8 6 Il1b * * ** ** a h c d l o F 4 2 0 Control Ethanol",3,ALD patent background + target paper.pdf,66,False
e2ffa722ceac59e9405ddddd06ac4522,g,3,ALD patent background + target paper.pdf,67,False
4691f661a3a03882c23eaa532cc46324,) % ( e c i M 100 80 60 40 20 **** **** **** **** 0 ND ND ND ND ND ND Control Ethanol,3,ALD patent background + target paper.pdf,68,False
18309b33a1388b7cb383ddfb9a32ca50,"Fig. 2 | Transplantation of faeces from cytolysin-positive patients with alcoholic hepatitis exacerbates ethanol-induced liver disease in gnotobiotic mice. a–g, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and subjected to the chronic–binge feeding model. a, Serum levels of ALT. b, Hepatic triglyceride content. c, Representative sections of liver stained with haematoxylin and eosin (H & E). d–f,",3,ALD patent background + target paper.pdf,69,False
9910f42a7fcd0544b1e8216a1cc703e5,"Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Lactate dehydrogenase (LDH) assay to measure cytotoxicity of hepatocytes isolated from mice that were fed an oral isocaloric control diet (five groups, left) or chronic–binge ethanol diet (five",3,ALD patent background + target paper.pdf,70,False
803be30d6b7b9beb9e0d255c9c9300e4,"groups, right), and incubated with vehicle, CylLS′′, CylLL′′ or both of the cytolysin subunits at the indicated concentrations without (–) or with (+) ethanol (25 mM) for 3 h. The survival of hepatocytes was determined in three independent experiments. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h). P values are determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures (g) or",3,ALD patent background + target paper.pdf,71,True
fd3e1df3ce5c323b45e75f5eaef59c84,"two-way ANOVA with Tukey’s post hoc test (h). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",3,ALD patent background + target paper.pdf,72,True
c721bc91a482f5706172d5baa91a3482,"were gavaged with cytolytic E. faecalis also had more liver inflamma- tion with higher expression levels of mRNAs that encode inflamma- tory cytokines and chemokines (Il1b, Cxcl1 and Cxcl2) (Extended Data Fig. 2d–f), compared with mice given PBS. Mice that were fed ethanol after they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver injury, steatosis and inflammation (Extended Data Fig. 2a–f) and longer survival times (Extended Data Fig. 2g), as compared",3,ALD patent background + target paper.pdf,73,True
55b00e1bcb01657867d762506aa72d32,with mice that were fed ethanol after they were administered with cytolytic E. faecalis.,3,ALD patent background + target paper.pdf,74,False
549e1cb07f3051eab773a26b636ae6b4,"To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in the liver. CylLS was significantly increased in the liver of mice given cytolytic E. faecalis but not in the liver of mice that were not given E. faecalis or of mice gavaged with non-cyto- lytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable in the liver of mice given cytolytic and",3,ALD patent background + target paper.pdf,75,True
b475e1e40238cbba321930bb216f97e5,"non-cytolytic E. faecalis and fed an ethanol diet, but not when mice were fed an isocaloric (control) diet (Extended Data Fig. 2i); this indicates that ethanol-induced changes in the gut barrier are necessary for the translocation of cytolytic E. faecalis from the intestine to the liver. The livers of ethanol-fed mice that were given cytolytic or non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed an increased intestinal permeability in ethanol-fed",3,ALD patent background + target paper.pdf,76,True
7d4ebbeeede3993511a3bce1787cd23e,"mice com- pared with mice fed with an isocaloric diet, but this was independent of gavaging cytolytic or non-cytolytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2k), indicating that cytolysin does not affect intestinal barrier function.",3,ALD patent background + target paper.pdf,77,False
c1a4bb6c553d4c3522586bf5dca2d7c3,"Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change the composition of the intestinal microbiota, as shown by 16S rRNA gene sequencing (Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic metabolism",3,ALD patent background + target paper.pdf,78,True
6563a4fb3326224380eb67e239b4f3dd,"Nature | www.nature.com | 3

3",3,ALD patent background + target paper.pdf,79,False
19a6f4c196234388e8a8acbaa1ee6592,Article,4,ALD patent background + target paper.pdf,80,False
0f4ccadb444959df47f80ec6b5d469b7,a Ef5.1 Ef5.2 Ef5.3 Ef5.4 Ef2.1 Ef2.2 Ef2.3,4,ALD patent background + target paper.pdf,81,False
78e12020e720a69b54ce09bcc7341104,b,4,ALD patent background + target paper.pdf,82,False
013a18ee735f1bb8648deda393d7ebc1,"s l e v e l m u r e S ) 1 – l U ( T L A f o 400 300 200 100 0 Patient no. 5 Patient no. 2 * Patient no. 5 ** Patient no. 2

) r e v i l g r e p g m ( t n e t n o c 50 40 30 20 10 0 Patient no. 5 Patient no. 2 * Patient no. 5 ** Patient no. 2 C. crescentus phages Cytolysin-positive E. faecalis phages C. crescentus phages Cytolysin-positive E. faecalis phages",4,ALD patent background + target paper.pdf,83,False
4400c8574cac974c6faf5bac99f26acf,"m

m

m

=",4,ALD patent background + target paper.pdf,84,False
ab412a1bbb7c15e2d79d3784d38aa6d4,d Control Ethanol C. crescentus phages Cytolysin-positive E. faecalis phages C. crescentus phages Cytolysin-positive E. faecalis phages,4,ALD patent background + target paper.pdf,85,False
ab91b16af9c1052874d2fa08a71e7972,"Patient no. 5

Patient no. 2",4,ALD patent background + target paper.pdf,86,False
3ea36ad5f4ef434af39f1e959df3745a,"f

e g n a h c d l o F",4,ALD patent background + target paper.pdf,87,False
1c6765e387db976aec2047d28756751a,12,4,ALD patent background + target paper.pdf,88,False
9cbd0d168fa705fe6956a5719b408d8f,RN ov®O,4,ALD patent background + target paper.pdf,89,False
2a6a074a66b424dc10f4f5ac68e0711b,"8

6

4

2",4,ALD patent background + target paper.pdf,90,False
564a0feba2735fd38cd4c7b5ab671f11,0,4,ALD patent background + target paper.pdf,91,False
f43c2702e38dc8c88ad130b8349138a4,Patient no. 5,4,ALD patent background + target paper.pdf,92,False
289df7d5ee7fc7e5c436ac12443af009,Cxcl1,4,ALD patent background + target paper.pdf,93,False
56d2ff2df1613aef448ed1a96cb95143,**,4,ALD patent background + target paper.pdf,94,False
6e68accc1b50f9215b23250af60bc417,"Patient no. 2

Patient no. 5",4,ALD patent background + target paper.pdf,95,False
97939730e441b14e6f98968aad19d4b4,"**

]",4,ALD patent background + target paper.pdf,96,False
cd59d679af71d122ac411e88c47bed5d,"Patient no. 2

g Col1a1 e g n a h c d l o F 18 15 12 9 6 3 0 * * Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2",4,ALD patent background + target paper.pdf,97,False
9d30c625e20a82632d805e7a1e2b9ba1,Control,4,ALD patent background + target paper.pdf,98,False
1b8e3c888964f82d160ca11a736638f0,"Ethanol

e g n a h c d l o F 12 10 8 6 4 2 0 Il1b * *** Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2 Control Ethanol",4,ALD patent background + target paper.pdf,99,False
78928cc0f21a1e88e0ed8fa6d2843b84,h Liver cylLS ) % ( e c i M 100 80 60 40 20 0 ND ND ND ND ** ** Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2,4,ALD patent background + target paper.pdf,100,False
7ce91cc6d320d567669d4fb41fb6e415,"Fig. 3 | Phage therapy against cytolytic E. faecalis abolishes ethanol-induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either siphophages (Ef5.1, Ef5.2, Ef5.3, Ef5.4 and Ef2.2) or myophages (Ef2.1 and Ef2.3). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin- positive patients with alcoholic hepatitis (faeces from one of these patients were also used in Fig. 2) and subjected to the",4,ALD patent background + target paper.pdf,101,False
087245f4a6bfbf0ce492cdb0a56d81d7,"chronic–binge feeding model, gavaged with control phages against C. crescentus (1010 plaque-forming units (PFUs)) or a cocktail of three or four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT.",4,ALD patent background + target paper.pdf,102,True
a7c39a657a64b712d359c9350f51198f,"c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. Results are expressed as mean ± s.e.m. (b, c, e–g). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–g) or two-sided Fisher’s exact test followed by FDR procedures (h). All results are generated from at least",4,ALD patent background + target paper.pdf,103,False
79afcc0aa50eef5f8916a4e374c1d1ab,"three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, *** P < 0.001.",4,ALD patent background + target paper.pdf,104,False
d253e3a43ab52f08a6245d521ebcb8d0,"of ethanol, as indicated by serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs (which encode the two primary enzymes that metabolize ethanol in the liver) (Extended Data Fig. 2m, n). These results indicate that E. faecalis that produce cytolysin promote ethanol- induced liver disease in mice.",4,ALD patent background + target paper.pdf,105,True
ffdc6a9c01768b9a6dedf3176294f83d,"To extend our findings to humans, we colonized germ-free mice with faeces from cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobi- otic C57BL/6 mice colonized with faeces from two cytolysin-positive patients developed more severe ethanol-induced liver injury, steatosis, inflammation and fibrosis than mice given faeces from two cytolysin- negative patients (Fig.",4,ALD patent background + target paper.pdf,106,True
672fc5b355217125329e3e73b68077ca,"2a–f, Extended Data Fig. 3a–d). Transplantation of faeces from cytolysin-positive patients reduced the survival time of the mice (Extended Data Fig. 3e) and increased translocation of",4,ALD patent background + target paper.pdf,107,False
be946ee458dd8cadbab40ea30a1ac588,4 | Nature | www.nature.com,4,ALD patent background + target paper.pdf,108,False
3575029f1aaf0a5f7162ca210a4d3957,"cytolytic E. faecalis to the liver after ethanol administration (Fig. 2g). The overall composition of the intestinal microbiota was not differ- ent between mice fed the control diet and colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, as shown by 16S rRNA gene sequencing. Mice transplanted with faeces from one of the cytolysin-positive patients with alcoholic hepatitis (patient no. 2) showed a microbiota that was significantly different from",4,ALD patent background + target paper.pdf,109,True
6e607ff4fcf96493e90864e165d30e92,"that of the other mouse groups after ethanol administration (Extended Data Fig. 3f). Non-cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorp- tion or hepatic metabolism of ethanol between mice colonized with faeces from cytolysin-positive versus cytolysin-negative patients (Extended Data Fig. 3h, i). Together, these results provide further evi- dence that cytolysin promotes",4,ALD patent background + target paper.pdf,110,True
cb929dc98c74ac74c28ad9529a28b4cf,ethanol-induced liver disease.,4,ALD patent background + target paper.pdf,111,False
1bbc7f86cfc32ba44f7dac2f2d8d82d5,a,5,ALD patent background + target paper.pdf,112,False
383cee10961937c5afdc15f5acbb5323,Ef6.1 Ef6.2 Ef6.3 Ef 6.4 Ef7.1 Ef7.2 Ef7.3 Ef 7.4,5,ALD patent background + target paper.pdf,113,False
52bcd86abf9c2f61c1d784d2ff65b6fa,"b

s l e v e l m u r e S",5,ALD patent background + target paper.pdf,114,False
be40cae9c914b69cc8cd0e49fe2f680c,400 300 200 100 0 Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,115,False
b09b7ce249e243b678124f200663978e,"– l U ( T L A

( T L A f",5,ALD patent background + target paper.pdf,116,False
6789bce27839360628aab58049480251,) r e v i l g r e p g m ( t n e t n o c 50 40 30 20 10 0 Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,117,False
efbb08dca037aa8e54161673e370adef,d,5,ALD patent background + target paper.pdf,118,False
4f22338333d83811d471321d21d3b805,Control Ethanol C. crescentus phages Cytolysin-negative E. faecalis phages C. crescentus phages Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,119,False
8a8610bbbb54402ef5460ae36aee6225,"Patient no. 6

Patient no. 7",5,ALD patent background + target paper.pdf,120,False
5129f03594b9fc237f688c34d4d59c2d,"e g n a h c d l o F

N w A O

1",5,ALD patent background + target paper.pdf,121,False
7e87bbb008cec09987c1d6b39ef8ad10,0,5,ALD patent background + target paper.pdf,122,False
36dc816028d9552fae039cc23294e45e,Patient no. 6,5,ALD patent background + target paper.pdf,123,False
b5fb7716d0a145a2b3a91596dc28eee6,Cxcl1,5,ALD patent background + target paper.pdf,124,False
735ca87b2aa81ac8acd8ddd635277c22,"Patient

&6 - - Patient 6",5,ALD patent background + target paper.pdf,125,False
b7b8b0ecdbe70429538bedca18f789dd,g Col1a1 h 6 4 2 0 Patient Patient Patient Patient no. 6 no. 7 no. 6 no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,126,False
e8dbb6b01412ed16ce50e36beae12bba,Control,5,ALD patent background + target paper.pdf,127,False
a5aefcd9aedee04c76c7ba4cbb7343c5,Ethanol,5,ALD patent background + target paper.pdf,128,False
d35c8dba98b33b6e78d0a7232c987eb5,m,5,ALD patent background + target paper.pdf,129,False
2cdedb2f03b8b1cf6d1b11bd060e5c50,C. crescentus phages,5,ALD patent background + target paper.pdf,130,False
0ead233afeb0a0af67b724ad29d3ca27,=,5,ALD patent background + target paper.pdf,131,False
3cb66aa8d757e14e3901ccd8308abe1f,Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,132,False
de27be43736a88de29e968fb59320629,m,5,ALD patent background + target paper.pdf,133,False
58f045e5569d88f5b890fd0c15518c3e,C. crescentus phages,5,ALD patent background + target paper.pdf,134,False
a43e6cc10507c26dffcf888900f3bc36,m,5,ALD patent background + target paper.pdf,135,False
9dd149b05fa9bf83da4eba2433c4d5eb,Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,136,False
005fe674c7a4688d1607fd0eb9c322ad,"e g n a h c d l o F 5 4 3 2 1 0 Il1b Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol

s u c 1010 * * c o c o r e t n E l a c ) 1 – g U F C ( 109 108 107 106 e a F 105 Patient Patient Patient Patient no. 6 no. 7 no. 6 no. 7",5,ALD patent background + target paper.pdf,137,False
c6cbc043cc897fa415b8dea12e72b77c,"Fig. 4 | Phages that target non-cytolytic E. faecalis do not reduce ethanol- induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either podophages (Ef6.2, Ef6.3, Ef7.2, Ef7.3 and Ef7.4) or siphophages (Ef6.1, Ef6.4 and Ef7.1). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis and subjected to the chronic–binge feeding model, gavaged with",5,ALD patent background + target paper.pdf,138,False
7973d2ef1c740959423bfdf593030801,control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target non-,5,ALD patent background + target paper.pdf,139,False
f4e427a72049170a6628d99269b98ce6,"To determine the mechanism by which cytolysin increases liver dis- ease, we isolated hepatocytes from mice fed ethanol or control diets, and stimulated them with pure bioactive cytolysin peptides (CylLL′′ and CylLS′′)6. Incubation of the primary mouse hepatocytes with the two cytolysin subunits caused a dose-dependent increase in cell death compared to hepatocytes that were incubated with vehicle or with one subunit only (Fig. 2h). When we isolated hepatocytes from ethanol-fed mice and then",5,ALD patent background + target paper.pdf,140,True
214ae1e568b34b33b939e97c1f233f1c,"incubated these hepatocytes with ethanol, we did not observe increased levels of cytolysin-induced cell death compared to hepatocytes isolated from mice on the control diet, which indicates that cytolysin-induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are possibly mediated by pore forma- tion, resulting in cell lysis14.",5,ALD patent background + target paper.pdf,141,True
a5f9ef32e8010a9e78b4bca3dbba2b1d,Bacteriophage treatment in liver disease,5,ALD patent background + target paper.pdf,142,False
135daf9ff022901479d21fc883ecc263,"To further demonstrate the potential causative role of cytolytic E. faecalis for the development of ethanol-induced steatohepatitis,",5,ALD patent background + target paper.pdf,143,False
04d57626eebd065a9b2a19bf645f8cf1,"cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT. c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Faecal colony-forming units (CFUs) of Enterococcus. Results are expressed as mean ± s.e.m. (b, c, e–h). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–h). All results were generated from at least three",5,ALD patent background + target paper.pdf,144,False
e2d7ecc53be51c1878e654a054f9085e,independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05.,5,ALD patent background + target paper.pdf,145,False
20fc8211be2207f7ebbc1f9da4b90d6b,"we investigated the effects of treatment with bacteriophages (here- after, phages). Phages are ubiquitous in bacteria-rich environments, including the gut16. E. faecalis phages that are highly strain-specific can be isolated17, which potentially makes the direct editing of gut microbiota feasible. It has previously been shown that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, which is associated with increased susceptibility to alcohol-induced",5,ALD patent background + target paper.pdf,146,True
f783833317fcda1d67fae16824103ca1,steatohepatitis11. The gavaging of wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice led to increased ethanol-induced steatohepatitis11. We found that this same E. faecalis strain expressed cytolysin. We then isolated four distinct phages from sewage water. These phages lyse the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type littermates,5,ALD patent background + target paper.pdf,147,True
c1196772abedcc34d482006821ba0b99,"were then placed on the chronic–binge ethanol diet and gavaged with the lytic phage cocktail. Phages directed against Caulobacter crescen- tus, a bacterium that is present in freshwater lakes and streams18 but that does not colonize humans or rodents19,20, were used as controls.",5,ALD patent background + target paper.pdf,148,False
e9bb6864c408924f4c8ff606770fd9f9,Nature | www.nature.com | 5,5,ALD patent background + target paper.pdf,149,False
fcd14ba7efbd76de57339e49d31a7130,Article,6,ALD patent background + target paper.pdf,150,False
d9ac1b615fdd2bf5e600d7df13fec8de,"Compared to Atp4aSl/Sl mice gavaged with control phages or vehicle, Atp4aSl/Sl mice gavaged with phages that target cytolytic E. faecalis had less severe liver injury, steatosis and inflammation after chronic ethanol feeding (Extended Data Fig. 5a–f). Administration of E. faecalis phages significantly reduced levels of cytolysin in the liver (Extended Data Fig. 5g) as well as faecal amounts of Enterococcus (Extended Data Fig. 5h). Phage administration did not affect the overall composition of",6,ALD patent background + target paper.pdf,151,True
6f0543ddeb923b7f7262b240d5b70aef,"the faecal microbiome, intestinal absorption or hepatic metabolism of ethanol (Extended Data Fig. 5i–k).",6,ALD patent background + target paper.pdf,152,False
fcaf8ee93aa30caad09e40b224cb1dc1,"To develop a therapeutic approach to precisely edit the intestinal microbiota, we cultured cytolytic E. faecalis strains from the faecal samples of patients with alcoholic hepatitis. We then isolated lytic phages from sewage water against these cytolytic E. faecalis strains; these phages had siphophage or myophage morphology (Fig. 3a, Extended Data Fig. 6). Gnotobiotic mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (Sup- plementary Table 8) and",6,ALD patent background + target paper.pdf,153,True
baf51e181775b4dcfa74544228c84273,"given three or four different—but patient- specific—lytic phages against cytolytic E. faecalis. The phages against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, as shown by lower levels of ALT, lower percentages of hepatic cells positive for terminal deoxynucleotide transferase-mediated dUTP nick-end labelling, and lower levels of hepatic triglycerides and oil red O-staining (Fig. 3b–d, Extended Data Fig. 7a, b), as well as by decreased hepatic levels of Il1b,",6,ALD patent background + target paper.pdf,154,True
10f2c121251e7865f10e7f5043ac0bc3,"Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLS, as compared with mice given control phages (against C. crescentus) (Fig. 3e–h, Extended Data Fig. 7c, d). Treatment with phages against cytolytic E. faecalis also reduced faecal amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were similar in all groups (Extended Data Fig. 7g, h).",6,ALD patent background + target paper.pdf,155,True
da9fd7f19241044c965123053eb42f33,"To demonstrate that the effect of phage treatment occurs via the targeting of cytolysin-positive E. faecalis, rather than a reduction in cytolysin-negative E. faecalis, we colonized gnotobiotic mice with faeces from cytolysin-negative patients with alcoholic hepatitis (Sup- plementary Table 8). Phages against non-cytolytic E. faecalis from patients were isolated from sewage water; they had siphophage or podophage morphology (Fig. 4a, Extended Data Fig. 8). These phages did not reduce features of",6,ALD patent background + target paper.pdf,156,True
60dd9e4ba9b6783c14557df1602b62e3,"ethanol-induced liver disease compared with control phages (Fig. 4b–g, Extended Data Fig. 9a–h), despite the reduc- tion of faecal Enterococcus (Fig. 4h). Our findings indicate that treat- ment with lytic phages can selectively attenuate the ethanol-induced liver disease caused by cytolysin-positive E. faecalis in humanized mice.",6,ALD patent background + target paper.pdf,157,True
834c2b5f1d22d4592d170d5436e54e4e,Discussion,6,ALD patent background + target paper.pdf,158,False
498f1d8b3a437ae999e672b742edacb6,"Phage-based therapies have predominantly been studied in patients with bacterial infections in the gastrointestinal tract21–23, urinary tract24,25 and other organ systems26–28. The results of these studies— although mixed in terms of efficacy—strongly suggest that phage treat- ment offers a safe alternative to antibiotics26,27. However, safety studies are required for complex populations (such as patients with alcoholic hepatitis), because phages can induce a strong immune reaction29. Further",6,ALD patent background + target paper.pdf,159,True
a7f4dd56d870f83786e1ded97b09e6de,"work is required to determine whether phages that target cyto- lytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening disease that at present has no effective treatment. Eradication of this specific bacterial strain might produce better out- comes than current treatments, and environmental sources can be used to easily isolate phages that target cytolysin-positive E. faecalis. Here we provide an example of the efficacy of approaches based on phages in mice",6,ALD patent background + target paper.pdf,160,True
c04244d11660c52310810cb9c64c925b,"for a disease that is not considered a classic infectious disease. Our data also suggest that cytolysin may be used as a predictive biomarker of severe alcoholic hepatitis; an independent, prospective",6,ALD patent background + target paper.pdf,161,True
44116a8025c84603062367c53a71cf79,"cohort is therefore needed to validate cytolysin as a biomarker, and to extend the phage findings in mice to human patients.",6,ALD patent background + target paper.pdf,162,False
c97e080f7535538b4bcff1b87fb53e01,Online content,6,ALD patent background + target paper.pdf,163,False
5bfd218ef4ad46d119866b15d45abca4,"Any methods, additional references, Nature Research reporting sum- maries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author con- tributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-019-1742-x.",6,ALD patent background + target paper.pdf,164,False
a13137949463911e54e84eb212a85ed1,"1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).",6,ALD patent background + target paper.pdf,165,False
b96f16ecb80f86600d7387df3acab991,"2. Lee, B. P., Vittinghoff, E., Dodge, J. L., Cullaro, G. & Terrault, N. A. National trends and long- term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern. Med. 179, 340–348 (2019).

3. Rehm, J. et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol. Clin. Exp. Res. 38, 1068–1077 (2014).",6,ALD patent background + target paper.pdf,166,False
82409951aa1ec6660c7df35caf176cdc,"4. Llopis, M. et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65, 830–839 (2016).",6,ALD patent background + target paper.pdf,167,False
8ad887d9a34433be7b2c84cc21aad66c,"5. Ike, Y., Clewell, D. B., Segarra, R. A. & Gilmore, M. S. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: Tn917 insertional mutagenesis and cloning. J. Bacteriol. 172, 155–163 (1990).",6,ALD patent background + target paper.pdf,168,False
059dccc7c46ff77f92ca0e43336a1e78,"6. Tang, W. & van der Donk, W. A. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat. Chem. Biol. 9, 157–159 (2013).",6,ALD patent background + target paper.pdf,169,False
dc5e40d76e0eab42204f6a8153750a98,"7. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193–199 (1978).

8. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747–2756 (2008).

9. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).

10. Mathurin, P. & Lucey, M. R. Management of alcoholic hepatitis. J. Hepatol. 56, S39–S45 (2012).",6,ALD patent background + target paper.pdf,170,True
6ab480a65fa21c7c89c54c7f244a5b0c,"11. Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).",6,ALD patent background + target paper.pdf,171,True
65cd9e8cb8b25d0a55dd5d3a1f9ec361,"12. Gilmore, M. S. et al. Genetic structure of the Enterococcus faecalis plasmid pAD1- encoded cytolytic toxin system and its relationship to lantibiotic determinants. J. Bacteriol. 176, 7335–7344 (1994).

13. Cox, C. R., Coburn, P. S. & Gilmore, M. S. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. 6, 77–84 (2005).",6,ALD patent background + target paper.pdf,172,False
9348fff1a52bba85dab00911391bd466,"14. Van Tyne, D., Martin, M. J. & Gilmore, M. S. Structure, function, and biology of the Enterococcus faecalis cytolysin. Toxins 5, 895–911 (2013).",6,ALD patent background + target paper.pdf,173,False
e56d385bac9407a71ba08add86f592f6,"15. Bertola, A., Mathews, S., Ki, S. H., Wang, H. & Gao, B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat. Protoc. 8, 627–637 (2013).",6,ALD patent background + target paper.pdf,174,False
c6e4e2d9d828f548f06c801ded0ca222,"16. Ogilvie, L. A. & Jones, B. V. The human gut virome: a multifaceted majority. Front. Microbiol. 6, 918 (2015).",6,ALD patent background + target paper.pdf,175,False
1f85cd3532b36ff333188aea9f8c0510,"17. Chatterjee, A. et al. Bacteriophage resistance alters antibiotic-mediated intestinal expansion of enterococci. Infect. Immun. 87, e00085-19 (2019).

18. Poindexter, J. S. Biological properties and classification of the Caulobacter group. Bacteriol. Rev. 28, 231–295 (1964).",6,ALD patent background + target paper.pdf,176,False
fc5d76be23e8678fcc32d6e3607ca7c8,"19. Shin, J. et al. Analysis of the mouse gut microbiome using full-length 16S rRNA amplicon sequencing. Sci. Rep. 6, 29681 (2016).",6,ALD patent background + target paper.pdf,177,False
5581ec145e2a45c07955f8ffad2a80f3,"20. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).",6,ALD patent background + target paper.pdf,178,False
778e402178c920ded3d8c65b5d62b3f6,"21. Marcuk, L. M. et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull. World Health Organ. 45, 77–83 (1971).

22. Sarker, S. A. et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137 (2016).",6,ALD patent background + target paper.pdf,179,False
7f248353e778ded2845b2b968204f4ff,"23. Dalmasso, M., Hill, C. & Ross, R. P. Exploiting gut bacteriophages for human health. Trends Microbiol. 22, 399–405 (2014).

24. Ujmajuridze, A. et al. Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9, 1832 (2018).

25. Khawaldeh, A. et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60, 1697–1700 (2011).",6,ALD patent background + target paper.pdf,180,False
b62ee0946460fd95485be49a96d8b1d4,"26. Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).

27. Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).",6,ALD patent background + target paper.pdf,181,False
fdb11bf0baf4b0acf722b950cc9a19b1,"28. Fish, R. et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).",6,ALD patent background + target paper.pdf,182,False
21f5cb7458898691beb95969a4e12c00,"effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).

29. Górski, A. et al. Phages and immunomodulation. Future Microbiol. 12, 905–914 (2017).",6,ALD patent background + target paper.pdf,183,False
151fcb89fa1bcbcb5a1930ca15732069,"Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2019",6,ALD patent background + target paper.pdf,184,False
c62045f8a89cc5fbb4a2d00ddfadea7d,6 | Nature | www.nature.com,6,ALD patent background + target paper.pdf,185,False
0011ab476f6353191b3beacfd474df93,"1Department of Medicine, University of California San Diego, La Jolla, CA, USA. 2Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. 4J. Craig Venter Institute, Rockville, MD, USA. 5J. Craig Venter Institute, La Jolla, CA, USA. 6Host–Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, UK. 7Division of Biostatistics and Bioinformatics,",7,ALD patent background + target paper.pdf,186,False
e60cf796821269f7923ccfa105761bc6,"Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 8Department of Biochemistry and Biophysics, Texas A & M University, College Station, TX, USA. 9Center for Phage Technology, Texas A & M AgriLife Research and Texas A & M University, College Station, TX, USA. 10Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 11Department of Pathology, University of California San Diego, La Jolla, CA, USA. 12Division of",7,ALD patent background + target paper.pdf,187,False
85c417fbd8b4c4b44e79142080b5ba39,"Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, PA, USA. 13Hospital Universitario, Departamento de Gastroenterología, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. 14Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 15Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.",7,ALD patent background + target paper.pdf,188,False
2039ee0dc36f927e1b17ff801da5693b,"16Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA. 17Liver Unit, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 18Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 19Liver Unit, Hospital Clinic, Barcelona, Spain. 20Liver Sciences, Department of Inflammation Biology, School of Infectious Diseases and Microbial Sciences, King’s College London, London, UK.",7,ALD patent background + target paper.pdf,189,False
82694c65a7b3d543d8151acdaeb20ae3,"21Service des Maladies de L’appareil Digestif et Unité INSERM, Hôpital Huriez, Lille, France. 22Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 23Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA. 24Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, CT, USA. 25Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana,",7,ALD patent background + target paper.pdf,190,False
4e56e2dcd0f0fe84746b4fe239b575b2,"IL, USA. 26Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 27St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 28Center for Innovative Phage Applications and Therapeutics, University of California San Diego, La Jolla, CA, USA. 29These authors contributed equally: Yi Duan, Cristina Llorente. *e-mail: beschnabl@ucsd.edu",7,ALD patent background + target paper.pdf,191,False
88867e5d9938c13a860b7250399c1d90,"Nature | www.nature.com | 7

7",7,ALD patent background + target paper.pdf,192,False
8c0b9249635e257a90e03cbf897611a3,"Methods

Methods",8,ALD patent background + target paper.pdf,193,False
58b63f2ac1b1120161190d90537f9369,No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.,8,ALD patent background + target paper.pdf,194,True
610827890350f0b935d3e1c4f21b7ca9,"Patient cohorts

Patient cohorts have previously been described* 2, We evaluated",8,ALD patent background + target paper.pdf,195,False
e042944def6cf71eb330b21b17b93bb3,"26 subjects without alcohol-use disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol-use disorder and 88 patients with alcoholic hepatitis. Patients with alcohol-use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption (self-reported >60 g/day) presented with various stages of liver disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index) (Supplementary Table 1). Patients with alcohol-use disorder",8,ALD patent background + target paper.pdf,196,True
c0ca7b327033c0e6165379376b8c68ba,"were recruited from an alcohol withdrawal unit in San Diego and Brussels, where they followed a detoxification and rehabilitation programme. At admission to the hospital, a complete medication and medical history was taken, and a complete physical examination was performed, including collection of bio-specimens, basic demographic data (such as age, gender, weight and height) and self-reported daily alcohol consumption. Patients were actively drink- ing until the day of admission. Controls or",8,ALD patent background + target paper.pdf,197,True
817fee613af66d171c4e3576ae0dc3dd,"patients with alcohol-use disorder did not take antibiotics or immunosuppressive medication during the two months preceding enrolment. Other exclusion criteria were diabetes, inflammatory bowel disease, known liver disease of any other aetiology, and clinically important cardiovascular, pulmonary or renal co-morbidities. Patients with alcoholic hepatitis were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centres in the USA, Mexico, UK, France and",8,ALD patent background + target paper.pdf,198,False
0f976c0e660004200f04da06431ab779,"Spain. Inclusion criteria for this study were active alcohol abuse (>50 g/day for men and >40 g/day for women) in the past 3 months, aspartate aminotransferase (AST) > ALT and total bilirubin >3 mg/dl in the past 3 months, and a liver biopsy and/or clinical picture consistent with alco- holic hepatitis. Exclusion criteria were autoimmune liver disease (ANA >1/320), chronic viral hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, pregnancy and a",8,ALD patent background + target paper.pdf,199,True
cd245ece245b24fa43712674060a852e,"lack of signed informed consent. In all patients, the clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology was consistent with the diagnosis of alco- holic hepatitis. Liver biopsies were only done if clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic hepatitis. Bio-specimens were collected during their admission to the hospital. The median time of specimen collection was 4 days fol- lowing",8,ALD patent background + target paper.pdf,200,True
38ce4f336a6096a4e0eb4efc385c6884,"admission to the hospital (range 0–24, n = 82). For one patient who underwent liver transplantation, the transplantation date was considered as date of death. Patients were censored at the time point at which they were last seen alive. The baseline characteristics are shown in Supplementary Tables 1, 2. Faecal 16S rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, ABIC score and discriminant function were calculated from all alcoholic hepatitis patients from whom",8,ALD patent background + target paper.pdf,201,True
d816fd6f4542d1b8eb4f77190745d144,"respective laboratory values were avail- able. The protocol was approved by the Ethics Committee of Hôpital Huriez, Universidad Autonoma de Nuevo Leon, Hospital Universitari Vall d’Hebron, King’s College London, Yale University, University of North Carolina at Chapel Hill, Weill Cornell Medical College, Columbia University, University of Wisconsin, VA San Diego Healthcare System, University of California San Diego (UCSD) and Université Catholique de Louvain. Patients were enrolled after written",8,ALD patent background + target paper.pdf,202,False
077ff414cee1eb0193dbc2ca6bd1badb,informed consent was obtained from each patient.,8,ALD patent background + target paper.pdf,203,False
8c2cd087d7482ec1cc860453e9de31fb,"Mice

C57BL/6 mice were purchased from Charles River and used in Fig. 2h and Extended Data Fig. 2. C57BL/6 germ-free mice were bred at UCSD and used in Figs. 2a–g, 3, 4, Extended Data Figs. 3, 7 and 9. Sublytic Atp4aSl/Sl",8,ALD patent background + target paper.pdf,204,True
43d130fb7cbac4d01b6a808303dff089,8 | Nature | www.nature.com,8,ALD patent background + target paper.pdf,205,False
0acac659a7a3f3c83930f1adf07c902d,"mice on a C57BL/6 background have previously been described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their wild-type littermates were used in Extended Data Fig. 5.",8,ALD patent background + target paper.pdf,206,True
db0feac9cc609c82c55d0c628caf10f8,"Female and male mice (age of 9–12 weeks) were placed on a chronic– binge ethanol diet (NIAAA model) as previously described15. Mice were fed with Lieber–DeCarli diet and the caloric intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in the early morning and killed 9 h later. Pair-fed control mice received a diet with an isocaloric substitution of dextrose.",8,ALD patent background + target paper.pdf,207,True
cb20161a2564d2d7216e477505fcbb8f,"Stool samples from patients with alcoholic hepatitis (Fig. 1) were used for faecal transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g stool dissolved in 30 ml Luria–Bertani (LB) medium containing 15% glycerol under anaerobic conditions), starting at an age of 5–6 weeks and repeated 2 weeks later. Two weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.",8,ALD patent background + target paper.pdf,208,True
8a6d17a0e3f64443f3390d86dca1c328,"In studies of the effects of cytolysin, 5 × 108 CFUs of a cytolytic E. fae- calis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2- 2(pAM771))5 (E. faecalis Δcytolysin) (kindly provided by M. S. Gilmore), or PBS (vehicle control) were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol feeding. Administration every third day was necessary, given that E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of phage",8,ALD patent background + target paper.pdf,209,True
f9d7bfe2eedac9500d5b3cdb1d356f97,"treat- ment, 1010 PFUs of E. faecalis phages (or C. crescentus phage phiCbK as control)35 were gavaged to the mice 1 day before the ethanol binge (at day 16). All animal studies were reviewed and approved by the Institu- tional Animal Care and Use Committee of UCSD.",8,ALD patent background + target paper.pdf,210,True
5a2bbaec774f4d4dc98598a1cefca12a,Bacteriophage isolation and amplification,8,ALD patent background + target paper.pdf,211,False
92ef1fa99dff370a9149c2961a1ed388,"The E. faecalis strain from Atp4aSl/Sl mice faeces has previously been isolated11 and was used to isolate phages Efmus1, Efmus2, Efmus3 and Efmus4 (phages specific to the E. faecalis strain isolated from mouse faeces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). E. faecalis strains from human stool samples were isolated using methods described below, and the cor- responding phages were named as Ef with patient number plus a digit (Ef for E.",8,ALD patent background + target paper.pdf,212,True
4f0069590b39e0075cc29c89eb86b6d8,"faecalis, last digit for isolation order). All E. faecalis strains were grown statically in brain–heart infusion (BHI) broth or on BHI agar at 37 °C. C. crescentus phage phiCbK was purified as previously described35.",8,ALD patent background + target paper.pdf,213,False
d3e8d3246d66c688354723e9dbcdf290,"E. faecalis phages were isolated from untreated raw sewage water obtained from North City Water Reclamation Plant in San Diego. Fifty millilitres of raw sewage water was centrifuged at 8,000g for 1 min at room temperature to pellet large particles. The supernatant was passed through a 0.45-μm and then a 0.2-μm syringe filter (Whatman, PES membrane). One hundred microlitres of the clarified sewage was mixed with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar)",8,ALD patent background + target paper.pdf,214,True
5a2ecb20b98679abe9ec4e7d4685525a,"and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, the resulting plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more times to ensure that the phages were clonal isolates.",8,ALD patent background + target paper.pdf,215,True
8aeb5a7c4f1f437cad055f2f2da16aae,"High-titre phage stocks were propagated by infecting 200 ml of expo- nentially growing E. faecalis at a multiplicity of infection of 0.1 in BHI broth containing 10 mM MgSO4. Lysis was allowed to proceed for up to six hours at 37 °C with shaking. The lysates were centrifuged at 10,000g for 20 min at room temperature to remove the remaining bacterial cells and debris. Supernatant was then vacuum-filtered through a 0.2-μm membrane filter and kept at 4 °C until use.",8,ALD patent background + target paper.pdf,216,True
b05d19fa5af188c7b8e5420e7cabc173,"Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF Concentrators with 100,000-molecular weight cutoff (MWCO) to a volume of approximately 1 ml. Following concen- tration, the culture medium was replaced with PBS via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml and adjusted to the required PFUs.",8,ALD patent background + target paper.pdf,217,True
127006a3bdcfa8ba2f6dd414c0e18a32,Whole-genome sequencing for phages,9,ALD patent background + target paper.pdf,218,False
a8bae4416c18abf2cac155e38c37d73a,"For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase and RNase at 37 °C for 1 h and phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4 °C overnight. Precipitated phages were then pel- leted by centrifugation at 10,000g for 10 min at 4 °C and resuspended in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA Clean-up kit (Promega). Phage genomes were",9,ALD patent background + target paper.pdf,219,True
59099ab5d3446bade1b274c1a33f5170,sequenced using a combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-based size selection before loading onto Illumina flow cells. Sequencing was performed with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) and loaded onto,9,ALD patent background + target paper.pdf,220,True
8bdbccea6236b8bbfd96fd480201388c,"MinION R9.4 flow cells. ONT reads were basecalled with Albacore v.2.3.4 (ONT). The sequence reads were demultiplexed and adapters trimmed from ONT reads using Porechop v.0.2.336. A hybrid Illumina-ONT de novo assembly was performed using the Unicycler v.0.4.7 pipeline37. Subsequently, Pilon v.1.2238 was used iteratively to polish the assemblies with Illumina reads until no addi- tional corrections could be made.",9,ALD patent background + target paper.pdf,221,True
ca35435b8ec55078f0a01c7a808831ea,"For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45-μm and 0.2-μm filters (VWR) and purified on a caesium chloride (CsCl) density gradient39. One millilitre of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qia- gen), amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a Bioruptor (Diagenode). Libraries were created using the Ion",9,ALD patent background + target paper.pdf,222,True
d2a1059394870487841ec6518e2f9ca7,"Plus fragment library kit and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 × coverage).",9,ALD patent background + target paper.pdf,223,True
1c53bab920a70926e09c18f7f7a39263,"Mapping of ONT reads to the hybrid assemblies was used to deter- mine the orientation and terminal ends of linear phage genomes, and reference genomes served as guides to orient circular phage genomes. Phage genome assemblies were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.",9,ALD patent background + target paper.pdf,224,True
91576a226a9cce9c84181d3e0cda5481,"Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3",9,ALD patent background + target paper.pdf,225,True
04cf83af215edc1f24728bc57e7b8a48,(MK721184) and Ef7.4 (MK721198).,9,ALD patent background + target paper.pdf,226,False
d23dd11e0d7d9d85c2aea1a91db70f28,"Genetic maps of phage genomes were generated by LinearDisplay. pl (https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://sourceforge.net/projects/mcj/) to render high- quality images. Preliminary annotation of genes was derived from the automated annotation and from Phage_Finder42, which uses curated hidden Markov models and databases of core phage gene to annotate core gene functions. Annotation was then manually reviewed to assign the final colours.",9,ALD patent background + target paper.pdf,227,True
a43d823c09b324b791bcb8beae797bac,"Phage phylogenetic tree

A phage whole-genome phylogeny tree was generated from a pairwise distance matrix calculated with the MASH program, which approxi- mates average nucleotide identity (ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated and sequenced in",9,ALD patent background + target paper.pdf,228,True
4e90311181576034039a159db8836df1,"this study plus 54 Enterococcus phage genomes obtained from Gen- Bank, with 5,000 12-mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial phage genome sequences to generate the ANI matrix using the mash distance command using default settings. The GGRaSP R package was used to calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI >99.985) were removed using the GGRaSP R package with a user",9,ALD patent background + target paper.pdf,229,True
006235dedb8b656ba8cae88658b1c5c8,"defined cutoff of 0.015 (ggrasp. cluster (threshold = 0.015)). The resulting dendrogram was translated into newick format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with taxonomic information and manually entered clade identification.",9,ALD patent background + target paper.pdf,230,True
400fe72e41345fd626b019a2b0c5eada,"Electron microscopy

Phage morphology was examined by transmission electron microscopy of negatively stained grids, prepared using the valentine method46 with either 2% uranyl-acetate or 2% phosphotungstic acid, and examined at an acceleration voltage of 100 kV in the JEOL 1200 EX transmission electron microscope.",9,ALD patent background + target paper.pdf,231,False
61a089e1c2d3c159c43d979a9a92e0f4,Bacterial DNA extraction and 16S rRNA sequencing,9,ALD patent background + target paper.pdf,232,False
26e716086b8135b36384ee83044eabb2,"DNA from human stool samples, mouse liver sections or bacterial cul- ture was extracted as previously described11, and DNA from mouse faeces was extracted using QIAamp Fast DNA Stool kit (Qiagen). 16S rRNA PCR was completed using Illumina adaptor and barcode-ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified using the Qiaquick PCR purification kit (Qiagen) using manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay",9,ALD patent background + target paper.pdf,233,True
702d4caabd5158cd933d728c9bc2cccf,"(Tecan), normalized and pooled in preparation for 16S rRNA sequencing. Pooled library was quantified and checked for qual- ity using Agilent 2100 Bioanalyzer (Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 cycles, 2 × 250-bp format using manufacturer’s specifications. 16S sequence reads were processed and operational taxonomic units were determined using our MOTHUR-based 16S rDNA analysis workflow as previously described11,49. Raw 16S",9,ALD patent background + target paper.pdf,234,True
3d18fea7254ecef51090d7c0a9695384,sequence reads can be found in the NCBI Sequence Read Archive (SRA) associated with Bioproject PRJNA525701.,9,ALD patent background + target paper.pdf,235,False
ed093f2bf7a85e0a56302918ccc7d1c7,Real-time qPCR,9,ALD patent background + target paper.pdf,236,False
ac97f219012f3111e9b6704302dea360,"Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and cylLL genes have previously been described50,51. All primers used in this study are listed in Supplementary Table 9. Mouse gene expression and amplification of bacterial genes were determined with Sybr Green",9,ALD patent background + target paper.pdf,237,True
bc267b0deb89a2c59e96f85c67de5eba,(Bio-Rad Laboratories) using ABI Ste- pOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 18S.,9,ALD patent background + target paper.pdf,238,True
e122346f051da594e24eff2597a12e74,E. faecalis isolation and whole-genome sequencing,9,ALD patent background + target paper.pdf,239,False
a9f464facaa1cbf817a9c2422eaf8e4e,"To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial dilutions were made and 100 μl was placed on plates with selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the production of dark brown or black colour, generated by hydrolysis of esculin to esculetin (which reacts with ferric ammonium citrate). Each Enterococcus colony was then picked, and qPCR was performed to identify E.",9,ALD patent background + target paper.pdf,240,True
89cc95f4a0731b39a24a6b54c5a6ab46,"faecalis, using specific primers against the E. faecalis 16S rRNA gene50. For each subject, between 1 and 6 E. faecalis colonies were analysed and bacterial genomic DNA was then extracted as described in ‘Bacterial DNA extraction and 16S rRNA sequencing’.",9,ALD patent background + target paper.pdf,241,True
36cb8e6b2ee7ecc23a2b9f5175b6d079,DNA sequencing was performed on the Illumina HiSeq Ten X generat- ing paired-end reads (2 × 151 bp). Bacterial genomes were assembled,9,ALD patent background + target paper.pdf,242,True
94978dc872b00f7e28f8ad3ffb09e08c,Article,10,ALD patent background + target paper.pdf,243,False
099b7dfd205c297ccfd990d3aa6e41c5,"and annotated using the previously described pipeline52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes carried by E. faecalis isolates were identified by comparing individual genome assemblies against the CARD and VFDB databases, respectively, using abricate v0.8.10 (https://github.com/tseemann/abricate)53,54.",10,ALD patent background + target paper.pdf,244,True
4cd207c672357b22bc736d7265606756,"For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cutoff was used, and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this study have been deposited in the European",10,ALD patent background + target paper.pdf,245,True
9d9bc99597f92ac870ed6fc92f396f4b,Nucleotide Archive (ENA) under the accession number PRJEB25007. Sequence reads are available at ENA under run acces- sion identifiers ERR3200171–ERR3200263.,10,ALD patent background + target paper.pdf,246,False
160b9572e75fc7f21313c5b6fe72b406,"E. faecalis culture

All E. faecalis strains were grown statically in BHI broth or on BHI agar plate at 37 °C. Fifty micrograms per millilitre erythromycin was added when cytolytic and non-cytolytic E. faecalis strains were grown (Extended Data Fig. 2).",10,ALD patent background + target paper.pdf,247,True
acdd7e01fb2c54d8d623c5224e27ffa7,Determination of levels of faecal Enterococcus,10,ALD patent background + target paper.pdf,248,False
0b3f87f0128253ff5d4a35973c23662d,"To determine levels of faecal enterococci in mice, 10–30 mg of mouse faeces was resuspended into 500 μl PBS and serial dilutions were made. Five microlitres of each dilution from each sample was spotted onto a plate with a selective medium, BBL enterococcosel broth (Becton Dickinson) and the plates were then incubated at 37 °C overnight. For Extended Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were identified by the production of a dark brown or black colour.",10,ALD patent background + target paper.pdf,249,True
ce9b9a313e1c7d2f80a952a7f3bdfd5d,"Colony numbers of each sample were then counted, and CFUs were calculated.",10,ALD patent background + target paper.pdf,250,False
1f879305f24c8f4a42df1b4bf9cf9d0e,Cytolysin expression and purification,10,ALD patent background + target paper.pdf,251,False
6fbc1965b9031eac7d8fe0a1f15c0b0e,"To purify bioactive CylLL′′ and CylLS′′, an Escherichia coli heterologous expression system was used. In brief, either 6×His–CylLL or 6×His–CylLS were co-expressed with CylM (the enzyme that performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. The His tag and leader peptide were then removed using recombinant CylA (27–412), the soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive",10,ALD patent background + target paper.pdf,252,True
5aa1494873b653edbf3376e5eda334ee,CylLL′′ or CylLS′′. The resulting core peptides were further purified by reversed-phase high-performance liquid chromatography (HPLC).,10,ALD patent background + target paper.pdf,253,True
b31c744b5081aaac404dd88ef2fddd09,"The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 backbone vector that contained the cylM gene in MCSII6. The cylA (27–412) gene was previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star (DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, cylLS_cylM:pRSFDuet or cylA (27–412):pRSFDuet plasmids via KCM chemical transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 μg/ml) and",10,ALD patent background + target paper.pdf,254,True
409aae3f1eba8cc017c19167bc703e6f,grown at 37 °C overnight. One colony was picked to inoculate 15 ml of LB broth supplemented with kanamycin overnight at 37 °C. The culture was used to inoculate 1.5 l of terrific broth supple- mented with kanamycin. Cultures were grown with shaking at 37 °C to an optical density at 600 nm (OD600) of 0.8. The temperature of the incu- bator was lowered to 18 °C and expression was induced with the addi- tion of 0.3 mM final concentration of isopropyl β-d-thiogalactoside. The cultures were allowed,10,ALD patent background + target paper.pdf,255,True
8e5b87a0a6d982b36d840a001ad89e9e,"to incubate at 18 °C for 18 h. The cells were collected by centrifugation at 5,000g for 12 min. The cell paste was collected and frozen at -70 °C.",10,ALD patent background + target paper.pdf,256,True
95b7fab4c3c4954353259b85595a6288,"For the purification of the protease CylA (27–412), the cell paste was thawed and resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension was lysed by homogenization. The lysate was clarified by centrifugation at 13,000g for 45 min and filtered through a 0.45-μm centrifugal filter (Thermo Scientific). The clarified",10,ALD patent background + target paper.pdf,257,True
34a8543d6f0ed82dc1b09027480afb04,"lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a peristaltic pump. The loaded column was con- nected to an ÄKTA pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as determined by 4–20% SDS–PAGE, were combined, concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into",10,ALD patent background + target paper.pdf,258,True
caeefdcf1084e77ff5e6857cc445e3ff,"storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). Protein concentration was determined by absorbance at 280 nm.",10,ALD patent background + target paper.pdf,259,True
dca8b89b3f4eba96883fe6595de92729,"For the purification of CylLL′′ and CylLS′′ peptides, the cell paste was thawed and resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2-s pulse on, 5-s pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation at 13,000g for 45 min. The clarified cell lysate was filtered through a 0.45-μm centrifugal filter and applied via gravity flow to a pre-equili-",10,ALD patent background + target paper.pdf,260,True
c0fe84d533b3c2dc3baec429d45bd71d,"brated, 2 ml bed volume of His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The peptides were eluted with 10 ml of LanA elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final",10,ALD patent background + target paper.pdf,261,True
c5c35ee95bdcc35de798b9a11aa9ed68,concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.,10,ALD patent background + target paper.pdf,262,True
e23a4d1755011379bc6eca0c3bce3bfa,"The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. The solution was centrifuged at 4,500g for 10 min and filtered through a 0.45-μm syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse-phase HPLC using a Phenomenex Jupiter Proteo column (10 mm × 250 mm, 4 μm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were separated using a linear gradient of 3% (v/v) solvent B",10,ALD patent background + target paper.pdf,263,True
e7b6e4f32f22069121b573fc9ad95185,"(acetonitrile + 0.1% trifluoroacetic acid) in solvent A (water + 0.1% trif- luoroacetic acid). The fractions were spotted on a matrix-assisted laser desorption/ionization (MALDI) target plate by mixing 1 μl of sample with 1 μl of a 25 mg/ml solution of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were analysed by MALDI–time of flight (TOF) mass spectrometry on a Bruker UltrafleXtreme MALDI–TOF/ TOF operating in positive ionization, reflector mode.",10,ALD patent background + target paper.pdf,264,True
8f7b943cd1c07dffb42ef78bb3ada19c,Primary mouse hepatocytes,10,ALD patent background + target paper.pdf,265,False
3a9f17d58ca5c1ed985aa20b6572a3e5,Hepatocytes were isolated from C57BL/6 female mice fed the chronic– binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced and filtered using a 70-μm nylon cell strainer. Hepatocytes were centrifuged at 50g for 1 min after 3 washes. Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher,10,ALD patent background + target paper.pdf,266,True
5507af1caa99c80bdb1e3ffd8d38a71b,"Scientific). Hepatocytes (1.5 × 105) were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin–transferrin–selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics. After 4 h, the culture was washed with DMEM-F12 medium and changed to the same complemented medium without FBS58. Then 16 h later, hepato- cytes were cultured with",10,ALD patent background + target paper.pdf,267,True
1292a03a6d1e4234fb6c3a8ac7031c7a,"0 or 25 mM ethanol and stimulated with 0, 200 or 400 nM CylLS′′ and/or CylLL′′ in the same culture medium without FBS. After 3 h stimulation, hepatocyte cytotoxicity was assessed using Pierce LDH cytotoxicity detection kit (Thermo Fisher Scientific).",10,ALD patent background + target paper.pdf,268,False
ca53f71f2c8fcfc0f706ae94f8767245,Biochemical analysis,10,ALD patent background + target paper.pdf,269,False
a7c38a89a8698c16dd863b474932e67e,Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride,10,ALD patent background + target paper.pdf,270,True
526871f039a3574903a419da5dbe52cd,"Liquid Reagents kit (Pointe Scientific). Levels of serum lipopolysac- charide and faecal albumin were determined by enzyme-linked immu- nosorbent kits (Lifeome Biolabs and Bethyl Labs, respectively). Serum levels of ethanol were measured using ethanol assay kit (BioVision).",11,ALD patent background + target paper.pdf,271,False
3feedfdcf36c414c3f83ef80ceecc03e,Staining procedures,11,ALD patent background + target paper.pdf,272,False
d49b5f36c647dff9812e57563fc16120,"Formalin-fixed tissue samples were embedded in paraffin and stained with H & E. To determine lipid accumulation, liver sections were embed- ded in OCT compound. Eight-micrometre frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). Representative images from each group of mice are shown in each figure. The terminal deoxynucleo- tide transferase-mediated dUTP nick-end labelling (TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly",11,ALD patent background + target paper.pdf,273,True
95e1be95a5fc12714d11ba3fba2e3456,selected five high-power fields for counting TUNEL-positive cells and normalized numbers to total cells.,11,ALD patent background + target paper.pdf,274,False
d39206785cc747d4e6b9e368bd61fd38,Statistical analysis,11,ALD patent background + target paper.pdf,275,False
266821d571654b9cf819491e7ad4f506,"Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and multivariate Cox regression analysis was used to detect associations of cytolysin with overall mortality. The multivariate model was adjusted for geographical origin of the patients, antibiotic treat- ment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. Univariate logistic regression analysis of laboratory and clinical parameters associated with the detection of cytolysin and",11,ALD patent background + target paper.pdf,276,True
49a403ab85cf1287247d0dee3c6104d2,"E. faecalis was performed. Univariate linear regression analysis of labo- ratory and clinical parameters associated with the log-transformed total amount of faecal E. faecalis measured with qPCR was performed. To associate log-transformed total E. faecalis and E. faecalis positiv- ity with mortality, univariate Cox regression was used. P values from univariate and multivariate Cox regression, univariate logistic regres- sion and univariate linear regression were determined by Wald test.",11,ALD patent background + target paper.pdf,277,True
8d804e9fc95ed2db69557c927cb77778,"Multicollinearity was examined using the variance inflation factor. Kaplan–Meier curves were used to compare survival between cytolysin- positive and cytolysin-negative patients with alcoholic hepatitis. Faecal E. faecalis, bacterial diversity and richness from controls and patients were compared using Kruskal–Wallis test with Dunn’s post hoc test. Region- and/or centre-specific clinical characteristics of patients with alcoholic hepatitis were compared with Kruskal–Wallis test for continu- ous",11,ALD patent background + target paper.pdf,278,True
7b8dbc9af15bbcc3e361831b11ca9cb8,"and Fisher’s exact test for categorical variables. Faecal E. faecalis in patients with alcoholic hepatitis with or without cytolysin, and with or without cirrhosis, were compared with Mann–Whitney-Wilcoxon rank-sum test. Faecal E. faecalis in patients with alcoholic hepatitis from different region and/or centres were compared with the Kruskal– Wallis test. The percentage of subjects with faecal samples that were positive for E. faecalis and cytolysin was compared using Fisher’s exact test,",11,ALD patent background + target paper.pdf,279,True
f76e2fd0575907e2393cf2e9bac23226,"followed by FDR procedures for multiple group comparisons. Jaccard dissimilarity matrices were used for PCoA, and P values were determined by PERMANOVA followed by FDR procedures to correct for multiple comparisons.",11,ALD patent background + target paper.pdf,280,True
14e86a0ecd10b0bdc033d9707701e4ea,"For mouse and cell culture studies, the significance of multiple groups was evaluated using one-way or two-way ANOVA with Tukey’s post hoc test. Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for multiple comparisons. Kaplan–Meier curves were used to compare survival between experi- mental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed between experimental mouse groups and the P values were determined by PERMANOVA",11,ALD patent background + target paper.pdf,281,True
c050356c803ef939e49dfdec8c6a021d,followed by FDR procedures to cor- rect for multiple comparisons.,11,ALD patent background + target paper.pdf,282,False
32c2ea73902ed3c942e714bd6eee2331,"Exact P values for all comparisons, together with group size for each group, were listed in Supplementary Table 10. Statistical analyses were performed using R statistical software, R v.3.5.1 (R Foundation for Sta- tistical Computing) and GraphPad Prism v.6.01. A value of P < 0.05 was considered to be statistically significant (adjusted for multiple comparisons when performing multiple tests).",11,ALD patent background + target paper.pdf,283,True
20895efe9efe890b2b9c587c948f1fe3,Reporting summary,11,ALD patent background + target paper.pdf,284,False
413a85d9454a030f8e01ab89a18c5b53,Further information on research design is available in the Nature Research Reporting Summary linked to this paper.,11,ALD patent background + target paper.pdf,285,False
538ce29f229eacf5622b5aef07e0b1a8,Data availability,11,ALD patent background + target paper.pdf,286,False
1bea2d99c1de3a43e7eef19cff96d941,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSa- mple identifiers (SAMN11089809–SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at the ENA under study PRJEB25007.,11,ALD patent background + target paper.pdf,287,True
5da732bbf729e12797d9c8075e604ed5,Code availability,11,ALD patent background + target paper.pdf,288,False
0b827e4a9d34b276bf03e7156d0e8bbb,The PERL script for making the genetic maps of phage genomes can be found at https://github.com/JCVenterInstitute/LinearDisplay.,11,ALD patent background + target paper.pdf,289,False
baedfe40e4f269fca25eb42d92f10ef7,"30. Brandl, K. et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 69, 396–405 (2018).

31. Gao, B. et al. Serum and fecal oxylipins in patients with alcohol-related liver disease. Dig. Dis. Sci. 64, 1878–1892 (2019).

32. Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology (2019).",11,ALD patent background + target paper.pdf,290,False
38d13c6e9eec5033ef302b04ff0e5be2,"33. Ball, S. A., Tennen, H., Poling, J. C., Kranzler, H. R. & Rounsaville, B. J. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers. J. Abnorm. Psychol. 106, 545–553 (1997).",11,ALD patent background + target paper.pdf,291,False
5394a8c018c88ac0536804b7b2d6477f,"34. Krieg, L. et al. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood 118, 6418–6425 (2011).",11,ALD patent background + target paper.pdf,292,True
6f0fd3c395dada604d8ef5bb6ef5505d,"35. Gill, J. J. et al. The Caulobacter crescentus phage phiCbK: genomics of a canonical phage. BMC Genomics 13, 542 (2012).

36. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Completing bacterial genome assemblies with multiplex MinION sequencing. Microb. Genom. 3, e000132 (2017).

37. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLOS Comput. Biol. 13, e1005595 (2017).",11,ALD patent background + target paper.pdf,293,False
e35095589a38bb2d1ad40d1db0694bcd,"38. Walker, B. J. et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS ONE 9, e112963 (2014).",11,ALD patent background + target paper.pdf,294,False
6a088455c3d71db852d725bb45e9824b,"39. Santiago-Rodriguez, T. M. et al. Transcriptome analysis of bacteriophage communities in periodontal health and disease. BMC Genomics 16, 549 (2015).

40. Haft, D. H. et al. RefSeq: an update on prokaryotic genome annotation and curation. Nucleic Acids Res. 46, D851–D860 (2018).

41. Tatusova, T. et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 44, 6614–6624 (2016).",11,ALD patent background + target paper.pdf,295,False
754ab1e19f0033df93026c1210264067,"42. Fouts, D. E. Phage_Finder: automated identification and classification of prophage regions in complete bacterial genome sequences. Nucleic Acids Res. 34, 5839–5851 (2006).",11,ALD patent background + target paper.pdf,296,False
70fd2c91de5297438cf2c55d5a859454,"43. Ondov, B. D. et al. Mash: fast genome and metagenome distance estimation using MinHash. Genome Biol. 17, 132 (2016).",11,ALD patent background + target paper.pdf,297,False
3f17dba3585624b45708b6cdb2c1a58d,"44. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

45. Letunic, I. & Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242–W245 (2016).",11,ALD patent background + target paper.pdf,298,True
231bf0b3d610160fac5aa0581eb990db,"46. Valentine, R. C., Shapiro, B. M. & Stadtman, E. R. Regulation of glutamine synthetase. XII. Electron microscopy of the enzyme from Escherichia coli. Biochemistry 7, 2143–2152 (1968).",11,ALD patent background + target paper.pdf,299,False
ddd068bd6053537d2ab93629d00d2a75,"47. Haas, B. J. et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504 (2011).

48. Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc. Natl Acad. Sci. USA 108 (Suppl 1), 4516–4522 (2011).",11,ALD patent background + target paper.pdf,300,False
f4bb22faef5daa08533bf8dfbc9d210b,"49. Chen, P. et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203–214.e16 (2015).",11,ALD patent background + target paper.pdf,301,True
223f1fe9a83970a249e8e22ff65b69ca,"50. Ryu, H. et al. Development of quantitative PCR assays targeting the 16S rRNA genes of Enterococcus spp. and their application to the identification of enterococcus species in environmental samples. Appl. Environ. Microbiol. 79, 196–204 (2013).",11,ALD patent background + target paper.pdf,302,False
f3ca9cab4c8781f6a8d08e2ca546e7f5,"51. Haas, W., Shepard, B. D. & Gilmore, M. S. Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature 415, 84–87 (2002).",11,ALD patent background + target paper.pdf,303,False
835210699cb70f748cd752e3269d7eb5,"52. Page, A. J. et al. Robust high-throughput prokaryote de novo assembly and improvement pipeline for Illumina data. Microb. Genom. 2, e000083 (2016).",11,ALD patent background + target paper.pdf,304,False
e8b73b89a0e6cec54141fc9ebc2c1e82,"53. Chen, L. et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 33, D325–D328 (2005).

54. Jia, B. et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 45, D566–D573 (2017)",11,ALD patent background + target paper.pdf,305,False
1b0a633a64879c41d24bc0f8ff0d2b37,"55. Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068–2069 (2014).

56. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312–1313 (2014).",11,ALD patent background + target paper.pdf,306,False
74ddde87e79bc8420281120ba97dfa07,Article,12,ALD patent background + target paper.pdf,307,False
f124b103101de64fc996b147c774e243,"57. Tang, W., Bobeica, S. C., Wang, L. & van der Donk, W. A. CylA is a sequence-specific protease involved in toxin biosynthesis. J. Ind. Microbiol. Biotechnol. 46, 537–549 (2019).",12,ALD patent background + target paper.pdf,308,True
4b69bb9281dd161172990165d96744ee,"58. Iwaisako, K. et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc. Natl Acad. Sci. USA 109, E1369–E1376 (2012).",12,ALD patent background + target paper.pdf,309,False
a5745eb642d7583c5c59426d5a6b7625,"59. Clarke, T. H., Brinkac, L. M., Sutton, G. & Fouts, D. E. GGRaSP: a R-package for selecting representative genomes using Gaussian mixture models. Bioinformatics 34, 3032–3034 (2018).",12,ALD patent background + target paper.pdf,310,False
728722f46f7c405bc25df62602aec8b5,"Acknowledgements S. Lang was supported by a DFG fellowship (LA 4286/1-1), C.L. was supported by an AASLD Pinnacle Research Award in Liver Disease and a pilot project award from Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis (P50 AA011999), Y.S. was supported by a Wellcome Trust PhD studentship and I.R.R. was supported by National Institute of General Medical Sciences (NIGMS)–NIH Chemistry–Biology Interface Training Grant (T32-GM070421). This",12,ALD patent background + target paper.pdf,311,False
9c6ab862bc0fba078df83ec34d84e2df,"study was supported in part by a Biocodex Microbiota Foundation Grant, NIH grants R01 AA24726, U01 AA026939, by Award Number BX004594 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.), the Wellcome Trust (WT098051) (to T.D.L.), NIH grant U01AA021908 (to R.B.) and services provided by P30 DK120515 and P50 AA011999.",12,ALD patent background + target paper.pdf,312,False
87cd1514dd382222eaa9679135af1cec,"Author contributions Y.D. was responsible for acquisition, analysis and interpretation of data, and drafting of the manuscript; C.L. was responsible for study concept and design, acquisition,",12,ALD patent background + target paper.pdf,313,False
185b9ea67d68e949dd1a9b4978ad85c7,"analysis and interpretation of data and key preliminary experiments; S. Lang, K.B., J.L. and X.M.T. provided assistance with statistical analysis; H.C., L.J., B.G., W.S., R.K., F.H. and S. Lee provided assistance with data acquisition; R.C.W., T.H.C., K.N., M.T. and D.E.F. were responsible for 16S rRNA sequencing, phage genome sequencing and data analysis; Y.S. and T.D.L. were responsible for bacterial genome sequencing and data analysis; A.H.-M., L.L. and R.Y. provided assistance with phage",12,ALD patent background + target paper.pdf,314,True
92213ec4a7e96cd9bf6d19f09ab9c4d3,"studies and were responsible for electron microscopy data; R.Y. provided critical revision of the manuscript; I.R.R. and W.A.v.d.D. were responsible for cytolysin expression and purification; Y.M. and L.E. provided assistance with the design and conduct of the gnotobiotic mouse studies; M.L. and D.P. provided assistance with phage isolation; M.V.-C., F.B.-P., E.C.V., J.G.A., R.S.B. Jr, V.V., J.A., J.C., D.L.S., S.B.H., A.L., M.R.L., P.M., G.G.-T., R.B. and P.S. were responsible for collection of",12,ALD patent background + target paper.pdf,315,False
d0a90c4eded56b73265a47a840d38b92,"human samples; D.E.F. and B.S. were responsible for the study concept and design, and editing the manuscript; B.S. was responsible for study supervision.",12,ALD patent background + target paper.pdf,316,False
87fd9ef724034ebf3b7aab3789cd5ee0,"Competing interests B.S. consults for the Ferring Research Institute; however, there is no competing interest with regard to this study. All other authors declare no competing interests.",12,ALD patent background + target paper.pdf,317,False
c5b479abffcc520e53c53aa65f1b58eb,Additional information,12,ALD patent background + target paper.pdf,318,False
8c985f7329343cae9d62f8921757e702,Supplementary information is available for this paper at https://doi.org/10.1038/s41586-019- 1742-x.,12,ALD patent background + target paper.pdf,319,False
f080cbbd727dd8670cfbba040cf60182,Correspondence and requests for materials should be addressed to B.S.,12,ALD patent background + target paper.pdf,320,False
801fc86f4206d87d1dea2d19265ca464,Reprints and permissions information is available at http://www.nature.com/reprints.,12,ALD patent background + target paper.pdf,321,False
46c705e16cd763c9771436ac18f81264,[ - 00 Bacterial Genera Bacteroides Unclassified Lachnospiraceae Unclassified Ruminococcaceae 80 Veelllonella Akkermansia 70 Prevotella Blautia 60 Rosebuna Escherichia/Shigella Streptococcus 50 Unclassified Clostndiales 40 Dialister Faecalibacterium Clostndium_XiVa 30 Ruminococcus Enterococcus 20 Megasphaera Mogamonas Ruminococcus2 Relative sequence abundance (%) 10 Bifidobacterium | | = B Q=) = = - B: B ... [remaining 309 | Alcoholic Controls AUD hepatitis,13,ALD patent background + target paper.pdf,322,True
2b2c7cde73a85089f619ad212239dd0b,o Jede X % % % = N Shannon diversity Controls AUD Alcoholic hepatitis,13,ALD patent background + target paper.pdf,323,False
053164ae9a555b8ddb5d2e5630834386,Simpson diversity,13,ALD patent background + target paper.pdf,324,False
30b17e3b17bd5b4484846b4685a31a06,5,13,ALD patent background + target paper.pdf,325,False
540e250dc00a308fd985843148ea2c61,"o

o o",13,ALD patent background + target paper.pdf,326,False
2891f844a90e0847ee3d1f76367ba192,(=] »,13,ALD patent background + target paper.pdf,327,False
3d1f14a43c599c4245d9d7c44e2eb71c,"o N

o",13,ALD patent background + target paper.pdf,328,False
414ebf526d0852de3a5389f930face87,Controls,13,ALD patent background + target paper.pdf,329,False
474dd4794b96bb0b816dbf1558b4b2b1,k x,13,ALD patent background + target paper.pdf,330,False
f72a2b087bddbdfd6c9d5444c6e857bf,AUD,13,ALD patent background + target paper.pdf,331,False
44779d1e41e6f07b9121599a3659ec6b,"%

%",13,ALD patent background + target paper.pdf,332,False
1f2b2471e2c6e31ae783f50099c13f78,Alcoholic hepatitis,13,ALD patent background + target paper.pdf,333,False
1a272df7744d04e39ac25f18e319c1d6,Chao richness,13,ALD patent background + target paper.pdf,334,False
7311cf9e11c513d4d02eb5a562d8bdac,— de kK —,13,ALD patent background + target paper.pdf,335,False
906a73ded42dfb91bf804c6bcaeb6935,"10,000",13,ALD patent background + target paper.pdf,336,False
c091b8fe56de0ca64aed7171564d17a7,"& 8 oo =34

H» , =34 00",13,ALD patent background + target paper.pdf,337,False
4664825036a85ec110643dcc3fc108ff,w &,13,ALD patent background + target paper.pdf,338,False
8b77a40e9c6a234afca2f72ddf500331,"2,000

1,000",13,ALD patent background + target paper.pdf,339,False
48d049e77b772bcb849770102e4ec7c7,Controls,13,ALD patent background + target paper.pdf,340,False
8b0ecf7bfd2b062f25b8681d862de4bd,AUD,13,ALD patent background + target paper.pdf,341,False
17f02b7eb90fbe3ecb39d7b5fcbf4e2a,Ll ],13,ALD patent background + target paper.pdf,342,False
bf17fcd184fe9afb37dcc598d1f2058d,Alcoholic hepatitis,13,ALD patent background + target paper.pdf,343,False
8a0491b100ebdf74802992a9a7447ba4,"1.0 0.8 -] » -Cytolysin, AUC=0.81 Sensitivity -MELD, AUC=0.70 0.2 -ABIC, AUC=0.66 -DF, AUC=0.63 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1 - Specificity",13,ALD patent background + target paper.pdf,344,False
9d76049faf77396566f91e0d4907f9ff,"Enterococcus faecalis ek e K 150,000 * % 100,000 50,000 "" - 300 300 Relative abundance 100 100 . Controls AUD Alcoholic hepatitis

@@ E. faecalis negative [ E. faecalis positive 100 80 60 40 20 Percent subjects (%) Controls AUD Alcoholic hepatitis",13,ALD patent background + target paper.pdf,345,False
fea9cf9b896e4e67a30ddd8ae4c34c83,@@,13,ALD patent background + target paper.pdf,346,False
bc86e6842e9d05e4fdd6efb7c14907d3,[,13,ALD patent background + target paper.pdf,347,False
b1d7bfe620abf6007ff6464f429bde29,"0.50 France Mexico 0.25 Spain 0.00 UK { USA East PC2 (16.74%) USA Midwest 0.25 L 0000 USA West -0.4 -0.2 0.4 PC1 A%)

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) P & « ¥",13,ALD patent background + target paper.pdf,348,False
31ac83d1cd9cee0fcc651709f115bd33,@@,13,ALD patent background + target paper.pdf,349,False
fba65d6a6c9a5dab581897e73d0dc980,3,13,ALD patent background + target paper.pdf,350,False
8f52a72387708e40619f305a4187a09a,mm Cytolysin negative Bl Cytolysin positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis,13,ALD patent background + target paper.pdf,351,False
9ec064b1ee321d8b644d379916677d3d,mm,13,ALD patent background + target paper.pdf,352,False
c1c4a0b2cf913e2752e9c0b3b4dfeb52,Bl,13,ALD patent background + target paper.pdf,353,False
b4ddbdca2b1f073d23e39d2818537122,Extended Data Fig. 1 | See next page for caption.,13,ALD patent background + target paper.pdf,354,False
44b6d23e5a06d05eb660143d15fde751,"Enterococcus faecalis 150,000 100,000 - 50,000 - - —— — Relative abundance 1,000 0007 | | Cytolysin Cytolysin negative positive

Enterococcus faecalis 150,000 100,000 8 < g Relative abundance _ I - s & & Sl & R & o

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis",13,ALD patent background + target paper.pdf,355,False
f883fa5aa7a9a601d7d35f4dfd6cbb5c,@@,13,ALD patent background + target paper.pdf,356,False
6e68c847369e703f76904cfa8543c972,3,13,ALD patent background + target paper.pdf,357,False
8a68ae2eae6b154052ee904f7596fb84,Em Cytolysin negative Cytolysin positive s [ o =2 o o Percent subjects (%) S 2 & & W & X,13,ALD patent background + target paper.pdf,358,False
5d51aa9472407a0b4f1ea73bbbc9f495,Em,13,ALD patent background + target paper.pdf,359,False
fb6211b92146e08800e98f2ee8f0bd49,Enterococcus faecalis,13,ALD patent background + target paper.pdf,360,False
f7a6e8a30c4dc8ea3962054de350c70e,"80,000",13,ALD patent background + target paper.pdf,361,False
010b4fac6be7259184351cb5a4d08455,Relative abundance,13,ALD patent background + target paper.pdf,362,False
8630c085d2ed446de326cb8dce2149e3,"60,000

40,000

20,000",13,ALD patent background + target paper.pdf,363,False
8c9d213a5cb176e3d7bb32008b437d87,),13,ALD patent background + target paper.pdf,364,False
9d3615216d3d6a22d2fa5ea37faf334c,"Cirrhosis

Non- cirrhosis",13,ALD patent background + target paper.pdf,365,False
65aabf0d31484033f4407ab7f34b7cc0,Article,14,ALD patent background + target paper.pdf,366,False
3919263ca56eb9cac86f7a0ab5ec3306,"Extended Data Fig. 1 | Intestinal dysbiosis in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43), or alcoholic hepatitis (n = 75). The graph demonstrates the relative abundance of sequence reads in each genus. b, Bacterial diversity (Shannon index and Simpson index) and richness (Chao richness) was calculated in controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n =",14,ALD patent background + target paper.pdf,367,False
13c2eda700daeea7cfac4eeb693fd871,"75). c, E. faecalis in faecal samples from controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. d, Percentage of faecal samples positive for E. faecalis in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. E. faecalis was detected in faeces from 80% of patients with alcoholic hepatitis, versus 36% of controls (P < 0.001). There was also a significant difference between",14,ALD patent background + target paper.pdf,368,True
5a8966cb66560b2cf24e21445cc8fdc9,"patients with alcohol-use disorder and patients with alcoholic hepatitis (P < 0.01). e, Receiver operating characteristic curves and area under the curve (AUC) for the comparison of 90-day mortality and cytolysin positivity (red; n = 57), MELD score (blue; n = 56), ABIC score (yellow; n = 57) and discriminant function (green; n = 42) in patients with alcoholic hepatitis. f, E. faecalis in faecal samples from patients with alcoholic hepatitis whose faecal samples were cytolysin- positive (n = 25)",14,ALD patent background + target paper.pdf,369,False
c6c794005ed2c243b6b65bc3dfd034cf,"or cytolysin-negative (n = 54), assessed by qPCR (P = 0.8174). g, 16S rRNA sequencing of faecal samples from patients with alcoholic hepatitis from different centres (France, n = 9; Mexico, n = 6; Spain, n = 5; UK, n = 11; USA (east), n = 16; USA (Midwest), n = 12; USA (west), n = 16 patients). We used PCoA based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between patients from different",14,ALD patent background + target paper.pdf,370,True
04f8e25335c7c097cf73a9f4a4bbef35,"regions (P < 0.01). h, Percentage of faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin- positive), in patients with alcoholic hepatitis from different centres (France,",14,ALD patent background + target paper.pdf,371,True
7da79d03ad17fe213d7c088ae389b3ef,"n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest), n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.6094). i, E. faecalis in faecal samples from patients with alcoholic hepatitis from different centres, assessed by qPCR (P = 0.5648). j, Percentage of faecal samples that were positive for E. faecalis in patients with alcoholic hepatitis from different centres (France, n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest),",14,ALD patent background + target paper.pdf,372,False
b5ef9926d10662dcfece05cb8ad1f403,"n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.0529). k, Percentage of subjects with faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin-positive), in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.3431). l, E. faecalis in faecal samples from patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.5736). m, Percentage of faecal samples that were",14,ALD patent background + target paper.pdf,373,False
110198f4cecac26794a2b9b07553eeb2,"positive for E. faecalis in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.2878). Results are expressed as mean ± s.e.m. (c, f, i, l). For the box and whisker plots in b, the box extends from the 25th to 75th percentiles, and the centre line represents the median; for all three groups, the bottom whiskers show the minimum values; for the control group (black), the top whisker shows the maximum value; for the other two groups, the top",14,ALD patent background + target paper.pdf,374,True
fce98a9079b5963ef312b9f85de722b8,"whiskers represent the 75th percentile plus 1.5× the inter-quartile distance (the distance between the 25th and 75th percentiles); all values greater than this are plotted as individual dots. P values were determined by Kruskal– Wallis test (i) with Dunn’s post hoc test (b, c), two-sided Fisher’s exact test (h, j, k, m) followed by FDR procedures (d), two-sided Mann–Whitney Wilcoxon rank-sum test (f, l) or PERMANOVA (g). The exact group size (n) and P values for each comparison are listed in",14,ALD patent background + target paper.pdf,375,True
a17407200028b60545284e2af3f2a3f2,"Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",14,ALD patent background + target paper.pdf,376,False
b4f6b083e9349a260a261dfd4f715f31,"Serum ALT 400 k 300 200 100 o1 A o Control Ethanol

b u Fold change oo H Fod Control Ethanol",15,ALD patent background + target paper.pdf,377,False
b42b9c48b0d45b28a90e59f6d7ea0c3a,«,15,ALD patent background + target paper.pdf,378,False
904df34fb50d9bd36ee8572bac8991e7,« ~ E. faecalis Acytolysin —— E. faecalis 100 920 80 70 Log-rank test 60 (Mantel-Cox) Percent survival (%) P<0.05 50 10 Days,15,ALD patent background + target paper.pdf,379,False
58701960095396c4827c93bca3c0e44b,"~

——",15,ALD patent background + target paper.pdf,380,False
8ddd7cee2d820f53fbae639a503ff763,"Fecal albumin

Fecal albumin 400 30 - l ~ 200 10 [ [a] il Control Ethanol",15,ALD patent background + target paper.pdf,381,False
6005b7683a92ff10f921f03b8bd7eb2f,"Serum ethanol 1,000 [T} 800 ] S 600 g —— 400 200 Ethanol",15,ALD patent background + target paper.pdf,382,False
ad224e4d1872659c439a67fc228d56fa,Extended Data Fig. 2 | See next page for caption.,15,ALD patent background + target paper.pdf,383,False
7958a66d5675689df66c12035d590729,") Control 3 Y Ethanol PBS E. faecalis E. faecalis Acytolysin

Hepatic triglycerides PBS 40 W E. faecalis u B E. faecalis Acytolysin 30 L 20 10 oo [ =] i i Control Ethanol",15,ALD patent background + target paper.pdf,384,False
8e6ee81d15ad03b8dd6a9bdccc58f120,"Cxcl1 — Fold change oo e 18 [ o Control Ethanol

Liver cyLg 100 k k k, 80 60 40 Percent mice (%) 20 nd nd nd Control Ethanol

Serum LPS 60 k —— 40 [N (ng/ml) 20 Qo l 2 [on] Control Ethanol

Adht & S . P oo 1] 5 Fold change i S Control Ethanol

Cxcl2 x 10 L] Fold change [al Control Ethanol",15,ALD patent background + target paper.pdf,385,False
5675c304cff0c3865658e4041d913e4b,"Liver E. faecalis 100 © = = S = Percent mice (%) = nd Control Ethanol

Liver Enterococcus",15,ALD patent background + target paper.pdf,386,False
0eedbd1d2ecc10515fe6443e965dd3c8,"1,500",15,ALD patent background + target paper.pdf,387,False
865b04eafaf086a71881f006d7ded3f2,L],15,ALD patent background + target paper.pdf,388,False
4343c3bbe5e58502abe102d81cb902ba,"1,000

500",15,ALD patent background + target paper.pdf,389,False
0ee636ef9844e4e1d78f578ebf5efc2d,"Ethanol

0.50 PBS E. faecalis Control 0.25 ' E. faecalis Acytolysin PBS B E. faecalis Ethanol 0.00 ‘& B E. faecalis Acytolysin -0.25: -0.4 0.4 PC1 .)

Cyp2e1 25 2.0 - o - = Fold change 1F 0.0 Control Ethanol",15,ALD patent background + target paper.pdf,390,False
3f5f8ebe0b5190b981eb01bec6499a63,Fecal Enterococcus 1010 108 1 104 102 24 48 72 Time (hrs),15,ALD patent background + target paper.pdf,391,False
244639aae3fecfe62518d29f2ab3e9b1,Article,16,ALD patent background + target paper.pdf,392,False
0e2785b2ea6bb8fcf61be2758e65dd64,"Extended Data Fig. 2 | Cytolytic E. faecalis causes the progression of ethanol-induced liver disease in mice. a–n, C57BL/6 mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with vehicle (PBS), a cytolytic E. faecalis strain (FA2-2(pAM714)) (denoted E. faecalis) (5 × 108 CFUs) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5 (denoted E. faecalis Δcytolysin) (5 × 108 CFUs) every third day. a, Serum levels of ALT. b, Hepatic triglyceride content. c,",16,ALD patent background + target paper.pdf,393,False
a25ffe06483580a9c9d97d5e48597abb,"Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding). Mice gavaged with PBS all survived, and are not included in the figure. A higher proportion of mice (n = 15) gavaged with non-cytolytic E. faecalis survived than did mice (n = 25) gavaged with cytolytic E. faecalis. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR",16,ALD patent background + target paper.pdf,394,False
20f6fe0bca9889708ae041a56576eaac,"for cylLS (the gene that encodes cytolysin subunit CylLS′′). i, Proportions of mice that were positive for E. faecalis in the liver, measured by qPCR. About 80% of mice colonized with cytolytic E. faecalis, as well as those colonized with non- cytolytic E. faecalis, were positive for E. faecalis in their livers. j, Liver CFUs of Enterococcus in mice on a chronic–binge ethanol diet. k, Paracellular intestinal permeability was evaluated by measuring faecal albumin content and serum levels of",16,ALD patent background + target paper.pdf,395,False
550684485674072abafcf4f167f8b82d,"lipopolysaccharide (LPS) by enzyme-linked immunosorbent assays. l, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices showed no significant differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following",16,ALD patent background + target paper.pdf,396,True
064f217c6f689fd99666e16faa4d30e3,"feeding with the control and ethanol diets. Compared to mice fed with a control diet, mice fed with an ethanol diet had significantly different faecal microbiomes after gavaging with E. faecalis (P < 0.05). m, n, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis after ethanol feeding. o, Mice were gavaged with cytolytic or non- cytolytic E. faecalis strains (carrying the",16,ALD patent background + target paper.pdf,397,True
f3de804e37dd92a77be6a081d904b203,"erythromycin resistance gene; 5 × 108 CFUs) at time 0, and faeces were collected 0, 8, 24, 48 and 72 h later. Faecal CFUs of Enterococcus were determined by culturing faecal samples on BBL enterococcosel broth agar plate with 50 μg ml-1 erythromycin. At time 0 and 72 h, five out of five and four out of five mice, respectively, had no detectable erythromycin-resistant Enterococcus in their faeces. These points are not shown on the graph, but have been included in the calculation of mean ± s.e.m.",16,ALD patent background + target paper.pdf,398,True
678fd25842a32d15af88e49a916e3396,"Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, j, k, m–o). P values among groups of mice fed with the control or ethanol diet were determined by one-way ANOVA with Tukey’s post hoc test (a, b, d–f, j, k, m, n), two-sided log-rank (Mantel–Cox) test (g), two-sided Fisher’s exact test followed by FDR procedures (h, i) or PERMANOVA followed by FDR procedures (l). All results were generated from at least three independent replicates. The exact group size (n) and P values for",16,ALD patent background + target paper.pdf,399,False
cc1254c2ed66b0763812d016ff8c63ca,"each comparison are listed in Supplementary Table 10. P values between mice fed with a control diet and mice fed with an ethanol diet were determined by two-way ANOVA (k). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",16,ALD patent background + target paper.pdf,400,False
66a5c17e414f00a8c6cbd4f18aef4db9,"TUNEL AH cytolysin positive #1 r AH cytolysin positive #2 AH cytolysin negative #3 [N AH cytolysin negative #4 Percent positive (%) i il l 1l Control Ethanol

R Control . 3 /3% ¥ Ethanol F R o Ve, AH cytolysin AH cytolysin AH cytolysin AH cytolysin positive #1 positive #2 negative #3 negative #4

Cxcl2 Fold change - o oo 3 i Control Ethanol

Acta2 10 Fold change Control Ethanol",17,ALD patent background + target paper.pdf,401,True
3223f30ed37315d8a4b20a1212176138,"AH Cytolysin negative AH Cytolysin positive "" 0 90; 80; 70 Log-rank test 60; (Mantel-Cox) Percent survival (%) P<0.05 50 2 10 Days

AH cytolysin positive #1 AH cytolysin positive #2 Control | AH cytolysin negative #3 ] AH cytolysin negative #4 H PC2 (24.13%) & 05 '..",17,ALD patent background + target paper.pdf,402,False
b5a5cdda47a2a098ee1b520b1c9c9729,"|

]",17,ALD patent background + target paper.pdf,403,False
d2bbabd87e48ba7675f3327f1659544a,"0.4- AH cytolysin pos ive #1 AH cytolysin posi #2 I Ethanol AH cytolysin negative #3 AH cytolysin negative #4 g [mmm|m i PC2 (22.82%) 1 A S | | y/ y 0. 02 0. Be (51%)

Cytolysin positive E. faecalis a 8 3 2 8 8 Percent colonies (%) nd nd o Patient Patient Patient Patient #1 # #3 # AH ¢y lysin AH cytolysin po: negative",17,ALD patent background + target paper.pdf,404,False
324c6381659d7efd354d8809231fdf2c,"Serum ethanol 1,000 800 600 400 - 200 Ethanol",17,ALD patent background + target paper.pdf,405,False
e5615af7c2c89de057ba25226f47e397,"Extended Data Fig. 3 | Transplantation of cytolysin-positive faeces increases ethanol-induced liver disease in gnotobiotic mice. a–f, h, i, C57BL/6 germ- free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and then fed isocaloric (control) or chronic–binge ethanol diets. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the",17,ALD patent background + target paper.pdf,406,False
af5a1aaba0134c1579fbfd8b1ba4b214,"inflammatory cytokine Cxcl2 and Acta2 (a marker of activated hepatic stellate cells). e, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding), gavaged with faeces from cytolysin-positive (n = 48 mice) or cytolysin-negative (n = 32 mice) patients with alcoholic hepatitis. f, Faecal samples were collected and 16S rRNA genes were sequenced. The graph shows PCoA of faecal microbiomes. No significant difference was observed between mice",17,ALD patent background + target paper.pdf,407,False
ff9d64831d16a0ded96ff2e6dbab66ca,"colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, following the control diet. Mice transplanted with faeces from a cytolysin-positive patient with alcoholic hepatitis (patient",17,ALD patent background + target paper.pdf,408,True
b36c1b741488ef2643a6003250c15651,Ad1 Cyp2et 2.5 2.0 2.0 - 1.5 o 15 e o - % . 1.0{ H - 1.0 H Fold change Fold change 0.5: = W 0.5: 0.0 il 0.0 Control Ethanol Control Ethanol,17,ALD patent background + target paper.pdf,409,False
8a092a9fc4f0f2e603dc4aec6e5ebda3,"no. 2) showed a microbiota that was significantly different to that of the other mouse groups following ethanol administration (P < 0.01). g, Percentage of cytolysin-positive E. faecalis in four patients with alcoholic hepatitis. Stool samples from the four patients were placed on plates with selective medium, and Enterococcus colonies were identified by the production of a dark brown or black colour. Enterococcus colonies were confirmed to be E. faecalis by qPCR. The cytolysin status of each E.",17,ALD patent background + target paper.pdf,410,True
9583ee1332d78f68cfb6cb2efb9030b1,"faecalis colony was determined by qPCR. h, Serum levels of ethanol were comparable among colonized mice after ethanol feeding. i, Hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice on control or ethanol diets. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, h, i). P values were determined by one-way ANOVA with Tukey’s post hoc test (a, c, d, h, i), two- sided log-rank (Mantel–Cox) test (e) or PERMANOVA followed by FDR procedures (f). All",17,ALD patent background + target paper.pdf,411,False
4a5bb1e756991a1edd43066e311c2280,"results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001.",17,ALD patent background + target paper.pdf,412,True
92b53e4a0604ff8f5eb56bdcc57efe3c,Article,18,ALD patent background + target paper.pdf,413,False
7685edd1a6f2798486848d3a1a0c112f,"a Head s v % | . 2 | % o . Tail Siphophage Myophage Podophage (long, flexible, (contractile tail) (short, noncontractile tail) noncontractile tail) S5 or ¥ @ ¥ % Efmus1 Efmus2 Efmus3 Efm us4 Efmus1 (17,927 bp) y b Efmus2 (18,366 bp) Efmus3 (18,286 bp) T SN Efmus4 (18,186 bp) D ol | encapsidation/terminase [ tail fiber DNA polymerase | [l endolysin/lysin | I hypothetical protein - major capsid [ tail components [ DNA binding intron/intein [ holin Il ortal",18,ALD patent background + target paper.pdf,414,True
5ba2c443e670dc5f792737949c3768f3,"Head

Tail",18,ALD patent background + target paper.pdf,415,False
fc00eabbdfe3a5d28e64ed2c6348661c,major capsid,18,ALD patent background + target paper.pdf,416,False
0a471dd183faa7287d48fc6647cb111d,"[

[

[",18,ALD patent background + target paper.pdf,417,False
fff155ad52d6712e2b72101c54253fbc,Il,18,ALD patent background + target paper.pdf,418,False
99d5b137eee6472c133aea06d6e0d470,ortal,18,ALD patent background + target paper.pdf,419,False
cff5e75f554195cd18cc432c1f904e6a,"Extended Data Fig. 4 | Isolation and amplification of phages against cytolytic E. faecalis isolated from mice. a, BHI agar plate showing phage plaque morphology. The phage cocktail (100 μl) (102–103 PFUs) was mixed with overnight-grown E. faecalis culture (100 μl) and then added to BHI broth top agar (0.5% agar) and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, images were captured on an Epson Perfection 4990 Photo scanner. b, Simplified illustration of the morphologies",18,ALD patent background + target paper.pdf,420,False
ea3deba3d301bf8a6784ed14a0631485,"of different phages. Siphophages have long, flexible noncontractile tails (left); myophages have contractile tails",18,ALD patent background + target paper.pdf,421,False
ba18e429ca55ff5b56d134b2a7f065b3,"(middle); and podophages have short noncontractile tails (right). c, Transmission electron microscopy revealed that phages we isolated were all podophages (Efmus1, Efmus2, Efmus3 and Efmus4). d, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories.",18,ALD patent background + target paper.pdf,422,False
dec71488ac36d4808c0933a8cb6c22a7,"Scale bar, 50 nm. All results were generated from at least three independent replicates.",18,ALD patent background + target paper.pdf,423,False
07050f0ff43493f216963888170f3067,"Serum ALT 500 — 400 ~300 200 - 100 ll WT II WT Atpas Control Ethanol

Hepatic triglycerides PBS C. crescentus phages 60 E. faecalis phages PBS C. crescentus phages EEEE E. faecalis phages '. i WT WT I/I Control Ethanol

S =y 5 Control "" | ey 3 - 3 Ethanol > R - 2 e PBS C. crescentus phages E. faecalis phages PBS C. crescentus phages E. faecalis phages WT Atp4ass

Cxcl1 15 es — e, 10 .- ""~ Fold change - o M | i WT WT /I Control Ethanol",19,ALD patent background + target paper.pdf,424,True
cfd6f71d41302ad17e0349d23f3478de,"Cxcl2 pes 3 — i - o - =3 Fold change ] . H - _ B L & WT I/ WT Control Ethanol

Liver cylLg 100 — s i 8 3 ] Percent mice (%) 8 2 nd o 3 /I WT / Control Ethanol

b S — e - o - o Fold change 5 SUs WT Atpda WT A Control Ethanol

Fecal Enterococcus 1010 10° 2108 108 10% il | 104 WT / WT / Control Ethanol

PBS a C. crescentus phages o8 E. faecalis phages o o & > Control PBS (10.08%) ] C. crescentus phages Atpdassi PC2 E. faecalis phages -1.0 4 17.1) 0",19,ALD patent background + target paper.pdf,425,True
d1e5b319b3409afe9fe7a57832c18e62,Serum ethanol,19,ALD patent background + target paper.pdf,426,False
6a9b53066605475f1336cf851dacdfe8,Adh1,19,ALD patent background + target paper.pdf,427,False
20abf38e55008d68044fd40473feb3b7,"800

600

400",19,ALD patent background + target paper.pdf,428,False
63df6a1f3c90137cb9c173df706ea4ea,20,19,ALD patent background + target paper.pdf,429,False
ae5b7428da71c892c4661ae8ddfa7ece,o S il i,19,ALD patent background + target paper.pdf,430,False
f03c7a7a1cf49350b3dcdac8910093f8,Fold change,19,ALD patent background + target paper.pdf,431,False
22315b4230922fa690c75b970c31d648,H,19,ALD patent background + target paper.pdf,432,False
a2979c91536f7440bf1a001ead675600,"I I

|

:",19,ALD patent background + target paper.pdf,433,False
942c826ff6d10f79e15829a1b934b577,WT,19,ALD patent background + target paper.pdf,434,False
8e919d0c66136a2fe604771856bef652,II,19,ALD patent background + target paper.pdf,435,False
59d17cdef09e5f2ff2b2c8cf0826b0c1,"WT

WT",19,ALD patent background + target paper.pdf,436,False
344ad24dbf5fb114282cb57d44ce1de3,/s,19,ALD patent background + target paper.pdf,437,False
52dfa4d0288b74906fba364b1c88347e,Ethanol,19,ALD patent background + target paper.pdf,438,False
69602007880a5e3baab9541e1906b935,Control,19,ALD patent background + target paper.pdf,439,False
c93657badc3fd11f19631e74fba44d37,Ethanol,19,ALD patent background + target paper.pdf,440,False
d320f1de19ea599a044cbc89feef8edd,Extended Data Fig. 5 | See next page for caption.,19,ALD patent background + target paper.pdf,441,False
5fd879f6cfb7204a19e24ed00a15d34f,"2 PBS C. crescentus phages WT 5 E. faecalis phages Ethanol PBS g (17.92%) C. crescentus phages Atpdasus PC2 E. faecalis phages B 0.4 0 5 PC1 'z.

Cyp2e1 S = - S P = 1.0 B Fold change 0.5 il I i 0.0 WT wT I I/I Control Ethanol",19,ALD patent background + target paper.pdf,442,False
8529d78db4cfda8acfe9f6d5a801f281,Article,20,ALD patent background + target paper.pdf,443,False
251a57bd201671dfa7051e175f12a942,"Extended Data Fig. 5 | Phages reduce translocation of cytolysin to the liver and reduce ethanol-induced liver disease in Atp4aSl/Sl mice. a–k, Wild-type (WT) and Atp4aSl/Sl littermates were fed oral isocaloric (control) or chronic– binge ethanol diets, and gavaged with vehicle (PBS), control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. a, Serum levels of ALT. b, Hepatic triglyceride",20,ALD patent background + target paper.pdf,444,False
9a8375ca91f81ed22aee38162e8e3aea,"content. c, Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Faecal CFUs of Enterococcus. i, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant",20,ALD patent background + target paper.pdf,445,False
de00ac12aa0e7be4da5736f4f59ef571,"difference in faecal microbiota among mice given PBS, control phage or phages that target cytolytic E. faecalis in each group. j, k, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h, j, k). P values were determined by two-way ANOVA with Tukey’s post hoc test (a, b, d–f, h, j, k), two-sided Fisher’s exact test followed by FDR",20,ALD patent background + target paper.pdf,446,False
97eea067db56287109cd9915c89a6f7c,"procedures (g) or PERMANOVA followed by FDR procedures (i). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",20,ALD patent background + target paper.pdf,447,True
6f3e50c4b9906a218faf67bacc81e5f5,<. 2. - 8s °s - Ef5 Ef2,21,ALD patent background + target paper.pdf,448,False
6732d98ddb71f08ec4cdd648f47f85a9,Ef2.1,21,ALD patent background + target paper.pdf,449,False
cb06323014af01f332d7889709d322e4,Ef2.3,21,ALD patent background + target paper.pdf,450,False
d9d851e2342951de959914430e46830b,"Ef5.1 F)- ) ) o l ) ) o (41,141 bp) Ef5.2 (41,418 bp) ) b o s i D Ef5.3 F)- b ) o ol e ) ) (39,115 bp) Ef5.4 (41,141 bp) W) e om Ef2.1 (140,938 bp) PP o ) ) s o ) ) o D DO O OO 0 0 ¢ Ef2.2 ( W W (58,400 bp) L Ef2.3 i oo ) ) o (147,289 bp) ) ) m) m) o m m Capsid structural components Tail and baseplate and assembly assembly [ encapsidation/terminase [ tail fibers - DNA polymerase - endolysin/lysin - hypothetical protein (] major capsid - tail component [ DNA binding I holin intron/intein I rortal",21,ALD patent background + target paper.pdf,451,True
632d7112d59fbbb3227bd5a9ba56d5c5,[ tail measure DNA recombination | regulatory [ protease (scaffold protein) I salvage of [ transcription factor nucleosides and Il other nucleotides | other known functions ] DNA restriction/ modification e tRNA || nucleotide degradation,21,ALD patent background + target paper.pdf,452,False
ca2ff0493a7859cbf26c64fc7c83a7b6,"Extended Data Fig. 6 | Isolation and amplification of phages against cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Transmission electron microscopy graphs of myophages Ef2.1 and Ef2.3, stained with phosphotungstic acid showing contracted tails. c, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage",21,ALD patent background + target paper.pdf,453,False
14fc8bbb7f38a8f10590590030b2c092,"genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. Scale bar, 50 nm. All results were generated from at least three independent replicates.",21,ALD patent background + target paper.pdf,454,False
ec8c9e5d7db71cc96bd36acda0ce8b90,"Article

a",22,ALD patent background + target paper.pdf,455,False
cd3bd91d5a5ca35c7291b3382fc225fc,"TUNEL C. crescentus phages Cytolysin-positive E. faecalis phages K k C. crescentus phages EE Cytolysin-positive E. faecalis phages Percent positive (%) Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

o e Control e A o ] Ethanol C. crescentus phages Cytolysin-positive C. crescentus phages ylin- ive E. faecalis phages E. faecalis phages Patient #5 Patient #2",22,ALD patent background + target paper.pdf,456,False
60625ff8a0b5576570aa2d313d373046,"Patient #2

Cxcl2 [T "" Fold change o H al Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,ALD patent background + target paper.pdf,457,False
db6af0b67489cfe3893bf1a5c56fe40b,"Acta2 10 I Fold change y B o H ¥ Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Fecal Enterococcus 1010 10° 2108 O 107 108 108 | Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Control C. crescentus phages 5 Cytolysin-positive E. faecalis phages | Patient #5 =) o C. crescentus phages Cytolysin-positive E. faecalis phages I Patient #2 =] o PC2 (7.13%) -0.5 -1.0 -0.5 c (80.98%) 0",22,ALD patent background + target paper.pdf,458,False
d7bafceb9012693c07d5bacb83e3fc01,"Ethanol C. crescentus phages 0.25 Cytolysin-positive E. faecalis phages Patient #5 C. crescentus phages Patient #2 LILILIL Cytolysin-positive E. faecalis phages PC2 (16.3%) -0.25 0.25 1.)

Serum ethanol 800 60 = 400 20 Patient Patient #5 #2 Ethanol

Adh1 2.0 - o oo o - ] Fold change 0.5 . 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,ALD patent background + target paper.pdf,459,False
d5687c084a4f242b36fdbdc997e9c530,"Extended Data Fig. 7 | Phages that target cytolytic E. faecalis reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (faeces from one patient were also used in Fig. 2). The mice were then fed oral isocaloric (control) or chronic–binge ethanol diets, and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of 3 or 4 different phages that target cytolytic",22,ALD patent background + target paper.pdf,460,False
bfb42bb260db14eb789fdd8600f0885d,"E. faecalis (1010 PFUs), one day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Faecal CFUs of Enterococcus. f, Faecal samples were",22,ALD patent background + target paper.pdf,461,False
990f5abd435071845b4a5bb7f9a1ae4d,Cyp2e1 s = o Oo T - = o Fold change 0.5 | 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol,22,ALD patent background + target paper.pdf,462,False
5e65bb528a0462abbeb41d6fda397cb8,"collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices shows no significant differences in the faecal microbiota of mice gavaged with control phage and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c–e, g, h). P values were determined by two-way",22,ALD patent background + target paper.pdf,463,True
3dcba7887dc4bafcba4fee83e5039e68,"ANOVA with Tukey’s post hoc test (a, c–e, g, h) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, ***P < 0.001.",22,ALD patent background + target paper.pdf,464,True
e56821eab81d0fc071508d7c191c7b80,"%, H % % 84 S X %3 s y 3 3 g H £ S & X3 2 & F o %, 8% , o o Yo, s, 5 2. & e, & B, By ® N ) S <1 G %, A 2. g5eC f54 PhiM1E, fal Ef6 VB-EfaM-£f23 vB-EfaSEf PhiEF17H. PMBT2 B-EfaM-Ef2.1 -vB-EfaS-Ef5.2 iEF24C P2 Si r , EfaP_igg KA s A S S, 103 & 253 o o, 62 ¥ & S, S, - kN N & %, G [ Siphoviridae P ne 5 % & § N N g3 & N % Podoviridae k) Ef7 B Myoviridae Tree scale: 1",23,ALD patent background + target paper.pdf,465,False
36746146626a68c1869d333cae1ffd69,"Ef6.1 ) b e o 4 (40,429 bp) Ef6.2 (17,966 bp) ) o Ef6.3 ) o (18,136 bp) Ef6.4 s ) o (41,133 bp) Ef7.1 D ) | (58,018 bp) - Ef7.2 1 ) o s (18,737 bp) Ef7.3 oo (18,818 bp) Ef7.4 (18,415 bp) C apsid structural components Other N and assembly || encapsidation/terminase [ tail fibers - DNA polymerase [ endolysin/ysin | [ hypothetical protein - tail component I intron/intein major capsid [ DNA binding [ holin I portal [ tail measure [ regulatory DNA recombination [l protease (scaffold protein) I",23,ALD patent background + target paper.pdf,466,True
d303711fd5e54e319fbbb615871757a0,salvage of RNA l other nucleosides and nucleotides [ DNA restriction/ modification (| nucleotide degradation,23,ALD patent background + target paper.pdf,467,False
bd5b3e2ba159f02832aaf7e04052ac13,Extended Data Fig. 8 | See next page for caption.,23,ALD patent background + target paper.pdf,468,False
15c686ef219e640d44797543b729ca56,Article,24,ALD patent background + target paper.pdf,469,False
7734dffb61c7174f1d28546501855c34,"Extended Data Fig. 8 | Isolation and amplification of phages against non- cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional",24,ALD patent background + target paper.pdf,470,False
9684cf995def83f21282c53411f39630,"role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. c, Phylogenetic tree of Enterococcus phages. A whole-genome average nucleotide distance tree was constructed for 73 available Enterococcus phage genomes: 54 of these were",24,ALD patent background + target paper.pdf,471,False
045bb667bb02c256e39972e6453647d8,from GenBank (denoted by black letters) and 19 were from this study (4 phages against cytolysin-positive E. faecalis isolated from mice (shown in blue letters); 7 phages against cytolysin-positive E. faecalis isolated from patients with alcoholic hepatitis (shown in pink letters); and 8 phages against cytolysin- negative E. faecalis isolated from patients with alcoholic hepatitis (shown in green letters)) with Mash43 using a sketch size of s = 5000 and a k-mer size of k = 12 and GGRaSP59,24,ALD patent background + target paper.pdf,472,True
8f3bc226826ffa26427dd375d96dbf81,"(Methods). Coloured branches denote specific phage genera or subfamily: Sap6virus, P68virus and Spounavirinae. The scale bar represents per cent average nucleotide divergence. All results were generated from at least three independent replicates.",24,ALD patent background + target paper.pdf,473,False
cbdef8a8f27333dcc05547a3f2e39985,TUNEL C. crescentus phages Cytolysin-negative E. faecalis phages C. crescentus phages L B | Cytolysin-negative E. faecalis phages Percent positive (%) | Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,474,False
1368e7b41b26d7f7a990555a69d20095,|,25,ALD patent background + target paper.pdf,475,False
4cfd00ef0efa5bdc27497da63c2557c4,"o o Control 2 . “ . L ‘ ok - -4 & l Ethanol 3 4 C. crescentus phages lyioiv C. crescentus phages lyin- ve E. faecalis phages E. faecalis phages Patient #6 Patient #7

Cxcl2 L] L oo Fold change 0 ] i Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol

Acta2 Ll Fold change T l ] g i Patient Patient Patient Patient #6 H#7 #6 H7 Control Ethanol

Liver cylLg 100 =3 =3 o o B o Percent mice (%) =3 nd nd nd nd nd nd nd nd [ Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol",25,ALD patent background + target paper.pdf,476,False
f8ab596b0e4d1fad49ecc15a595e4570,Control,25,ALD patent background + target paper.pdf,477,False
87eb08b389fe482e1c2c91f83d1b7139,Ethanol,25,ALD patent background + target paper.pdf,478,False
3339a5608a94dffc480710212d1278bb,"Control 1.0 C. crescentus phages g Cytolysin-positive E. faecalis phages | Patient #6 2 C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #7 g ] PC2 (19.54%) -0.5 -1.0 -1.0 1.0 PC1

Ethanol . - C. crescentus phages Cytolysin-positive E. faecalis phages Patient #6 0. C. crescentus phages u|| Cytolysin-positive E. faecalis phages Patient #7 0.0 PC2 (15.2%) -0.3 -0.2 0.2 0.50 (.)

Serum ethanol 1,000 800 (1] 600 I (mg/dl) 400 200 Patient Patient #6 #7 Ethanol",25,ALD patent background + target paper.pdf,479,True
332df11e6b212d3035a69c71ea0865cf,Adh1 25 20 - LT - Fold change & S Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,480,False
e082f2210f85b74bb74f09ffc7ad7d30,"Extended Data Fig. 9 | Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages targeting non-cytolytic E. faecalis (1010 PFUs),",25,ALD patent background + target paper.pdf,481,True
7685b742c8dacbe399d857540289a192,"1 day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. f, Faecal samples were collected and 16S rRNA",25,ALD patent background + target paper.pdf,482,False
c3f99829b15e4a01973877a3f5b78a8f,Cyp2e1 25 2.0 O - e - o Fold change = o Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,483,False
1d7af732e5a50753c3d4a4b86ee5665e,"genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant difference in faecal microbiota among mice gavaged with control phages and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, g, h). P values were determined by two-way ANOVA with Tukey’s post",25,ALD patent background + target paper.pdf,484,True
b9bbd412a629bc8d0ed6fbdbc73d0fb3,"hoc test (a, c, d, g, h), two-sided Fisher’s exact test followed by FDR procedures (e) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",25,ALD patent background + target paper.pdf,485,False
fe77b74c0db0141a1b726159c1df4f62,natureresearch,26,ALD patent background + target paper.pdf,486,False
d2b0adfb1e59aca0688bb9c981ee8c71,Reporting Summary,26,ALD patent background + target paper.pdf,487,False
77b2051064438668626de2b377d56c79,"Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.",26,ALD patent background + target paper.pdf,488,False
7f043129783e9ebdd43415f9e8d44ef9,Statistics,26,ALD patent background + target paper.pdf,489,False
a59fceee82250b70b476ce79598c3840,"For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described",26,ALD patent background + target paper.pdf,490,True
7283176899e9359a7761c62c0e8578cd,"solely by name; describe more complex techniques in the Methods section. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis",26,ALD patent background + target paper.pdf,491,True
744b1ea1b50d5157015a0ccb020f44ff,"testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated",26,ALD patent background + target paper.pdf,492,True
1143ba3a1f4b39452ffb4a1874006eb0,Our web collection on statistics for biologists contains articles on many of the points above.,26,ALD patent background + target paper.pdf,493,False
3b67389966c555e3abe89f45bab1e931,"Software and code

Policy information about availability of computer code",26,ALD patent background + target paper.pdf,494,False
dac4bbe82e53ce41122430ac09e2b09f,Data collection All biochemical assays were measured using SoftMax Pro 7.0.3; gPCRs were run with StepOnePlus real-time PCR system; Liver histological pictures were taken with DP Controller and DP Manager (Olympus); Phage electronic microscopy pictures were taken using Maxim DL5; Plates were scanned using EPSON 4990 Photo; All pictures were viewed using Image,26,ALD patent background + target paper.pdf,495,False
1935a40d230fed96831e2809d1db8109,Data analysis,26,ALD patent background + target paper.pdf,496,False
59cb227458d0170c095d9a964b471e9c,"Bacteriophage sequencing and phage tree: Albacore v2.3.4 (ONT), Porechop v0.2.3, Unicycler v0.4.7 pipeline, Pilon v1.22, CLC Genomics Workbench 4.9, NCBI Prokaryotic Genome Annotation Pipeline, in-house PERL script using Xfig, Phage_Finder, MASH program, GGRaSP and APE R-package, iTOL tree viewer 16S sequencing: MOTHUR-based 16S rDNA analysis workflow E. faecalis genome sequencing and tree: abricate v0.8.10 , Prokka, Roary, RAXML, iTOL Statistical analyses: R",26,ALD patent background + target paper.pdf,497,True
3fce177312421169ff9ea853c344b69b,"statistical software 3.5.1, GraphPad Prism v6.01",26,ALD patent background + target paper.pdf,498,False
db919547ce2b2fb8114099bdb5949cb6,"For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",26,ALD patent background + target paper.pdf,499,True
4598ab42b4ffa38be6d03c1bd3be18c9,"Data

Policy information about availability of data",26,ALD patent background + target paper.pdf,500,False
02eed19603761eb3a5a1bfcd12f13125,"All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets",26,ALD patent background + target paper.pdf,501,True
cf22d75f60f3dee1281945fdc0c21bb4,- A list of figures that have associated raw data,26,ALD patent background + target paper.pdf,502,False
39043b7d94c31ef62236577d78eca663,- A description of any restrictions on data availability,26,ALD patent background + target paper.pdf,503,False
da692ddd31c3de12249645eb02db0c94,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Bacteriophage raw sequence reads and annotated genomes are,26,ALD patent background + target paper.pdf,504,False
242d1f5339cab833978c9ac28f94bfd5,Corresponding author(s): Bernd Schnabl,26,ALD patent background + target paper.pdf,505,False
c6c3f3441c9dcda5311237650ede6039,"Last updated by author(s): Sep 5, 2019",26,ALD patent background + target paper.pdf,506,False
1c8f855b4911e63523887baa395996ad,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 1,26,ALD patent background + target paper.pdf,507,False
83791a2c67b42e2b3d1b1394bc0f3a9d,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 2,27,ALD patent background + target paper.pdf,508,False
a45bda3b81483a87565a5c5d14f72869,available at NCBI under the following consecutive BioSample IDs (SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at ENA under Study PRJEB25007.,27,ALD patent background + target paper.pdf,509,True
6cfd21a395bcd6e3f4eaba77ae4b5df3,Field-specific reporting,27,ALD patent background + target paper.pdf,510,False
6ea03404d04de76df42adba19a97d1f7,"Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf",27,ALD patent background + target paper.pdf,511,False
fb8346b41da7b2783265e16ff7670267,Life sciences study design,27,ALD patent background + target paper.pdf,512,False
e191f760ebd1bb86366aaf5274f6b401,All studies must disclose on these points even when the disclosure is negative.,27,ALD patent background + target paper.pdf,513,False
1782d002a5db530f4f0491d834b12409,"Sample size No power analyses or other calculations were used to predetermine sample sizes. Sample sizes were chosen based on prior literature using similar experimental paradigms (Nat Commun. 2017;8:2137; Gut. 2019;68:1504-1515) Data exclusions No data were excluded Replication In vivo experiments: more than two technical replicates (from different cohorts, on different dates), as well as biological replicates were performed to ensure data reproducibility; In vitro experiments: three",27,ALD patent background + target paper.pdf,514,True
31287eec58409495d16539420bfe7d0f,independent experiments and also replicates were performed on different dates to ensure data reproducibility. All replications were successful. Randomization Mice of similar age and weight were randomly assigned to experimental and control groups. Blinding The investigators were not blinded during cell and animal experiment assays.,27,ALD patent background + target paper.pdf,515,True
dbe3dc6363295054617f7cb56083d632,"Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.",27,ALD patent background + target paper.pdf,516,False
6b81c4664da8790749e844ead5ba05fc,Methods n/a Involved in the study Antibodies ChIP-seq Eukaryotic cell lines Flow cytometry Palaeontology MRI-based neuroimaging Animals and other organisms Human research participants Clinical data,27,ALD patent background + target paper.pdf,517,False
3de50d4ad769fe5bd196c54c4f7b069f,Animals and other organisms,27,ALD patent background + target paper.pdf,518,False
ad97ec75cb11f35e0af9b99afc5d73bc,"Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Female and male C57BL/6 mice (age, 9-12 weeks) (strain: wild type, Atpdasl/sl) Wild animals No wild animals were involved in the study. Field-collected samples No field-collected samples were involved in the study",27,ALD patent background + target paper.pdf,519,False
2a5b0b192987cbbcb213e79f0f5b91fc,"Ethics oversight All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.",27,ALD patent background + target paper.pdf,520,True
881e496cb267d9dc466d9f995ce715a1,Note that full information on the approval of the study protocol must also be provided in the manuscript.,27,ALD patent background + target paper.pdf,521,False
ef18784ff9b04a25c832c1a5de2f55b7,"Human research participants

Policy information about studies involving human research participants",27,ALD patent background + target paper.pdf,522,False
de087d79e22d382901fd3edcd24e8e90,Population characteristics,27,ALD patent background + target paper.pdf,523,False
330a1d172ffee2071b3606d297971db3,"Alcoholic hepatitis patients were from multiple centers from United States, Mexico and Europe, with the age ranged from 30 to",27,ALD patent background + target paper.pdf,524,False
9dbd38caba28b3366151e6a1001bd66d,"Population characteristics 75. Alcohol use disorder patients and non-alcoholic controls were from United States and Europe, with the age ranged from 27 to 74. Both genders were included in all populations. Detailed descriptions in Methods, Extended Data Tables 1 and 2",28,ALD patent background + target paper.pdf,525,False
c512aa2d465bb297896f4d8cd043a614,Recruitment,28,ALD patent background + target paper.pdf,526,False
60bb3c1268359bab70329f41a916b08e,"Patients with alcohol use disorder fulfilling the DSM IV criteria (J Abnorm Psychol. 1997;106:545-553) were recruited from an alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a detoxification and rehabilitation program. Alcoholic hepatitis patients were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers in the USA, Mexico, United Kingdom, France and Spain. Detailed inclusion and",28,ALD patent background + target paper.pdf,527,True
a36dcf5b60089e8b129d10b0b75d06be,exclusion criteria are listed in Methods,28,ALD patent background + target paper.pdf,528,False
51e997308e3cbe402b516987a27fdce5,Ethics oversight,28,ALD patent background + target paper.pdf,529,False
9f978083d35ae2daa32d7ef55673dd5b,"The protocol was approved by the Ethics Committee of Hopital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San Diego",28,ALD patent background + target paper.pdf,530,True
a09eac428bc3c834f53b07f29fea2432,"Healthcare System (San Diego, USA) and Université Catholique de Louvain (Brussels, Belgium).",28,ALD patent background + target paper.pdf,531,False
78136cb738ed122039139ea7fa9bafff,Note that full information on the approval of the study protocol must also be provided in the manuscript.,28,ALD patent background + target paper.pdf,532,False
01accb07fb2d6eb3aa370e0559ac6a11,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 3,28,ALD patent background + target paper.pdf,533,False
bde5947c3aa128a08aa3bcc7e187ed42,RES EARCH,1,GvHD-paper.pdf,534,False
20d1dc3add40542e9cd01b4cc74b68cb,MICROBIOME,1,GvHD-paper.pdf,535,False
2f47343d09539d18cbccd39f8e7ea358,Lactose drives Enterococcus expansion to promote graft-versus-host disease,1,GvHD-paper.pdf,536,False
331d5ae435ddb18fbe20eb92cad90f4d,"C. K. Stein-Thoeringer1,2,3, K. B. Nichols1,2, A. Lazrak1,2, M. D. Docampo1,2, A. E. Slingerland1,2, J. B. Slingerland1,2, A. G. Clurman4, G. Armijo1,2, A. L. C. Gomes1,2, Y. Shono1,2, A. Staffas1,2, M. Burgos da Silva1,2, S. M. Devlin5, K. A. Markey1,2,4, D. Bajic6, R. Pinedo7, A. Tsakmaklis8,9, E. R. Littmann1,10, A. Pastore1, Y. Taur11, S. Monette12, M. E. Arcila13, A. J. Pickard14, M. Maloy4, R. J. Wright1, L. A. Amoretti1, E. Fontana1, D. Pham15, M. A. Jamal15, D. Weber16, A. D. Sung17, D.",1,GvHD-paper.pdf,537,False
c847c58771cb21f8867b40c841c1c7d6,"Hashimoto18, C. Scheid8, J. B. Xavier19, J. A. Messina20, K. Romero21, M. Lew17, A. Bush17, L. Bohannon17, K. Hayasaka22, Y. Hasegawa18, M. J. G. T. Vehreschild8,9,23, J. R. Cross14, D. M. Ponce2,4, M. A. Perales2,4, S. A. Giralt2,4, R. R. Jenq15, T. Teshima18,22, E. Holler16, N. J. Chao17, E. G. Pamer1,2,10, J. U. Peled1,2,4*†, M. R. M. van den Brink1,2,4*†",1,GvHD-paper.pdf,538,False
3dff5bf0dd3d987610c819245891f764,"Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and",1,GvHD-paper.pdf,539,True
aaa0885b0f55e841fb07099e59cf25f8,"exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.",1,GvHD-paper.pdf,540,True
97816344e044637e689d1a6574cab252,"community of mostly anaerobic bacteria, and a hallmark of microbial imbalance (dysbiosis) observed in many disease states involves the expansion of facul- tative anaerobic bacteria (1). Enterococci are facultative anaerobes that colonize the intes- tines of almost every species, from insects to mammals (2), and make up a very small proportion (<0.1%) of the gut microbiota in healthy humans (3). However, enterococci are also pathogens; the species Enterococcus faecium and Enterococcus faecalis",1,GvHD-paper.pdf,541,False
43c6d0fc9904d9d1a853af41520f416c,"are impor- tant causes of multidrug-resistant infections in patients (4). In single-center studies, E. faecium has been observed to dominate the fecal microbiota of immunocompromised patients after allogeneic hematopoietic cell transplantation (allo-HCT), a curative-intent therapy for hematological malignancies (5–7). Moreover, fecal domination with vancomycin- resistant enterococci increases the risk of",1,GvHD-paper.pdf,542,True
1b22244d9546e48c7c6e6d5783287762,"bloodstream infection in allo-HCT patients (5, 8). Patients with severe graft-versus-host disease (GVHD) after allo-HCT have poor outcomes with only ~30% long-term survival (9). Gut microbiota perturbations caused by broad-spectrum antibiotics and a reduction in microbial diversity are associated with in- creased transplant-related mortality and lethal GVHD in humans and mice (10–13). Besides causing infections, experimental studies in gno- tobiotic mice have revealed that enterococci play an",1,GvHD-paper.pdf,543,True
f61465198e6440e5f43238f30249cc80,"important role in colitis (14) by stimulat- ing antigen-presenting cells and CD4+RORg+ T cell infiltration, causing intestinal inflam- mation (15). In this study, we investigated the role of enterococci in the development of acute GVHD, both in allo-HCT patients and preclinical allo-HCT mouse models.",1,GvHD-paper.pdf,544,True
e4f3a612c5044eda5f3f1695a85bc930,We used 16S ribosomal RNA (rRNA) gene sequencing to study the fecal microbiota of 1325 adult allo-HCT recipients at four HCT centers: Memorial Sloan Kettering Cancer,1,GvHD-paper.pdf,545,True
b59c3859e6f00b6fade6679a559fc46d,"Center (MSKCC) (United States), Duke Uni- versity (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). Patient characteristics are shown in table S1. We observed high abundance of enterococci soon after transplantation in samples from all four transplant centers (Fig. 1B and fig. S1B). We defined Enterococcus domination as relative genus abundance ≥0.3 (≥30%) in any fecal sample, following a thresh- old we have used previously (5) (materials and methods and",1,GvHD-paper.pdf,546,True
ba5a7cd89a0dd0e1e025134ac812d2fa,"fig. S2C). The incidence of domination rose comparably across cen- ters, with up to 65% of patients exhibiting a domination event after allo-HCT (Fig. 1A). E. faecium was the dominant species in both the MSKCC and the multicenter-validation cohort (Duke, Hokkaido, and Regensburg) (Fig. 1B, fig. S1, and table S2), where 40.1% of MSKCC patients (441 of 1101 patients) and 46.0% of multicenter-validation patients (103 of 224 patients) met criteria for domination at any time point between day −20 and",1,GvHD-paper.pdf,547,True
6eccc4e5d3edefb82d95c98ac3129fa8,"day +80 relative to the date of allo-HCT, in which cells are infused on day 0.",1,GvHD-paper.pdf,548,False
07dfeaf72aaa01606b402fc242d17978,"early posttransplant period (day 0 to +21) was associated with significantly reduced overall survival and increased GVHD-related mortality in both the MSKCC and multicenter- validation cohort, as well as an increased risk of moderate-to-severe acute GVHD in the MSKCC cohort (Fig. 1, C and D, fig. S2, A and B, and table S3). The risk of relapse or disease progression was not associated with enterococcal domination in either cohort. The association of domination by genus Enterococcus with clinical",1,GvHD-paper.pdf,549,True
0b3f9ba03bbc4a8ad978c5a6129cefeb,"outcomes in the MSKCC cohort remained significant in a multivariate analysis adjusted for graft source, disease, conditioning intensity, gender, and age (table S4). In a subset of MSKCC patients, the vanA operon was found in 152 (37.4%) of 406 patients that had samples available for analysis, indicating the presence of vancomycin-resistant enterococci (VRE) (fig. S2E). Notably, expansions of several different taxa were detected in fecal samples in this study, but the Enterococcus genus was the",1,GvHD-paper.pdf,550,True
6037f488f5b1672e4f9895b7d56806b7,one most commonly observed dominating the microbiota in all four transplant centers (fig. S3 and tables S5 and S6).,1,GvHD-paper.pdf,551,False
ec48ff5348e8f896d4fa3940c0a3d20f,"1Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2Weill Cornell Medical College, New York, NY, USA. 3German Cancer Research Center (DKFZ), Heidelberg, Germany. 4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Department of Internal Medicine II, Technical University",1,GvHD-paper.pdf,552,False
4a7e36bf8a772cba2e6fa481b9acb93a,"of Munich, Munich, Germany. 7Gnotobiotic Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. 9German Center for Infection Research, Partner site Bonn-Cologne, Cologne, Germany. 10Department of Medicine, Section of Infectious Medicine and Global Health, University of Chicago, Chicago, IL, USA. 11Infectious Disease Service, Department of",1,GvHD-paper.pdf,553,False
764e2196e70d7470591cd5dbdb538f5c,"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY, USA. 13Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15Department of Genomic Medicine, The University of",1,GvHD-paper.pdf,554,False
ac4505a946b43b3ec8b7aa5bf2465df9,"Texas MD Anderson Cancer Center, Houston, TX, USA. 16Internal Medicine III, University Clinic Regensburg, Regensburg, Germany. 17Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA. 18Department of Hematology, Hokkaido University, Faculty of Medicine, Sapporo, Japan. 19Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 20Division of Infectious Diseases, Department of",1,GvHD-paper.pdf,555,False
d35d0ae01aa2bf19a227b3c1a314657c,"Medicine, Duke University, Durham, NC, USA. 21Office of Clinical Research, Duke University School of Medicine, Durham, NC, USA. 22Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan. 23Department of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.",1,GvHD-paper.pdf,556,False
fa6f57dbeba09163cd5d009e6df48d30,"*These authors contributed equally to this work.

†Corresponding author. Email: peledj@mskcc.org (J.U.P.); vandenbm@mskcc.org (M.R.M.v.d.B.)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",1,GvHD-paper.pdf,557,False
009d44f00d27142ab787cdd968d8f68b,29 November 2019,1,GvHD-paper.pdf,558,False
9fdf714d2dd986f360093fee4dc16178,"1 of 7

D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",1,GvHD-paper.pdf,559,False
0e95ffef31a285d4f3613b1a065c9426,RES EARCH | R E P O R T,2,GvHD-paper.pdf,560,False
7167bbe87dc96d8199e21579ac3e08d9,"To further investigate these clinical obser- vations, we examined the fecal microbiota of mice early after transplantation using well- established mouse models of allo-HCT. In a major histocompatibility complex (MHC)– matched, minor-antigen-mismatched allo-HCT model [C57BL/6-to-129S1/Sv transplant (C57BL/ 6→129S1/Sv)], we performed 16S rRNA gene sequencing of fecal samples and found that E. faecalis dominated the fecal microbiota at posttransplant day +8 in mice who re- ceived T cell–replete",2,GvHD-paper.pdf,561,True
43839c87eb8aace015e7723f9fa7f14a,"grafts and developed lethal, acute GVHD (Fig. 2A and fig. S4A). In contrast to the patients who had pro- longed antibiotic exposures, this expansion of E. faecalis was independent of antibiotic administration and dependent upon GVHD, as it was not observed in control recipients of T cell–depleted allografts in which GVHD did",2,GvHD-paper.pdf,562,True
7684a55062ee8af4fdf8d0c77304a56f,"not develop. This posttransplant expansion of enterococci was consistently found in two additional lethal GVHD models: C57BL/6→ BALB/c mice (MHC-disparate model after ir- radiation conditioning) (Fig. 2B) and LP/ J→C57BL/6 mice [MHC-matched, minor- antigen–mismatched after busulfan and cyclophosphamide conditioning (16)] (Fig. 2C). The expansion of enterococci in murine allo- HCT recipients with GVHD was accompanied by an increase in Enterococcus colony–forming units recovered from mesenteric",2,GvHD-paper.pdf,563,True
a70530c67f9017ad9e3c21664b10aa87,"lymph nodes, consistent with increased bacterial translo- cation (Fig. 2B).",2,GvHD-paper.pdf,564,False
aee0e1b81e7d3b79483c65310b022827,"Although we observed E. faecium domina- tion in patients and a transient expansion of E. faecalis in GVHD mice, we hypothesized that both members of this genus might be associated with GVHD. Of note, E. faecium",2,GvHD-paper.pdf,565,True
89027271151d4580fc1e3ab5a68f82c5,"only recently became recognized as a major human pathogen; before the 1990s it was E. faecalis that caused >90% of clinical in- fections (17). Because E. faecalis expands in mice with GVHD and is the major Enterococcus species in laboratory mice, we next investigated whether E. faecalis contributes to GVHD. We colonized germ-free C57BL/6 mice with a com- munity of six bacterial strains (Akkermansia muciniphila, Lactobacillus johnsonii, Blautia producta, Bacteroides sartorii, Clostridium bolteae,",2,GvHD-paper.pdf,566,True
0196242abc12beb7b4005908f58cc2d7,"and Parabacteroides diastonis; see materials and methods) (10, 18, 19) 21 days prior to allo-HCT (LP/J→gnotobiotic C57BL/6). One group of mice was cocolonized on day −21 with E. faecalis OG1RF, which remained detectable in mouse feces on days 0 and +7 (Fig. 2D, right panel, and fig. S4E). GVHD was exacerbated in E. faecalis–harboring mice",2,GvHD-paper.pdf,567,True
7e720d9cd1cdd9de337d2fede74d5355,A,2,GvHD-paper.pdf,568,False
f611ec9449d36eac76f849197793cf43,Incidence of domination,2,GvHD-paper.pdf,569,False
7662d7986d070968e094b451b5815018,"0.75 n f o o i e t a c 0.50 n n i e m d o i c d n i s u e c v c i t o a 0.25 c l o u m r e t u n c E 0 20 0 -20 day relative to HCT

Prevalence of domination MSKCC 0.6 Duke s e Hokkaido l p Regensburg m a s d 0.4 e t f o a n n i m o i t o c d a r s 0.2 f u c c o c o r e t n E 0 -20 20 0 day relative to HCT",2,GvHD-paper.pdf,570,False
840f24b6c5851f9c7d2e4caff4882a83,"«

=

«",2,GvHD-paper.pdf,571,False
c12163a6c434cb30622db48554235e05,B,2,GvHD-paper.pdf,572,False
2e02651b2bf34489c2fbb4d5d62e9e86,E. faecium other E. spp. 1.00 E. faecium 0.60 E. cecorum M S E. durans 0.30 K C E. mundtii C 0.10 e c E. rivorum n a d E. moraviensis 0.01 n u E. gallinarum b a v 1.00 a E. lactis e l v i i d t E. malodoratus a a 0.60 l t e i r o E. ureasiticus n 0.30 c E. faecalis o h o 0.10 r t 0.01 20 60 80 −20 0 60 40 20 40 0 −20 80 day relative to HCT,2,GvHD-paper.pdf,573,True
771d951b168958fce453b78d5759e6af,"®

®

®",2,GvHD-paper.pdf,574,False
9318c4f48cac82762cc552b298742c10,%,2,GvHD-paper.pdf,575,False
47eba74ad1a65abd402727a9e8d23f61,"Fig. 1. Enterococcus domination occurs globally and increases risk of GVHD and mortality after allo-HCT. Fecal microbiota were profiled using 16S rRNA gene sequencing of 1325 adult allo-HCT recipients. The patients attended one of four HCT centers in different countries: MSKCC (United States), Duke University (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). (A) (Left) Cumulative incidence of patients who experienced at least one instance of genus",2,GvHD-paper.pdf,576,False
d570fef3b0c8b7a841f6aa39ed31f5a9,Enterococcus domination of the gut microbiota [domination defined as a genus relative abundance of ≥0.3 (on a unitless scale from 0 to 1) over the course of allo-HCT (day −20 to +24 relative to HCT; using 7-day sliding windows) at different transplant centers]. (Right) Fraction of fecal specimens with enterococcal domination of the gut microbiota. (B) Relative abundance of different Enterococcus spp. in the microbiota of allo-HCT patients from the MSKCC and multicenter-validation cohort over the,2,GvHD-paper.pdf,577,True
669f418279ec6c04ef4e954c90d01136,"course of HCT, determined by 16S rRNA gene sequencing of fecal samples. Each",2,GvHD-paper.pdf,578,False
f2110261ad3895a598ff0fea631fe0e8,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019

29 November 2019",2,GvHD-paper.pdf,579,False
1f850bdbbceffe30694af9d537ca7965,spp.,2,GvHD-paper.pdf,580,False
8a3cdbeeeaf7707926528f0b90493512,"C

D",2,GvHD-paper.pdf,581,False
9e19d279e6827f592f18b6b5d4434fdd,"Overall survival 1.0 0.8 g n i v i v 0.6 r u s n o i t 0.4 r o p o Enterococcus ≥ 0.3 (n=149) r p < 0.3 (n=389) Enterococcus 0.2 HR, 1.97; p < 0.001 0 15 10 5 0 20 months after HCT

1.0 0.8 g n i v i 0.6 v r u s n o i 0.4 t r o p Enterococcus ≥ 0.3 (n=54) o r p Enterococcus < 0.3 (n=113) 0.2 HR, 1.95; p = 0.03 0 0 5 15 20 10 months after HCT",2,GvHD-paper.pdf,582,False
b6694168b8e0a0d433134651d8af0e54,GVHD-related mortality,2,GvHD-paper.pdf,583,False
c6a7ce5b5e771466d28650523b34315a,Enterococcus ≥ 0.3 (n=148),2,GvHD-paper.pdf,584,False
644e1dd36c2c23c371aa6d875eacd52e,—,2,GvHD-paper.pdf,585,False
188d429f62d558277df0959b0ed2d50f,Enterococcus < 0.3 (n=389),2,GvHD-paper.pdf,586,False
caeee2db1da23fbb7b8fdf3b449c838e,---,2,GvHD-paper.pdf,587,False
9f7a5883365a80434689195880507b58,"0.2

HR, 2.04; p = 0.01",2,GvHD-paper.pdf,588,False
e7ddd9965a66baf74cc3fcf7130e431b,"e c n e d i c n i e v i t a l u m u c

4",2,GvHD-paper.pdf,589,False
2bf747180263d2bf8df2f86bad8ec7a7,"0.15

0.1",2,GvHD-paper.pdf,590,False
7ce294b47f48f9e343236968db89270a,4,2,GvHD-paper.pdf,591,False
fdb6520fb39ef05445edc2f667ef806f,"0.05

0",2,GvHD-paper.pdf,592,False
f669bbd52ede6757c0206e4031759f87,o1,2,GvHD-paper.pdf,593,False
2284770f81988712a8dc1372a9ec2246,"10

5

15

20",2,GvHD-paper.pdf,594,False
5949162eb34b6aa3376934230477c478,months after HCT,2,GvHD-paper.pdf,595,False
828e3d7554e59588cca8ddf4d1db363a,"GVHD-related mortality Enterococcus ≥ 0.3 (n=53) < 0.3 (n=111) Enterococcus 0.2 HR, 5.8; p = 0.002 e c n e 0.15 d i c n i e 0.1 v i t a l u m 0.05 u c 0 20 5 15 10 0",2,GvHD-paper.pdf,596,False
9699d347d90b3ff6d6ed7bf145b4b245,"point represents a fecal sample, and color indicates the different Enterococcus spp.; the red dotted line indicates the threshold for domination set at a relative abundance ≥0.3. (C) Overall survival (left) and cumulative incidence of GVHD- related mortality (right) in the T cell replete graft recipients in the MSKCC patient cohort (see table S3), stratified into nondominated and Enterococcus- dominated groups (domination is defined as the relative genus abundance ≥0.3 in at least one sample",2,GvHD-paper.pdf,597,True
10ac17b617ed6906ffae7f3f788f203e,"between day 0 and +21). n, number of individuals. (D) Overall survival (left) and cumulative incidence of GVHD-related mortality (right) in Enterococcus-dominated (at genus level) versus nondominated allo-HCT patients in the combined multicenter-validation cohort (table S3). Clinical outcomes in (C) and (D) were analyzed using the R packages survival and cmprsk. Wald values of P <0.05 signify higher risks (HR, hazard ratios) of mortality among patients with Enterococcus domination as compared",2,GvHD-paper.pdf,598,False
ba25ff6c46b5bba6c5e2795bfcda92d4,with those without domination.,2,GvHD-paper.pdf,599,False
f73b871ed5f104c18f8b1bc12bee8eaf,2 of 7,2,GvHD-paper.pdf,600,False
101071406f97f6417944961f850945d5,D,2,GvHD-paper.pdf,601,False
4269271d1a465a36ede8905f3f219876,o,2,GvHD-paper.pdf,602,False
4b0c1520e75f2344e78e0ebc6bae2704,"n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",2,GvHD-paper.pdf,603,False
9cbea3c6c29a18e938744d190bda5b26,RES EARCH | R E P O R T,3,GvHD-paper.pdf,604,False
bc3eb75a3b4aaa789f00ed47f8e2a3c1,A,3,GvHD-paper.pdf,605,False
89c55bab1365ea269e589eee2ddbdcf0,C57BL/6 = 12951/Sv Survival Enterococcus Akkermansia 100 0.5 M Bacteroides M Blautia x50 rel. abundance 0 Pl i Clostridium 0 10 20 30 0 10 20 30 0O 10 20 30 0 10 20 30 0 10 20 30 [ Lactobacillus 1.0 Oscillospira A p=0013 W Roseburia 0 20 40 60 80 100 days after HCT 0.5 — BM (n=5) — BM+T (n=5) rel. abundance 0 0 10 20 30 10 20 30 O 10 20 30 0 10 20 30 0 10 days after HCT C57BL/6 — BALB/c 16S rRNA feces o before HCT Enterococcus feces Enterococcus mLN Survival e BM -~ 4x10* e BM 10°% e BM+T 8 ®,3,GvHD-paper.pdf,606,False
51c5aab43d05e63127bbe42b6cc4ad68,"BM+T 100 10"" ° 1 3x10* — BM (n=20) 102 107 2x10* — BM+T ® 50 102 10¢ g Enterococcus el.abundance 10+ A 19 o CFUs/g stool CFUs/mLN 1x10* 10° ° ) 10° o p<0.001 10 -1 4 7 10 10 7 10 0 5 10 15 20 days after HCT days after HCT days after HCT days after HCT c LP/J C57BL/6 16S rRNA feces Survival 14 days rel. to HCT o before bu/cy-cond 100 @ before HCT VVVYVYY v 1074 e BM ® BM+T — BM (n=9) AAA 1074 ¥ 50 g — BM+T (n=10) V busulfan g 'V cyclophosphamide Enterococcus rel. abundance 10° o 8 HCT p<0.01 10",3,GvHD-paper.pdf,607,True
f3a76bd4695117cb149ee21a0a841256,-7 -1 10 0 20 40 60 80 100 days after HCT days after HCT D LP/ - C57BL/6 Survival 16S rRNA feces -7 days rel. to HCT B 0 m -21 100 EF] (n=4) - day 0 day 7 v \AAAA v > o AAA BM [+ EF] (n=5) BM+T [- EF] (n=10) Se 'V colonization V busulfan 50 | BM+T [+ EF] (n=12) o e -1+ EF g WV cyclophosphamide WV HCT p<0.001 Enterococcus rel. abundance 0 0 20 40 60 80 HCT: - BM BM+T days after HCT,3,GvHD-paper.pdf,608,False
8ad0dc96c7ec8df463110cf7d83f9653,(n=32),3,GvHD-paper.pdf,609,False
381c9819218574db461b7056242abde4,"Fig. 2. Enterococcus dominates mouse gut microbiota after HCT and can exacerbate GVHD. (A) (Left) High-density sampling and 16S rRNA gene sequencing of fecal microbiota from 129S1/Sv mice (1 box = 1 mouse) receiving bone marrow (BM; upper row) or T cell–replete bone marrow [BM+T (2 × 106 T cells); lower row]. (Right) BM+T transplanted mice develop lethal GVHD as shown by survival analysis. rel., relative. (B) (Left) Relative abundance of the genus Enterococcus in BALB/c host mice transplanted",3,GvHD-paper.pdf,610,False
75c46e2a2d726c9af9fdafd73add297b,with C57BL/6 BM or BM+T (1 × 106 T cells) at different time points relative to HCT. (Middle) Colony-forming units (CFUs) of enterococci in fecal samples and in mesenteric lymph nodes (mLN). Scatter plot data show means ± SEM. (Right) Survival of BALB/c recipient mice after HCT [BM versus BM+T (1 × 106 T cells)]. (C) (Left) Schematic showing HCT of LP/J BM versus BM+T (4 × 106 T cells) into C57BL/6 mice after chemotherapy conditioning. (Middle) Relative abundance of the genus Enterococcus in the,3,GvHD-paper.pdf,611,False
bcca109caaf96cad56eaaaac7fb94925,feces of,3,GvHD-paper.pdf,612,False
aa574ba6864efdddc6fcac48649f613e,"transplanted mice at different time points relative to HCT. (Right) Comparison of overall survival between BM and BM+T mice. bu/cy-cond., busulfan/ cyclophosphamide conditioning. (D) (Left) Schematic showing colonization of germ-free C57BL/6 mice with a 6-strain minimal microbiota with (+EF) or without (-EF) E. faecalis OG1RF (2 × 107 CFUs per mouse); after 14 days, colonized mice received chemotherapy conditioning with busulfan and cyclophosphamide and, subsequently, an HCT of LP/J BM versus",3,GvHD-paper.pdf,613,False
e354dcc9d7acc85fe3682f03625fa994,"BM+T (4 × 106 T cells). (Middle) Comparison of overall survival. (Right) Relative abundances of E. faecalis spiked to the minimal microbiota in the EF+ group with samples collected at the day of HCT (day 0) and 7 days later (n = 4 to 11 mice per group; P = 0.09, paired testing of relative abundances of enterococci of day 0 versus BM+T day +7). Scatter plot data are presented as means ± SEM **P < 0.01, ***P < 0.001 (independent t test for BM versus BM+T); survival data were statistically analyzed",3,GvHD-paper.pdf,614,False
0f9556dd72bd9f83510d8771a5639c2b,using Mantel-Cox log-rank test.,3,GvHD-paper.pdf,615,False
f31404c860fb71941ecd4699114f6cba,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

29 November 2019",3,GvHD-paper.pdf,616,False
da8a97e4819b4e1abbe09ed96baa2a52,"3 of 7

o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",3,GvHD-paper.pdf,617,False
0265cd329e927e508b2fc02709affa74,RES EARCH | R E P O R T,4,GvHD-paper.pdf,618,False
6464d42cbded84d95353460653a01e18,"A allo HCTin AML patients == pre HCT/ non-dom. (i == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ Superpath. alanine biosyn. ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Calvin-Banson-Bassham cycld GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. Glycolysis IV P-diacylglycerol biosyn. | CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. N -2denosyl-L-methionine cycte | I",4,GvHD-paper.pdf,619,True
2ca4b4e6da6075fe38c0c8e3228ebcb5,Chorismate biosyn. 2ch degradataion V i hoshote | 3 E B 0 1 2 3 LDA score (log 10),4,GvHD-paper.pdf,620,False
31cddea802aa517fb42fe13a7a3f3d9b,"A allo HCTin AML patients pre HCT (diverse) == pre HCT/ non-dom. (i M Enterococcus == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ B Akkermansia Superpath. alanine biosyn. W Blautia ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ W Clostridium Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Dorea Calvin-Banson-Bassham cycld Eubacterium GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. biosyn. ost HCT Glycolysis IV (E. F. domin.) I",4,GvHD-paper.pdf,621,True
8059ee5dd393fe36945a19e491ac9594,Lactobacillus P-diacylglycerol biosyn. | Faecalibacterium CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. 1| Oscillospira N -2denosyl-L-methionine cycte | I Chorismate biosyn. Ruminococcus 2ch degradataion V i hoshote | [ Streptococcus 3 E B 0 1 2 3 W Veillonella LDA score (log 10) I Other,4,GvHD-paper.pdf,622,False
b7aa4d5eebc77e9b42e03d9e7b1cce0c,pre HCT (diverse) M Enterococcus B Akkermansia W Blautia W Clostridium Dorea Eubacterium Lmeth. biosyn. ost HCT (E. F. domin.) I Lactobacillus Faecalibacterium 1| Oscillospira | Ruminococcus | [ Streptococcus W Veillonella I Other,4,GvHD-paper.pdf,623,False
08e34909941fd39f8cd66b0b3125b8a7,B C57BL/6 — 12951/Sv,4,GvHD-paper.pdf,624,False
d380954f6cbddb4b0ed01875994c6e25,"M

B",4,GvHD-paper.pdf,625,False
f6522bb511f6a4e511334e575aa7e4db,"W

W",4,GvHD-paper.pdf,626,False
5b5ac51ebda17acc4a44aed8374f3af3,"I

1|",4,GvHD-paper.pdf,627,False
e178c0bfbb1cf01e5c5bf1d88dda2593,day 7 after HCT = BM (n=5) == BM+T (n=5) Lactose and galactose degradation — Thiamine formation from pyrithiamine Pyrimidin deoxyriboncl. salvage Lysine iosynthesis hamnose degradation | ! s-aminoiidazole ribdncl. biosyn supepath 5+ aminoimid. fiboncl.biosyn. Inogine- Inosine- phosph biosyn. | — Peptifloglycanbigsynthesis || hosph biosyn. I I scrine and ycne biosyn. | S-adenosyL-methionne cycle | -1 0 i 2 LDA score (log 10),4,GvHD-paper.pdf,628,False
71d32ec9bc9b10583d0ad558ab6278bc,"=

==

[",4,GvHD-paper.pdf,629,False
9bb0ade00488a9fd42667098449dfe48,W,4,GvHD-paper.pdf,630,False
737106136865f574ebf96e4c6f211d33,I,4,GvHD-paper.pdf,631,False
ac3c9ee44b3deaeb087c6f32e0cc4ac7,D,4,GvHD-paper.pdf,632,False
08904f8b0be8c01df88fa56ba02d3739,invitro Enterococcus growth,4,GvHD-paper.pdf,633,False
3c7f9970f5fcd292852b68baada1ca50,E. faecalis - ° & Incubation in 0D600 nm regular BHI 02462810 hours < Regular BHI -+ Lactase pretreatment,4,GvHD-paper.pdf,634,False
b84aeb7cac022466f433fb978bdf2aad,15 0.0 —— = 024681 hours,4,GvHD-paper.pdf,635,False
7654b27289fe4e1e15bda9b08e675333,"E. faecium - Regular BHI -+ Lactase pretreatment 15 - - ° 10 Incubation in 0D600 nm o 0D600 nm 05 regular BHI | [= 0.0 0246 810 024 8 10 hours hours

- Regular BHI -+ Lactase pretreatment 15 - 10 0D600 nm 05 0.0 024 8 10 hours

- ° Incubation in 0D600 nm o regular BHI | [= 0246 810 hours",4,GvHD-paper.pdf,636,False
851447f60b5755773ad526b4c7b664ba,F Clostridum vs. Enterococcus (genera) in allo-HCT patients Kendall tau =-0.21; p<0.001 1 3 o = 3 2 B o Clostridium 3 2 rel. abundance - 0 107 107 1 Enterococcus rel. abundance,4,GvHD-paper.pdf,637,True
3df53188854786cb5fad48654920483c,"Butyrate in C57BL/6 — BALB/c

cecal content . 100- * BM BM+T 50- B butyrate pm/mg",4,GvHD-paper.pdf,638,False
f033f8fe9746c75496976e1bbf1abb9d,"or in BHI broth pretreated with lactase. (Right) E. faecalis or E. faecium incubated in lactase-pretreated BHI were put into regular BHI broth after 8 hours to assess growth dynamics in regular BHI (gray symbols). Data are results of four experiments combined; values represent means ± SEM. (E) (Left) Fecal butyrate concentrations (means ± SEM) from pre- and posttransplant fecal samples from AML patients from MSKCC, who received allo-HCT and were selected based on a highly diverse pre-HCT",4,GvHD-paper.pdf,639,False
cd0db599eafc0f07ee61881be7c11af3,"microbiota and a posttransplant E. faecium domination [by 16S rRNA gene sequencing; 6 (out of 8) patients are presented in (A)]. (Right) Correlation of butyrate concentrations with relative abundances of the genus Enterococcus (n = 139 patients; 8 patients from left panel), and 131 allo-HCT patients from a dataset published by Haak et al. (28); statistical analysis was performed using Kendall’s tau rank correlation coefficient. (F) Stool samples were collected at the time of engraftment (~24",4,GvHD-paper.pdf,640,False
cc17c894eef552ae475edbff3d286a62,days after allo-HCT). Data show Kendall’s tau rank correlation of relative abundances of the genera Clostridium and Enterococcus from the dataset of Haak et al. (G) Butyrate concentration (mean ± SEM) in cecal contents of BALB/c mice transplanted with C57BL/6 BM or BM+T (1 × 106 T cells) at day +7 after HCT. Statistical analysis: *P < 0.05 [paired t test (E) or independent t test (F)].,4,GvHD-paper.pdf,641,False
7116f204bf4de77f75b214d0c26f826f,4 of 7,4,GvHD-paper.pdf,642,False
fa8d86e3ebcb9d88d4f620fb3b77c718,"==

==",4,GvHD-paper.pdf,643,False
2e942ac9918d59671f6e34957851bade,C,4,GvHD-paper.pdf,644,False
d4babf903a390e3ec4ecfc4095195909,"Metagenomic metabolic pathways Enterococcus isolates

Amino sugar and nucleotide Pyrimidine metabolism sugar metabolism Purine metabolism Lactose and ‘metabolism alactose AminoacytRNA meta Glycolysis/ gluconeogenesis Pyruvate metabolism Arginine proline metab. Methane metabolism Cysteine methionine metab. Glycine serine threonine metab. Other pathways Oxidative phosphorilation E. faecalis (BALB/c mice, GVHD) Pentose phosphate pathway Fructose mannose metabolism",4,GvHD-paper.pdf,645,False
8b27ed067d7311d05479c96733fbfee1,E. faecium (human isolate),4,GvHD-paper.pdf,646,False
f42452bc77880df1abd9db2a1d69d953,Amino sugar and nucleotide sugar metabolism Pyrimidine metabolism Glycolysis/ Purine metabolism gluconeogenesis Sucrose metabolism Methane metabolism Fructose mannose metabolism l Pentose pathway Pyruvate metabolism AminoacyHRNA metab. Other pathways Pentose glucuronate interconversions Glycine serine threonine metabolism,4,GvHD-paper.pdf,647,False
64bac0311ed85a3d6add58446c81e362,E Butyrate in allo-HCT patients,4,GvHD-paper.pdf,648,False
e5a69dbd3810b89dfb77dbbd0a262bb5,feces 15 —_— © preHCT postHCT 10 butyrate mM,4,GvHD-paper.pdf,649,False
c67041e3bab0318d51fe098303530d13,©,4,GvHD-paper.pdf,650,False
2498ac75135d91cdb2352300d0b9073f,Kendall tau =-0.15; p = 0.008 20 0o butyrate mM oo 3 - orts o 0 107 10 _I- Enterococcus rel. abundance,4,GvHD-paper.pdf,651,True
0a0ff0d0e84af95d79bc7242c1dce9c3,"Fig. 3. Metagenomic and metabolomic analyses of Enterococcus-dominated fecal specimens in human HCT patients and mice. (A) (Left) Differential abundances of shotgun-sequenced and HUMAnN2-annotated bacterial metabolic pathways between paired pre- and post-HCT fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia (AML) analyzed by linear discriminant analysis (LDA) coupled with effect size measurements (LEfSe). pre HCT, day −8 to −1 before allo-HCT; post HCT, day +3 to",4,GvHD-paper.pdf,652,False
e7ff5cec6b91c12c303d21db094b002b,"+25 after allo-HCT. (Right) Pie chart showing mean relative abundances of bacterial genera (analyzed by MetaPhlAn2) found in patient fecal samples pre- and post-HCT; data are aggregated across all patients. non-dom., nondominated; domin., dominated. (B) LEfSe analysis of bacterial metabolic pathway abundances in HCT day +7 fecal samples of 129S1/SV mice transplanted with C57BL/6 BM versus BM+T (2 × 106 T cells) (see Fig. 2A). (C) Pie charts with metabolic pathway abundances determined by",4,GvHD-paper.pdf,653,False
3a37b7dd7b78501e39fe8ad058c1dc5a,"whole-genome sequencing of E. faecalis (isolated from feces of a BALB/c GVHD mouse, day +7 after HCT; upper panel) and E. faecium (human isolate; ATCC #700221; lower panel); only pathways with an abundance ≥2% are shown in both panels. (D) (Left) In vitro growth of E. faecalis (mouse GVHD isolate; upper panel) and E. faecium (ATCC #700221; lower panel) in nontreated BHI broth",4,GvHD-paper.pdf,654,False
892262af77036211776a4afcd2c3a3a2,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

29 November 2019",4,GvHD-paper.pdf,655,False
e1bcf685f93c39db31e3f369be79bd25,"D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",4,GvHD-paper.pdf,656,False
b1809ff96ac474bf7e4dcc6c03ede0cc,RES EARCH | R E P O R T,5,GvHD-paper.pdf,657,False
cffa761b3293f1bad8dc1fd8805a8bb6,"vated and proliferating CD4+ T cells (fig. S4D; CD4+CD25+; CD4+Ki67+), and an increased number and percentage of CD4+RORg+ T helper 17 (TH17) cells in colon lamina propria (fig. S4D). Posttransplant administration of E. faecalis",5,GvHD-paper.pdf,658,True
800978a75dc4064315cc89df1820b2ab,Survival 100 += ' - BM [ctr] (n=10) ' - BM [LF] (n=10) — BM+T [ctr] (n=20) 50 — BM+T [LF] (n=20) survival [%] p<0.05 %020 40 60 80 100 days after HCT,5,GvHD-paper.pdf,659,False
e3893d2315b78cc679d42a41d25739f7,"' -

' -

—",5,GvHD-paper.pdf,660,False
30b8556340e413cdacd92bde63e02948,Survival 100 BM [ctr] (n=8) BM [LF] (n=10) BM+T [ctr] (n=19) 50 BM+T [LF] (n=13) survival [%] p<0.01 0 20 40 60 80 100 days after HCT,5,GvHD-paper.pdf,661,False
5930457a87d4904bdfc3b4f0d64f227a,day-7to 0 1.0 0.5 Enterococcus rel. abundance day 25 1.0 N 05 Enterococcus rel. abundance TT+ / T/C,5,GvHD-paper.pdf,662,False
6c18a965da23926ebf5cb44ff4b5e423,T/C,5,GvHD-paper.pdf,663,False
dcee265dde1662d9b5135c2a51aa3aa4,"OG1RF to conventionally housed, T cell–replete bone marrow (BM+T)–transplanted BALB/c mice also aggravated GVHD (fig. S5A). These findings indicate that E. faecalis can aggravate GVHD severity.",5,GvHD-paper.pdf,664,True
44a50777888f491ce95b360b3871c681,"16S rRNA feces

16S rRNA feces o BM [ctr] © BMI[LF] ¥ 107 © BM+T [ctr] © BM+T[LF] 102 Enterococcus rel. abundance 10° days r HCT",5,GvHD-paper.pdf,665,False
501bedc5154e146ecba8da94eb442ba6,o,5,GvHD-paper.pdf,666,False
9ee37b786701642ccd238ffd14bf3ce0,"©

©

©",5,GvHD-paper.pdf,667,False
9853613213f9c9ceafe2b4ff001198d5,"165 rRNA feces 107! o BM [ctr] o BM[LF] 102 © BM+T [ctr] 10, . © BM+T [LF] Enterococcus 10 2, .1 rel. abundance 10 14 days after HCT",5,GvHD-paper.pdf,668,False
5088c76be19dbad3bec3ebc842538154,"o

o",5,GvHD-paper.pdf,669,False
f8c7312886c2decb3cc33a74f13c8574,"Acute GVHD (grade 2-4) 06 — — T/T+T 04 0.2 cumulative incidence HR, 1.08; p=0.62 20 40 60 80 100 days after HCT",5,GvHD-paper.pdf,670,False
fbc2cf194eb750e2130cb674e5bf2141,—,5,GvHD-paper.pdf,671,False
ad6d880433115eb1b7fde6a73abfcf22,"SEM; *P < 0.05 (independent t test). (C) (Left) Relative abundance (log10) of Enterococcus (genus) by days relative to the day of antibiotic cessation (broad- spectrum antibiotics for neutropenic fever: intravenous piperacillin-tazobactam, intravenous imipenem-cilastatin, or intravenous meropenem). Box plot inserts display the median relative abundances of the genus Enterococcus of time binned in the indicated day ranges relative to antibiotic cessation; whiskers represent maximum and minimum.",5,GvHD-paper.pdf,672,False
0e59ef689baac0d6e83daed3d3dc10b2,"Statistical analysis of box plot data: *P < 0.05 (Wilcoxon rank test). (D) Cumulative incidence of acute GVHD grade 2 to 4 in rs4988235 SNP-genotyped MSKCC patients (T cell–depleted grafts excluded; graft source: BM/PBSC unmodified = 213 patients; cord blood = 102 patients; C/C = 175, T/C+T/T = 140). The cumulative incidence of grade 2 to 4 acute GVHD was compared between genotype groups using the R package cmprsk.",5,GvHD-paper.pdf,673,True
339a4b3c9b60bd865932458df8bfbf6d,5 of 7,5,GvHD-paper.pdf,674,False
04bb720ca1a632416a49b40bcc919b42,"(Fig. 2D and fig. S4B). Serum interferon-g con- centrations were significantly elevated in E. faecalis–colonized mice (fig. S4C), and we observed a significantly increased num- ber of donor T cells, an increase of acti-",5,GvHD-paper.pdf,675,False
8f85b4202fdbe2d88ef1f91bcfdc91aa,A,5,GvHD-paper.pdf,676,False
d6ef5338cf897ab2a0626724b531c2f3,C57BL/6 — BALB/c days rel. to HCT -7 0 14 v W HCT ctr vs. LF chow,5,GvHD-paper.pdf,677,False
b32f0d0436dfc5f18c7aa6c1d659d30b,W,5,GvHD-paper.pdf,678,False
bef59d3d2616e16e3dc49c915668985a,B LP/J = C57BL/6,5,GvHD-paper.pdf,679,False
5fda4236bb5f93d1bf4a036e38159bf9,days rel. to HCT -7 -3 14 YVVYV V AAA W busulfan W HT W cyclophosphamide ctrvs. LF chow,5,GvHD-paper.pdf,680,False
9a42fdfe6f58042b867c231189558435,"W

W",5,GvHD-paper.pdf,681,False
86cecbe80d68e11b01c260c53ec29e05,"C Allo HCT patients: Enterococcus abundance by lactase genotype

0 o { - 153 -1 ’ -2 Enterococcus log10 rel. abundance -4 -20 -10 0 10 20 days relative to antibiotic termination T/T+T/C ~ C/C lactose absorber non-absorber

day-7to 0 1.0 0.5 Enterococcus rel. abundance day 25 1.0 N 05 Enterococcus rel. abundance TT+ / T/C",5,GvHD-paper.pdf,682,False
49eae528833a329259a3a015b2ae1380,~,5,GvHD-paper.pdf,683,False
39fe7053aa26c34f2a9149f4bbb04748,Fig. 4. Lactose-free diet reduces experimental GVHD and lactase genotypes associated with microbiota dynamics after allo-HCT in humans. (A) (Left) Schematic showing that BALB/c recipient mice received C57BL/6 BM or BM+T (5 × 105 T cells) and were fed control chow (ctr) versus lactose-free chow (LF) from day −7 to +14 relative to transplant. Comparison of survival between BM and BM+T mice (middle) and relative abundance of the genus Enterococcus in mouse feces (right) are shown. Scatter plot data,5,GvHD-paper.pdf,684,False
b82aa2a05ff20906c201f935bbbcddc5,presented as means ± SEM; *P < 0.05 (independent t test). (B) (Left) Schematic showing HCT of LP/J BM versus BM+T (4 × 106 T cells) into C57BL/6 mice after chemotherapy conditioning. Comparison of survival between BM and BM+T mice (middle) and relative abundance of the genus Enterococcus at different time points relative to HCT (right) are shown. Scatter plot data presented as means ±,5,GvHD-paper.pdf,685,False
962cffefddce35078e33625401e464ce,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",5,GvHD-paper.pdf,686,False
f8037f069cd3f1e745427a6c11106b29,"o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",5,GvHD-paper.pdf,687,False
e4a432928794f03e7ed4f8ce295caf8c,RES EARCH | R E P O R T,6,GvHD-paper.pdf,688,False
5a6c1e16a3e36906a3e2d3a8a327fc54,"We next considered whether posttransplant defects of mucosal defense mechanisms facil- itate enterococcal expansion. Immunoglobulin A (IgA) coating of intestinal bacteria can be protective in colitis and is important for maintaining mucosal integrity (20). How- ever, we did not observe members of the genus Enterococcus to be enriched in either IgA- negative or IgA-positive fecal fractions, even though total fecal IgA was significantly re- duced in allo-HCT recipients with GVHD (fig. S5, B to D).",6,GvHD-paper.pdf,689,True
d2fd496bdfe0b7e7b6ce33f463067ead,"Reduction of IgA by transplant- ing IgA-deficient bone marrow (BM) from activation-induced cytidine deaminase knock- out mice did not further increase enterococcal expansion (fig. S5E). Intestinal antimicrobial peptides of the Reg3 family can suppress the growth of VRE (21) and are reported to play a major role in GVHD (22). Accordingly, we found that both Reg3B/G transcripts and interleukin-22 protein, which regulates Reg3 expression (23), were reduced in the ileum of GVHD mice (fig. S5F).",6,GvHD-paper.pdf,690,True
f437430e0d1cd83772d368fde5605c8c,"Next, we analyzed microbiota-intrinsic fac- tors and used shotgun metagenomic sequenc- ing to characterize the metabolic potential of the Enterococcus-dominated fecal microbiota. Pre- and posttransplant fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia were selected for sequencing on the basis of having a highly diverse pre-HCT microbiota and posttrans- plant E. faecium domination (by 16S rRNA gene sequencing). We focused on microbial metabolic pathways that",6,GvHD-paper.pdf,691,True
954c9a9e57f11308dd3b33e7774937ff,"specifically charac- terize domination by comparing them with the highly diverse pretransplant microbiota from the same patients. Pathways involved in DNA synthesis and, notably, in lactose and galactose degradation were enriched in the E. faecium–dominated, posttransplant micro- biota. In contrast, amino acid synthesis and starch-degradation pathways were more prev- alent in pretransplant specimens (Fig. 3A). The lactose-and-galactose degradation path- way was also significantly enriched in the",6,GvHD-paper.pdf,692,True
1763b36f0e868d4f3f751a78c1fadc47,posttransplant E. faecalis–dominated samples of mice with GVHD (Fig. 3B). Comparison of whole-genome sequencing from isolates of E. faecium (from a human allo-HCT patient) and of E. faecalis (from a mouse with GVHD) revealed that genes encoding lactose and galactose metabolism accounted for ~3% of their genomes (Fig. 3C). In silico analysis of these Enterococcus genomes and publicly available genomes of other members of the gnotobiotic six-strain consortium revealed that enterococci are,6,GvHD-paper.pdf,693,True
5fb0585b5d598332dbfa0df06c2d09af,"specifically enriched in enzymes of the tagatose-type galactose path- way for galactose-to-glucose degradation (24) (materials and methods and fig. S6, A and B). Enterococcal growth depends on lactose in vitro, as both E. faecalis and E. faecium strains cultured in brain-heart",6,GvHD-paper.pdf,694,True
7aec7f7e9a931198bd599848cf29dcfd,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)",6,GvHD-paper.pdf,695,False
f40eea9163a0eafca1c765d2532619da,"infusion (BHI) broth depleted of lactose (by lactase; fig. S7A) did not grow (Fig. 3D). Growth was reinstated upon transfer to re- gular BHI, excluding antibacterial effects of lactase treatment (Fig. 3D). Enterococcal expansion after allo-HCT was accompanied by a loss of Clostridium spp. in the microbiota of allo-HCT patients (Fig. 3, A and F) and of mice with GVHD (fig. S8, A to C, and table S7). This may be important for allo-HCT patients, as high abundances of clostridia are associated with",6,GvHD-paper.pdf,696,True
83a84cf1c218335bbe5608707fd742dd,"better survival and low- er incidence of GVHD (12, 25). Commen- sal clostridia are known to produce large amounts of butyrate (26), which mitigates lethal GVHD in mice through protecting energy homeostasis of enterocytes (27). We observed that posttransplant enterococcal domination and a loss of clostridia were accompanied by a significant reduction in fecal butyrate in both allo-HCT patients and mice with GVHD (Fig. 3, E and G) (28). A loss of this key metabolite may contribute to the poor",6,GvHD-paper.pdf,697,True
206481ba15f1340438c11ac77753ac7f,outcomes in Enterococcus-dominated patients and mice.,6,GvHD-paper.pdf,698,False
b588c6e7e34cada90b753ddcecf6c937,"Given that the optimal growth of enterococci depends on lactose availability in vitro, we investigated whether enterococcal expansion can be mitigated by feeding mice lactose-free chow (fig. S7B and table S8). In the C57BL/ 6→BALB/c model, the absence of dietary lactose significantly reduced posttransplant Enterococcus bloom and mitigated GVHD (Fig. 4A and fig. S9B). Flow cytometric anal- ysis of donor T cells on day +14 revealed a reduction in the percentage of activated and proliferating CD4+",6,GvHD-paper.pdf,699,True
bbddbe11309e15be8746bc6e6d43c2f6,"T cells (CD4+CD69+; CD4+ Ki67+) as well as a reduction in the percent- age of CD4+Tbet+ (TH1) T cells (fig. S9). The effect of a lactose-free diet on enterococcal outgrowth and GVHD was replicated in the LP/J→C57BL/6 mouse model (Fig. 4B and table S9 for changes in non-enterococcal taxa). Intestinal mucosal damage by irradiation or allo-reactive T cells may affect the expres- sion of lactase, the enzyme found on small- intestine enterocytes that facilitates lactose absorption through",6,GvHD-paper.pdf,700,True
82449275e21b83a2772d56d81a11e386,"disaccharide cleavage. Duodenal lactase transcript abundance pro- gressively declined in BM+T recipients over the course of transplantation (fig. S9C), which may induce a lactose-intolerant–like state in mice, allowing nondigested lactose to reach the lower intestinal tract and serve as a car-",6,GvHD-paper.pdf,701,False
9580a38a6bd2010ce8455948bca92bea,"Next, we explored whether enterococci ex- pansion is associated with lactose tolerance in human allo-HCT patients by genotyping 602 patients from the MSKCC cohort with available pretransplant germline DNA sam- ples for the gene polymorphism rs4988235 (-13910*T). This single-nucleotide polymorphism (SNP) regulates lactase expression and pre- dicts lactose absorption and/or tolerance (C/T",6,GvHD-paper.pdf,702,True
5fa9f328d5e590d4b64f2731096f135e,29 November 2019,6,GvHD-paper.pdf,703,False
e5a71d616a1f5fa0cabb719adc207bb7,"or T/T alleles) and malabsorption (C/C alleles) in the upper gut (29). Although abundance of the genus Enterococcus increased comparably during exposure to broad-spectrum antibiotics in both lactose absorbers and malabsorbers, enterococcal domination was significantly prolonged in malabsorbers after cessation of antibiotics (Fig. 4D and fig. S10). This finding suggests that the maintenance of enterococ- cal domination and microbiota recovery after broad-spectrum antibiotic exposure is signif-",6,GvHD-paper.pdf,704,True
78830cec35677b5a6e4f50c5689ab0b4,icantly modulated by the luminal availability of lactose as a growth substrate.,6,GvHD-paper.pdf,705,False
b6a05d64d49450dd0c8ef03617fcb46d,"significant risk factor for the development of acute GVHD and for increased overall and GVHD-related mortality after allo-HCT. Our findings extend previous reports from smaller single-center analyses that posttransplant VRE bacteremia and fecal domination are associated with worse outcomes after allo-HCT (7, 8, 30). In gnotobiotic mouse models, enterococci exacerbate GVHD, consistent with previous reports of aggravated colitis in models of in- flammatory bowel disease (14) or systemic autoimmune",6,GvHD-paper.pdf,706,True
1c6bb1dfa8db30e79c638bec74376d1f,"responses (31). We previously identified Blautia abundance (a genus within class Clostridia) as a predictor of protection from lethal GVHD (12), whereas here we describe Enterococcus domination as a risk factor for GVHD. These two findings are noteworthy in light of our recent observa- tion that a B. producta strain can inhibit VRE growth via the production of a lantibiotic pro- tein (32). We identified a microbiota-intrinsic mechanism that is dependent on lactose uti- lization and favors the",6,GvHD-paper.pdf,707,True
cc33c91f1130a936ee46c6ae310e78a0,"expansion of enterococci. This process may be triggered through a loss of lactase produced by enterocytes damaged by conditioning or allo-reactive T cells. We validated this concept experimentally, by showing that depletion of lactose in vitro and in vivo inhibited enterococcal expan- sion and mitigated GVHD, and clinically, by showing that patients harboring a lactose- malabsorption allele experienced prolonged Enterococcus domination after antibiotic ex- posure. These observations in mice and",6,GvHD-paper.pdf,708,True
a3d4043417ac85988207774dac189cfc,"allo- HCT patients provide proof-of-concept for a novel, non–antibiotic-based therapeutic strategy, such as a lactose-free diet, to attenu- ate the outgrowth of pathobionts like enter- ococci and possibly improve clinical outcomes by modulating dietary sources of nutrients for",6,GvHD-paper.pdf,709,False
00a5825f57a05875cd0f7fc479113fab,REFERENCES AND NOTES,6,GvHD-paper.pdf,710,False
f39c62fdd3cd29e70f2d954d50009f4e,"1. Y. Litvak, M. X. Byndloss, A. J. Bäumler, Science 362, eaat9076 (2018).

2. M. S. Gilmore, F. Lebreton, W. van Schaik, Curr. Opin. Microbiol. 16, 10–16 (2013).

3. S. Schloissnig et al., Nature 493, 45–50 (2013).

4. F. Lebreton et al., Cell 169, 849–861.e13 (2017).

5. Y. Taur et al., Clin. Infect. Dis. 55, 905–914 (2012).

6. C. Ubeda et al., J. Clin. Invest. 120, 4332–4341 (2010).

7. E. Holler et al., Biol. Blood Marrow Transplant. 20, 640–645 (2014).",6,GvHD-paper.pdf,711,False
dd59080d8c938b601f17cba8b0974672,"6 of 7

o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",6,GvHD-paper.pdf,712,False
9d221ded558814e6317b4ba124b936b8,RES EARCH | R E P O R T,7,GvHD-paper.pdf,713,False
ecabee0112eaf7379ad6bd8a3d9b563b,"8. C. D. Ford et al., Biol. Blood Marrow Transplant. 23, 340–346 (2017).

9. H. J. Khoury et al., Haematologica 102 , 958–966 (2017).

10. Y. Shono et al., Sci. Transl. Med. 8, 339ra71 (2016).

11. Y. Taur et al., Blood 124, 1174–1182 (2014).

12. R. R. Jenq et al., Biol. Blood Marrow Transplant. 21, 1373–1383 (2015).

13. Y. Taur et al., Sci. Transl. Med. 10, eaap9489 (2018).

14. N. Steck et al., Gastroenterology 141, 959–971 (2011).

15. N. Geva-Zatorsky et al., Cell 168, 928–943.e11 (2017).",7,GvHD-paper.pdf,714,False
f98e448083fb8b012f78d194832d0af0,"16. K. Riesner, M. Kalupa, Y. Shi, S. Elezkurtaj, O. Penack, Bone Marrow Transplant. 51, 410–417 (2016).",7,GvHD-paper.pdf,715,False
2b1cefcfe11890ef7a98cb3eb3350980,"17. K. Dubin, E. G. Pamer, Microbiol. Spectr. doi:10.1128/ microbiolspec.BAD-0014-2016 (2014).

18. R. R. Jenq et al., J. Exp. Med. 209, 903–911 (2012).

19. S. Caballero et al., Cell Host Microbe 21, 592–602.e4 (2017).

20. N. W. Palm et al., Cell 158, 1000–1010 (2014).

21. K. Brandl et al., Nature 455, 804–807 (2008).

22. D. Zhao et al., J. Clin. Invest. 128, 4970–4979 (2018).

23. C. A. Lindemans et al., Nature 528, 560–564 (2015).",7,GvHD-paper.pdf,716,False
844f03a80df8824203382ac8a66b42ac,"24. K. H. Schleifer, A. Hartinger, F. Götz, FEMS Microbiol. Lett. 3, 9–11 (1978)

25. D. Weber et al., Biol. Blood Marrow Transplant. 23, 845–852 (2017).

26. P. A. Gill, M. C. van Zelm, J. G. Muir, P. R. Gibson, Aliment. Pharmacol. Ther. 48 , 15–34 (2018).

27. N. D. Mathewson et al., Nat. Immunol. 17, 505–513 (2016).

28. B. W. Haak et al., Blood 131, 2978–2986 (2018).",7,GvHD-paper.pdf,717,False
f6b98e530bc67dd68f8f5687a97a2932,"29. C. J. Ingram, C. A. Mulcare, Y. Itan, M. G. Thomas,",7,GvHD-paper.pdf,718,False
60b5e08e880db750dfac334ad240cf18,"D. M. Swallow, Hum. Genet. 124, 579–591 (2009).

30. J. Vydra et al., Clin. Infect. Dis. 55, 764–770 (2012).

31. S. Manfredo Vieira et al., Science 359, 1156–1161 (2018).

32. S. G. Kim et al., Nature 572, 665–669 (2019).",7,GvHD-paper.pdf,719,False
4a4fe6d4742a212bd8f1911839a25611,ACKN OW LEDG MEN TS,7,GvHD-paper.pdf,720,False
cd1abda4119c77820e44c5f6043b14ef,"We thank G. M. Dunny and J. Willett (Department of Microbiology, University of Minnesota) as well as R. Zbasnik and V. Schlegel (Department of Food Science, University of Nebraska) for helpful discussion and for providing materials for revision of the manuscript. Funding: This work was supported by a German Research Foundation (DFG) scholarship to",7,GvHD-paper.pdf,721,False
cc03def43a24e60552a9b5ad0569d094,"Bone Marrow Transplantation to C.K.S.-T.; partially supported by the DFG research consortium TR221 “GvH/GvL” (project B13) to E.H.; by NCI awards R01-CA228358 (M.R.M.v.d.B.), R01-CA228308 (M.R.M.v.d.B.), MSKCC Cancer Center Core Grant P30 CA008748, and Project 4 of P01-CA023766 (M.R.M.v.d.B.); NHLBI award R01-HL125571 (M.R.M.v.d.B.), R01-HL123340 (M.R.M.v.d.B.), and K08-HL143189 (J.U.P.); NIA National Institute of Aging award Project 2 of P01-AG052359 (M.R.M.v.d.B.); NIAID award U01 AI124275",7,GvHD-paper.pdf,722,False
5f489ce125e5317c2d466c67c9bcff5e,(M.R.M.v.d.B.); R01 AI032135 (E.G.P.); AI095706 (E.G.P.); U01 AI124275 (E.G.P. and J.B.X.); Tri-Institutional Stem Cell Initiative award 2016-013 (M.R.M.v.d.B.); the Lymphoma Foundation (M.R.M.v.d.B. and N.K.); the Susan and Peter Solomon Divisional Genomics Program (M.R.M.v.d.B.); the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center (M.R.M.v.d.B. and J.U.P.); the Sawiris Foundation (J.U.P.); the Society of Memorial Sloan Kettering Cancer Center (J.U.P.); MSKCC,7,GvHD-paper.pdf,723,False
334d94a329fb129325afc5bc3478c8b2,"Cancer Systems Immunology Pilot Grant (J.U.P.); Empire Clinical Research Investigator Program (J.U.P.); Seres Therapeutics (M.R.M.v.d.B., J.U.P., J.B.S., A.L.C.G., A.G.C., A.E.S., and A.D.S.); Japan Society for the Promotion of Science KAKENHI (17H04206 to T.T. and 17K09945 to D.H.); the Center of Innovation Program from Japan Science and Technology Agency (T.T.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (D.H.); R56 AI137269-01 (J.B.X.); Conquer Cancer Foundation Young",7,GvHD-paper.pdf,724,False
1871f55a7f0f2c529f132e462c348f1a,"Investigator Award/Gilead Sciences (N.K.); NIH KL2 TR001115-03 (NCATS CTSA to A.D.S.); NIA 2P30AG028716-11 (Claude D. Pepper Older Americans Independence Center to A.D.S.); NCI R01CA203950-01 (to N.J.C., A.D.S., L.B., M.L, and A.B.); NIH 1R01HL124112-01A (A.D.S. and R.R.J.); and NIA R21AG066388- 01 (A.D.S. and N.J.C.). Author contributions: C.K.S.-T., E.G.P., J.U.P, and M.R.M.v.d.B. conceptualized the project; C.K.S.-T., A.L.C.G., A.S., S.D., A.P., J.R.C., Y.T., R.R.J., J.B.X., E.R.L., and",7,GvHD-paper.pdf,725,True
27b96da7aaba4ffa978c81b0588369cb,"J.U.P. were involved in data curation and formal analyses; C.K.S.-T., K.B.N., A.L., M.D.D., A.E.S., J.B.S., A.G.C., G.A., Y.S., M.B.d.S., K.A.M., D.B., R.P., A.T., S.M., M.E.A., A.J.P., M.M., R.J.W., L.A.A., E.F., D.P., M.A.J., D.W., A.D.S., D.H., C.S., J.A.M., K.R., M.L., A.B., L.B., K.H., and Y.H. conducted",7,GvHD-paper.pdf,726,False
7ec483f2224a8f2392e0bc836fcea6c8,"and M.R.M.v.d.B.

the",7,GvHD-paper.pdf,727,False
098e8540f566a36f09c7ff336ae43224,"project and provided validation; and C.K.S.-T., J.U.P., A.L.C.G., and M.R.M.v.d.B. prepared data presentation and wrote the manuscript with contributions from all other authors. Competing interests: M.R.M.v.d.B has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia",7,GvHD-paper.pdf,728,True
b85d8dc30fb90891dae4ff89521909cc,"Forum (ALF), and DKMS Medical Council (Board); and has IP Licensing with Seres Therapeutics and Juno Therapeutics and stock options from Smart Immune. J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics and consulting fees from Davolterra. A.D.S. received research support from Seres Therapeutics, Merck, and Novartis. E.G.P. has received speaker honoraria from Bristol-Myer Squibb, Celgene, Seres Therapeutics, MedImmune, Novartis, and",7,GvHD-paper.pdf,729,False
3ce3922fd862b683589b6308cb40b131,"Ferring Pharmaceuticals; is an inventor on patent application number WPO2015179437A1, entitled “Methods and compositions for reducing Clostridium difficile infection,” and patent number WPO2017091753A1, entitled “Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization”; and holds patents that receive royalties from Seres Therapeutics Inc. Other authors have no competing interests. Data and materials availability: All data are available in the manuscript",7,GvHD-paper.pdf,730,True
c5d7e17d22ae9815bc9276c1ae2e7731,or the supplementary materials. Sequencing data have been deposited into Sequence Read Archive under Bioproject number PRJNA545312.,7,GvHD-paper.pdf,731,False
b86b112b68e089e2ccc141d9bf134976,"SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/366/6469/1143/suppl/DC1 Materials and Methods",7,GvHD-paper.pdf,732,False
88c106e577df0ac4a12965f4ad81d4f7,"Table S1 to S10

Fig S1 to S10",7,GvHD-paper.pdf,733,False
c323fd5cf565794de8d5b347309531b5,References (33–53),7,GvHD-paper.pdf,734,False
6ed3e026ad2343dec4a659bb013686c3,"View/request a protocol for this paper from Bio-protocol.

18 March 2019; accepted 22 October 2019 10.1126/science.aax3760",7,GvHD-paper.pdf,735,False
3430d068bf0ac74e284767b7e1e129e3,"D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",7,GvHD-paper.pdf,736,False
ac9c3055469a5127f3b82f8a6d66f516,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",7,GvHD-paper.pdf,737,False
f14dec2373fedbe6dff40a95eb608568,7 of 7,7,GvHD-paper.pdf,738,False
02099e1d2e387216ba2b8a68ac35519d,Science,8,GvHD-paper.pdf,739,False
95242abae2592d3655f378dd677c95b1,Lactose drives Enterococcus expansion to promote graft-versus-host disease,8,GvHD-paper.pdf,740,True
8734c737217262e9a8bc0594af3dcc4d,"C. K. Stein-Thoeringer, K. B. Nichols, A. Lazrak, M. D. Docampo, A. E. Slingerland, J. B. Slingerland, A. G. Clurman, G. Armijo, A. L. C. Gomes, Y. Shono, A. Staffas, M. Burgos da Silva, S. M. Devlin, K. A. Markey, D. Bajic, R. Pinedo, A. Tsakmaklis, E. R. Littmann, A. Pastore, Y. Taur, S. Monette, M. E. Arcila, A. J. Pickard, M. Maloy, R. J. Wright, L. A. Amoretti, E. Fontana, D. Pham, M. A. Jamal, D. Weber, A. D. Sung, D. Hashimoto, C. Scheid, J. B. Xavier, J. A. Messina, K. Romero, Lew, A.",8,GvHD-paper.pdf,741,False
0ee78abf427c8c727b361eeac860f7db,"Bush, L. Bohannon, K. Hayasaka, Y. Hasegawa, M. J. G. T. Vehreschild, J. R. Cross, D. M. Ponce, M. A. Perales, S. A. Giralt, R. R. Jenq, T. Teshima, E. Holler, N. J. Chao, E. G. Pamer, J. U. Peled and M. R. M. van den Brink M.",8,GvHD-paper.pdf,742,False
da8b6b9c96b5c1e95d953cec18703fee,"Science 366 (6469), 1143-1149. DOI: 10.1126/science.aax3760",8,GvHD-paper.pdf,743,False
6f807ca803e28e00e4b68668828e6ed1,Lactose can fuel GVHD,8,GvHD-paper.pdf,744,False
3a2aa0457adcaff586239378cb1d9d6e,"Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to",8,GvHD-paper.pdf,745,True
4b00abb7d1147c6075f334a2fe5f2f66,"provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models.",8,GvHD-paper.pdf,746,True
f9bf510acd31f4ac1aed82f7cca5e062,"Science , this issue p. 1143; see also p. 1077

ARTICLE TOOLS http://science.sciencemag.org/content/366/6469/1143 SUPPLEMENTARY MATERIALS http://science.sciencemag.org/content/suppl/2019/11/25/366.6469.1143.DC1 RELATED CONTENT http://science.sciencemag.org/content/sci/366/6469/1077.full REFERENCES This article cites 52 articles, 15 of which you can access for free http://science.sciencemag.org/content/366/6469/1143#BIBL PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions",8,GvHD-paper.pdf,747,False
6b10d0e8a86c5ba571d15af9275eae2e,"o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",8,GvHD-paper.pdf,748,False
1fa82183f174a28e533c2a9cd205cd05,Use of this article is subject to the Terms of Service,8,GvHD-paper.pdf,749,False
c8e6b200448abed775db27c170ce4684,"Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title Science is a registered trademark of AAAS.",8,GvHD-paper.pdf,750,False
e04c640ef2eefc98b058908fb41e69b4,"Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works",8,GvHD-paper.pdf,751,False
=======
element_id,text,page_number,filename,chunk_id,relevant
38dc4ba7c2bf7ed7323042c35312ad5f,Article,1,ALD patent background + target paper.pdf,1,False
26e2ffa12765874ed647b25892f5742c,Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease,1,ALD patent background + target paper.pdf,2,True
c63fdce5cb4625e212fa4efac8896883,"https://doi.org/10.1038/s41586-019-1742-x Received: 9 April 2019 Accepted: 2 October 2019 Published online: 13 November 2019

https://doi.org/10.1038/s41586-019-1742-x",1,ALD patent background + target paper.pdf,3,False
d0c8e114f7b68a282cb37bd9079e3521,"Received: 9 April 2019

Accepted: 2 October 2019

Published online: 13 November 2019",1,ALD patent background + target paper.pdf,4,False
c6459af67a5b5bcbc573101561e95a20,"Yi Duan1,2,29, Cristina Llorente1,2,29, Sonja Lang1, Katharina Brandl3, Huikuan Chu1, Lu Jiang1,2, Richard C. White4, Thomas H. Clarke4, Kevin Nguyen4, Manolito Torralba5, Yan Shao6, Jinyuan Liu7, Adriana Hernandez-Morales8, Lauren Lessor9, Imran R. Rahman10, Yukiko Miyamoto1, Melissa Ly11, Bei Gao1, Weizhong Sun1, Roman Kiesel1, Felix Hutmacher1, Suhan Lee1, Meritxell Ventura-Cots12, Francisco Bosques-Padilla13, Elizabeth C. Verna14, Juan G. Abraldes15, Robert S. Brown Jr16, Victor Vargas17,18,",1,ALD patent background + target paper.pdf,5,False
ce9eb7d75f558f48a95a559ddca7a40c,"Jose Altamirano17, Juan Caballería18,19, Debbie L. Shawcross20, Samuel B. Ho1,2, Alexandre Louvet21, Michael R. Lucey22, Philippe Mathurin21, Guadalupe Garcia-Tsao23,24, Ramon Bataller12, Xin M. Tu7, Lars Eckmann1, Wilfred A. van der Donk10,25,26, Ry Young8,9, Trevor D. Lawley6, Peter Stärkel27, David Pride1,11,28, Derrick E. Fouts4 & Bernd Schnabl1,2,28*",1,ALD patent background + target paper.pdf,6,False
a97990c757688b2ad9f9547223e628af,"Chronic liver disease due to alcohol-use disorder contributes markedly to the global burden of disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease. The gut microbiota promotes ethanol- induced liver disease in mice4, but little is known about the microbial factors that are responsible for this process. Here we identify cytolysin—a two-subunit exotoxin that is secreted by Enterococcus faecalis5,6—as a cause of hepatocyte death",1,ALD patent background + target paper.pdf,7,True
7700e213119d995bb900c028b2058ba8,"and liver injury. Compared with non-alcoholic individuals or patients with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with the severity of liver disease and with mortality in patients with alcoholic hepatitis. Using humanized mice that were colonized with bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic effects of",1,ALD patent background + target paper.pdf,8,True
55628f8d8fcd11065a2f49008a2a0a12,"bacteriophages that target cytolytic E. faecalis. We found that these bacteriophages decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our findings link cytolytic E. faecalis with more severe clinical outcomes and increased mortality in patients with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, which provides a method for precisely editing the intestinal microbiota. A clinical trial with a larger cohort",1,ALD patent background + target paper.pdf,9,True
c89b81b155163e63a1fc1b3046eaa555,"is required to validate the relevance of our findings in humans, and to test whether this therapeutic approach is effective for patients with alcoholic hepatitis.",1,ALD patent background + target paper.pdf,10,False
4d0808dcc0de15622ab920197f3e824e,"The most severe form of alcohol-related liver disease is alcoholic hepa- titis; mortality ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a diagnosis of severe alcoholic hepatitis7–9. Therapy with corticosteroids is only marginally effective9. Early liver transplantation is the only curative therapy, but is offered only at select centres and to a limited group of patients10.",1,ALD patent background + target paper.pdf,11,True
06eaaa92b96ca86c0147a2adb438eadb,Alcohol-related liver disease can be transmitted via faecal micro- biota4. We investigated the microorganisms and microbial factors that are responsible for this transmissible phenotype and for progression of alcohol-related liver disease.,1,ALD patent background + target paper.pdf,12,True
4d2733e4cdaa6f457e875d11f778b79d,Cytolysin linked to increased mortality,1,ALD patent background + target paper.pdf,13,False
06099ce696361c3be7c57600551dbda6,We performed 16S ribosomal RNA (rRNA) gene sequencing to deter- mine whether chronic alcohol use and alcoholic hepatitis are associated,1,ALD patent background + target paper.pdf,14,False
3c75a20ca0d5bdc385ad95ad226bec3e,A list of affiliations appears at the end of the paper.,1,ALD patent background + target paper.pdf,15,False
7d4f7d11058fefb73c25d74168a266b2,"with an altered composition of the faecal microbiota. Differences in faecal microbiota composition were noted in patients with alcohol-use disorder and alcoholic hepatitis, compared to subjects without alcohol- use disorder (controls) (Fig. 1a, Extended Data Fig. 1a, b, Supplementary Tables 1, 2). One substantial difference that we observed was an increase in the proportion of Enterococcus spp. in patients with alcoholic hepa- titis: in these patients, 5.59% of faecal bacteria were Enterococcus",1,ALD patent background + target paper.pdf,16,True
5d8c1ebe16d59c1d317dffc791695a29,"spp. compared with almost none in controls (0.023%; for comparison, 0.004% of all reads were Enterococcus spp. in the Human Microbiome Project) or patients with alcohol-use disorder (0.024%). Faecal sam- ples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls, as measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), which is consistent with the 16S rRNA sequencing results. About 80% of patients with alcoholic hepatitis are positive for",1,ALD patent background + target paper.pdf,17,True
23eb93f6a5a4adf3124516a9c68c369f,E. faecalis in their faeces (Extended Data Fig. 1d).,1,ALD patent background + target paper.pdf,18,False
1b56a72a75d88bec0d17852044764348,"Nature | www.nature.com | 1

1",1,ALD patent background + target paper.pdf,19,False
73c263972496be4b420d04d0716712e2,Article,2,ALD patent background + target paper.pdf,20,False
76d6ee0795bc5c05a1c1e0cd1dc54a55,Controls 0.2 Alcohol-use disorder Alcoholic hepatitis ) % 5 7 . 7 1 ( 2 C P 0.1 0 −0.1 –0.2 –0.1 0 0.1 0.2 PC1 (29.25%),2,ALD patent background + target paper.pdf,21,False
1ee3a58fce339219f39ea9c5f9837725,"m

b",2,ALD patent background + target paper.pdf,22,False
735a5be842bab422a9a4f67f034f1160,100 Cytolysin-negative Cytolysin-positive ) % ( s t c e j b u S 80 60 40 20 0 Controls AUD Alcoholic,2,ALD patent background + target paper.pdf,23,False
a75eeac34e5709b9036e011db140cfe9,"m

=",2,ALD patent background + target paper.pdf,24,False
113d2dbdac5ce846a979532264d47059,) % ( l a v i v r u S 100 75 50 25 0 0 30 Cytolysin-negative Cytolysin-positive 60 90 120 150 180 Time (d),2,ALD patent background + target paper.pdf,25,False
98d5cb71dc3bd8a7ac9d5bdee0ce3872,d,2,ALD patent background + target paper.pdf,26,False
124ad639f11e561ec410ed0d94906c5c,0.15 Cytolysin-negative Cytolysin-positive,2,ALD patent background + target paper.pdf,27,False
712a9a756bc344c83b2da17daab96e2d,"@

@",2,ALD patent background + target paper.pdf,28,False
2fa8aa848b6439279c98de0fa1e9d8cd,"Fig. 1 | E. faecalis cytolysin is associated with mortality in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n = 75). We use principal coordinate analysis (PCoA) based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between each group (P < 0.01). b, Percentage of subjects",2,ALD patent background + target paper.pdf,29,False
2a0fa3f8a748f185786faa503f15c12e,"with faecal samples that were positive for both cylLL and cylLS DNA sequences (cytolysin-positive), in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. Statistically significant differences were detected between controls and patients with alcoholic hepatitis (P < 0.01), and between patients with alcohol- use disorder and patients with alcoholic hepatitis (P < 0.001). c, Kaplan–Meier curve of survival of patients with alcoholic",2,ALD patent background + target paper.pdf,30,True
c0cb33fc914a181a931f63d3f064994f,"hepatitis whose faecal samples were cytolysin-positive (n = 25) or cytolysin-negative (n = 54) (P < 0.0001). d, Core genome single-nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis (n = 93 strains, from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. faecalis. Genomically identical isolates from the same patient were combined, and are shown as a single dot. Scale bar represents the nucleotide substitutions per",2,ALD patent background + target paper.pdf,31,True
5f83e60c4dddb2f0280d1a7e278bce89,"SNP site. P values are determined by permutational multivariate analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR procedures (b) or two-sided log- rank (Mantel–Cox) test (c). The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",2,ALD patent background + target paper.pdf,32,True
561904fc909fe66441a85e2fd6b522a7,"The colonization of mice with E. faecalis induces mild hepatic stea- tosis and exacerbates ethanol-induced liver disease11, by mechanisms that are unclear. Cytolysin is a bacterial exotoxin (or bacteriocin) that is produced by E. faecalis12, and which contains two post-translationally modified peptides (CylLL′′ and CylLS′′) in its bioactive form6. The two peptides are encoded by two separate genes: cylLL and cylLS, respec- tively12. Cytolysin has lytic activity against not only Gram-positive",2,ALD patent background + target paper.pdf,33,True
611eb13b2d6e50c5fddc28b53f5e5681,"bacte- ria, but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA (cytolysin-positive) in faecal samples from 30% of patients with alco- holic hepatitis; none of the faecal samples from controls and only one sample from a patient with alcohol-use disorder was cytolysin-positive, as detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-positive patients with alcoholic hepatitis died within 180 days of admission, compared to only 3.8% of cytolysin-negative patients (P < 0.0001)",2,ALD patent background + target paper.pdf,34,True
143566463ffffbf593619724e143bd32,"(Fig. 1c). Among the cytolysin-positive patients, 72.2% (13 out of 18) died owing to liver failure (including complications related to liver",2,ALD patent background + target paper.pdf,35,True
df50d5c1f7816dd69d7ccb9fe933280b,2 | Nature | www.nature.com,2,ALD patent background + target paper.pdf,36,False
caa8512566105619e699d5975503c375,"failure, such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not associated with 30-day, 90-day or 180-day mortality (P = 0.403, 0.234 or 0.098) in patients with alcoholic hepatitis.",2,ALD patent background + target paper.pdf,37,True
79535293be1afc815d786a3f02a7f4b1,"Our univariate logistic and Cox regression of laboratory and clinical parameters found an association between the detection of cytolysin- encoding genes in faeces and the international normalized ratio (INR), platelet count, the model for end-stage liver disease (MELD) score, the sodium MELD score, the age, serum bilirubin, INR and serum creatinine (ABIC) score and death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding genes in faeces was associated with",2,ALD patent background + target paper.pdf,38,True
e6d629f4b1c9cb4dc395249f617132df,"90-day (P = 0.004) and with 180-day mortality (P = 0.001) (Supple- mentary Table 3), even after we adjusted for the geographical origin of the patient, antibiotic treatment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. We found no multicollinear- ity between the detection of faecal cytolysin-encoding genes and these cofactors (variance inflation factor < 1.6), which indicates that cytolysin is an independent predictor of mortality in patients with alcoholic",2,ALD patent background + target paper.pdf,39,True
94cde9ce9ef95ccd106fb02ae05cfb3e,"hepatitis. When we performed receiver-operating-characteristic curve analysis for 90-day mortality, cytolysin had an area under the curve of 0.81, which was superior to other widely used predictors for mortality in clinical practice (Extended Data Fig. 1e). On the basis of our findings, we propose that the detection of cytolysin may be a prognostic factor for more severe liver- related outcomes and increased risk of death, and a stronger predictor of mortality than MELD, ABIC and the",2,ALD patent background + target paper.pdf,40,True
1d4eff578119b5aee479d42cbd917a44,discriminant function score.,2,ALD patent background + target paper.pdf,41,False
902cf4996a4515d0de2f125dc02eddb3,"To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed targeted culturing from stool samples. Whole- genome sequencing of 93 E. faecalis isolates revealed a broad phylo- genetic diversity of cytolysin-positive E. faecalis from patients with alcoholic hepatitis (Fig. 1d), which indicates that cytolysin production is a variable trait among E. faecalis isolates and that cytolysin is car- ried in mobile genetic elements, which include both chromosomally encoded",2,ALD patent background + target paper.pdf,42,True
ebbb35022ddcef9c9c90ac7e6187c74d,pathogenicity islands and plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Table 4).,2,ALD patent background + target paper.pdf,43,True
4715251334e04eee26610aa45866c63d,"The total amount of faecal E. faecalis, or faecal E. faecalis positivity, did not correlate with disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5, 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar amounts of faecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the composition of the gut microbiota in patients with alcoholic hepatitis from different geographical regions (Extended Data",2,ALD patent background + target paper.pdf,44,True
f6ecdb28a54e5d4d94f4a14a103736db,"Fig. 1g), the proportion of cytolysin-positive patients, total amount of faecal E. faecalis, faecal E. faecalis positivity (Extended Data Fig. 1h–j), treatment and clinical outcomes (30-day and 90-day mortality) did not differ significantly among the regions or centres (Supplemen- tary Table 7). In addition, cirrhosis was not associated with cytolysin positivity, the total amount of faecal E. faecalis or faecal E. faecalis positivity in patients with alcoholic hepatitis (Extended Data Fig. 1k–m,",2,ALD patent background + target paper.pdf,45,True
e6db8bdc4405a6e2124134e9bb1b881b,Supplementary Tables 4–6). These results confirm our findings that the presence of cytolysin-producing E. faecalis rather than the total amount or presence of E. faecalis per se determines the severity of alcoholic hepatitis and mortality.,2,ALD patent background + target paper.pdf,46,True
a9175ffd6b2a8c9d9369c88800c62de5,Cytolysin and ethanol-induced liver disease,2,ALD patent background + target paper.pdf,47,False
4394ea43077688af40457154fcf3fe86,"To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we gavaged mice with a cytolytic E. faecalis strain (FA2- 2(pAM714)) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol diet15. Compared to mice gavaged with phosphate-buffered saline (PBS), mice fed with ethanol after they were gavaged with cytolytic E. faecalis developed more severe liver injury as indicated by a higher level of alanine amino-",2,ALD patent background + target paper.pdf,48,True
fd11f9ad465e4f18bbedd2fd7a5c22b7,"transferase (ALT) (Extended Data Fig. 2a) and increased hepatic stea- tosis (Extended Data Fig. 2b, c). Mice that were fed ethanol after they",2,ALD patent background + target paper.pdf,49,False
95f53b61b8996663894a1aaf9ef13479,") 1 – l U ( T L A f o 400 300 200 100 0 * *** *** ** Control Ethanol

b e d i r e c y l g i r t c i t a p e H ) r e v i l g r e p g m ( t n e t n o 50 40 30 20 10 0 **** **** *** * c",3,ALD patent background + target paper.pdf,50,False
f783712950b6a6e589e7a209e225ac81,c Control Ethanol Alcoholic hepatitis cytolysin-positive Alcoholic hepatitis cytolysin-positive Alcoholic hepatitis cytolysin-negative Alcoholic hepatitis cytolysin-negative no. 1 no. 2 no. 3 no. 4,3,ALD patent background + target paper.pdf,51,False
7d5351f64a8e7cbe13a79113871b1981,e,3,ALD patent background + target paper.pdf,52,False
190a75bfdec6ebfed3223da5fdc372e7,Cxcl1 e g n a h c d l o F 8 6 4 2 ** ** ** ** 0 Control Ethanol,3,ALD patent background + target paper.pdf,53,False
8f0e8eb8f52f9d1bc2c7b5fdef895f67,f,3,ALD patent background + target paper.pdf,54,False
75ec8a01e024eaadee39774b53737e37,Col1a1,3,ALD patent background + target paper.pdf,55,False
82b39a7f876867084f29cff5f9ea31bd,20 15 10 5 ** *** * * 0,3,ALD patent background + target paper.pdf,56,False
1df93d55e9f82344369a97e9ba92c93c,"h

LDH",3,ALD patent background + target paper.pdf,57,False
57573269094a7f78415d8f85eb3319d4,) % 40 * * ** ** ( y t i c i x o 30 20 t o t 10 y C 0 0 0 0 200 0 400 200 200 400 400 0 0 0 200 0 400 200 200 400 400 CylLS″ (nM) CylLL″ (nM) – + Ethanol,3,ALD patent background + target paper.pdf,58,False
dc7c1afebf70597a5de085db44d80dda,B,3,ALD patent background + target paper.pdf,59,False
e810dd71da3b6a70eb0070087726cf23,Alcoholic hepatitis cytolysin-positive no. 1,3,ALD patent background + target paper.pdf,60,False
f128b6cff45e0fde3b9b4273a97874b4,B,3,ALD patent background + target paper.pdf,61,False
c10c304c517e30fcf8ca5d265da88077,Alcoholic hepatitis cytolysin-positive no. 2,3,ALD patent background + target paper.pdf,62,False
bc91e1614e9736869b124fd97b938a92,B,3,ALD patent background + target paper.pdf,63,False
1fc4a1351455f6b45915414aef592df2,Alcoholic hepatitis cytolysin-negative no. 3,3,ALD patent background + target paper.pdf,64,False
fa39277d6ecdc7cb47baff17b520ec0e,B,3,ALD patent background + target paper.pdf,65,False
13642507312e158b14bd814c07aadd42,"Alcoholic hepatitis cytolysin-negative no. 4

e g n 8 6 Il1b * * ** ** a h c d l o F 4 2 0 Control Ethanol",3,ALD patent background + target paper.pdf,66,False
e2ffa722ceac59e9405ddddd06ac4522,g,3,ALD patent background + target paper.pdf,67,False
4691f661a3a03882c23eaa532cc46324,) % ( e c i M 100 80 60 40 20 **** **** **** **** 0 ND ND ND ND ND ND Control Ethanol,3,ALD patent background + target paper.pdf,68,False
18309b33a1388b7cb383ddfb9a32ca50,"Fig. 2 | Transplantation of faeces from cytolysin-positive patients with alcoholic hepatitis exacerbates ethanol-induced liver disease in gnotobiotic mice. a–g, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and subjected to the chronic–binge feeding model. a, Serum levels of ALT. b, Hepatic triglyceride content. c, Representative sections of liver stained with haematoxylin and eosin (H & E). d–f,",3,ALD patent background + target paper.pdf,69,False
9910f42a7fcd0544b1e8216a1cc703e5,"Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Lactate dehydrogenase (LDH) assay to measure cytotoxicity of hepatocytes isolated from mice that were fed an oral isocaloric control diet (five groups, left) or chronic–binge ethanol diet (five",3,ALD patent background + target paper.pdf,70,False
803be30d6b7b9beb9e0d255c9c9300e4,"groups, right), and incubated with vehicle, CylLS′′, CylLL′′ or both of the cytolysin subunits at the indicated concentrations without (–) or with (+) ethanol (25 mM) for 3 h. The survival of hepatocytes was determined in three independent experiments. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h). P values are determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures (g) or",3,ALD patent background + target paper.pdf,71,True
fd3e1df3ce5c323b45e75f5eaef59c84,"two-way ANOVA with Tukey’s post hoc test (h). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",3,ALD patent background + target paper.pdf,72,True
c721bc91a482f5706172d5baa91a3482,"were gavaged with cytolytic E. faecalis also had more liver inflamma- tion with higher expression levels of mRNAs that encode inflamma- tory cytokines and chemokines (Il1b, Cxcl1 and Cxcl2) (Extended Data Fig. 2d–f), compared with mice given PBS. Mice that were fed ethanol after they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver injury, steatosis and inflammation (Extended Data Fig. 2a–f) and longer survival times (Extended Data Fig. 2g), as compared",3,ALD patent background + target paper.pdf,73,True
55b00e1bcb01657867d762506aa72d32,with mice that were fed ethanol after they were administered with cytolytic E. faecalis.,3,ALD patent background + target paper.pdf,74,False
549e1cb07f3051eab773a26b636ae6b4,"To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in the liver. CylLS was significantly increased in the liver of mice given cytolytic E. faecalis but not in the liver of mice that were not given E. faecalis or of mice gavaged with non-cyto- lytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable in the liver of mice given cytolytic and",3,ALD patent background + target paper.pdf,75,True
b475e1e40238cbba321930bb216f97e5,"non-cytolytic E. faecalis and fed an ethanol diet, but not when mice were fed an isocaloric (control) diet (Extended Data Fig. 2i); this indicates that ethanol-induced changes in the gut barrier are necessary for the translocation of cytolytic E. faecalis from the intestine to the liver. The livers of ethanol-fed mice that were given cytolytic or non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed an increased intestinal permeability in ethanol-fed",3,ALD patent background + target paper.pdf,76,True
7d4ebbeeede3993511a3bce1787cd23e,"mice com- pared with mice fed with an isocaloric diet, but this was independent of gavaging cytolytic or non-cytolytic E. faecalis after chronic ethanol administration (Extended Data Fig. 2k), indicating that cytolysin does not affect intestinal barrier function.",3,ALD patent background + target paper.pdf,77,False
c1a4bb6c553d4c3522586bf5dca2d7c3,"Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change the composition of the intestinal microbiota, as shown by 16S rRNA gene sequencing (Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic metabolism",3,ALD patent background + target paper.pdf,78,True
6563a4fb3326224380eb67e239b4f3dd,"Nature | www.nature.com | 3

3",3,ALD patent background + target paper.pdf,79,False
19a6f4c196234388e8a8acbaa1ee6592,Article,4,ALD patent background + target paper.pdf,80,False
0f4ccadb444959df47f80ec6b5d469b7,a Ef5.1 Ef5.2 Ef5.3 Ef5.4 Ef2.1 Ef2.2 Ef2.3,4,ALD patent background + target paper.pdf,81,False
78e12020e720a69b54ce09bcc7341104,b,4,ALD patent background + target paper.pdf,82,False
013a18ee735f1bb8648deda393d7ebc1,"s l e v e l m u r e S ) 1 – l U ( T L A f o 400 300 200 100 0 Patient no. 5 Patient no. 2 * Patient no. 5 ** Patient no. 2

) r e v i l g r e p g m ( t n e t n o c 50 40 30 20 10 0 Patient no. 5 Patient no. 2 * Patient no. 5 ** Patient no. 2 C. crescentus phages Cytolysin-positive E. faecalis phages C. crescentus phages Cytolysin-positive E. faecalis phages",4,ALD patent background + target paper.pdf,83,False
4400c8574cac974c6faf5bac99f26acf,"m

m

m

=",4,ALD patent background + target paper.pdf,84,False
ab412a1bbb7c15e2d79d3784d38aa6d4,d Control Ethanol C. crescentus phages Cytolysin-positive E. faecalis phages C. crescentus phages Cytolysin-positive E. faecalis phages,4,ALD patent background + target paper.pdf,85,False
ab91b16af9c1052874d2fa08a71e7972,"Patient no. 5

Patient no. 2",4,ALD patent background + target paper.pdf,86,False
3ea36ad5f4ef434af39f1e959df3745a,"f

e g n a h c d l o F",4,ALD patent background + target paper.pdf,87,False
1c6765e387db976aec2047d28756751a,12,4,ALD patent background + target paper.pdf,88,False
9cbd0d168fa705fe6956a5719b408d8f,RN ov®O,4,ALD patent background + target paper.pdf,89,False
2a6a074a66b424dc10f4f5ac68e0711b,"8

6

4

2",4,ALD patent background + target paper.pdf,90,False
564a0feba2735fd38cd4c7b5ab671f11,0,4,ALD patent background + target paper.pdf,91,False
f43c2702e38dc8c88ad130b8349138a4,Patient no. 5,4,ALD patent background + target paper.pdf,92,False
289df7d5ee7fc7e5c436ac12443af009,Cxcl1,4,ALD patent background + target paper.pdf,93,False
56d2ff2df1613aef448ed1a96cb95143,**,4,ALD patent background + target paper.pdf,94,False
6e68accc1b50f9215b23250af60bc417,"Patient no. 2

Patient no. 5",4,ALD patent background + target paper.pdf,95,False
97939730e441b14e6f98968aad19d4b4,"**

]",4,ALD patent background + target paper.pdf,96,False
cd59d679af71d122ac411e88c47bed5d,"Patient no. 2

g Col1a1 e g n a h c d l o F 18 15 12 9 6 3 0 * * Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2",4,ALD patent background + target paper.pdf,97,False
9d30c625e20a82632d805e7a1e2b9ba1,Control,4,ALD patent background + target paper.pdf,98,False
1b8e3c888964f82d160ca11a736638f0,"Ethanol

e g n a h c d l o F 12 10 8 6 4 2 0 Il1b * *** Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2 Control Ethanol",4,ALD patent background + target paper.pdf,99,False
78928cc0f21a1e88e0ed8fa6d2843b84,h Liver cylLS ) % ( e c i M 100 80 60 40 20 0 ND ND ND ND ** ** Patient no. 5 Patient no. 2 Patient no. 5 Patient no. 2,4,ALD patent background + target paper.pdf,100,False
7ce91cc6d320d567669d4fb41fb6e415,"Fig. 3 | Phage therapy against cytolytic E. faecalis abolishes ethanol-induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either siphophages (Ef5.1, Ef5.2, Ef5.3, Ef5.4 and Ef2.2) or myophages (Ef2.1 and Ef2.3). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin- positive patients with alcoholic hepatitis (faeces from one of these patients were also used in Fig. 2) and subjected to the",4,ALD patent background + target paper.pdf,101,False
087245f4a6bfbf0ce492cdb0a56d81d7,"chronic–binge feeding model, gavaged with control phages against C. crescentus (1010 plaque-forming units (PFUs)) or a cocktail of three or four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT.",4,ALD patent background + target paper.pdf,102,True
a7c39a657a64b712d359c9350f51198f,"c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. Results are expressed as mean ± s.e.m. (b, c, e–g). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–g) or two-sided Fisher’s exact test followed by FDR procedures (h). All results are generated from at least",4,ALD patent background + target paper.pdf,103,False
79afcc0aa50eef5f8916a4e374c1d1ab,"three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, *** P < 0.001.",4,ALD patent background + target paper.pdf,104,False
d253e3a43ab52f08a6245d521ebcb8d0,"of ethanol, as indicated by serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs (which encode the two primary enzymes that metabolize ethanol in the liver) (Extended Data Fig. 2m, n). These results indicate that E. faecalis that produce cytolysin promote ethanol- induced liver disease in mice.",4,ALD patent background + target paper.pdf,105,True
ffdc6a9c01768b9a6dedf3176294f83d,"To extend our findings to humans, we colonized germ-free mice with faeces from cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobi- otic C57BL/6 mice colonized with faeces from two cytolysin-positive patients developed more severe ethanol-induced liver injury, steatosis, inflammation and fibrosis than mice given faeces from two cytolysin- negative patients (Fig.",4,ALD patent background + target paper.pdf,106,True
672fc5b355217125329e3e73b68077ca,"2a–f, Extended Data Fig. 3a–d). Transplantation of faeces from cytolysin-positive patients reduced the survival time of the mice (Extended Data Fig. 3e) and increased translocation of",4,ALD patent background + target paper.pdf,107,False
be946ee458dd8cadbab40ea30a1ac588,4 | Nature | www.nature.com,4,ALD patent background + target paper.pdf,108,False
3575029f1aaf0a5f7162ca210a4d3957,"cytolytic E. faecalis to the liver after ethanol administration (Fig. 2g). The overall composition of the intestinal microbiota was not differ- ent between mice fed the control diet and colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, as shown by 16S rRNA gene sequencing. Mice transplanted with faeces from one of the cytolysin-positive patients with alcoholic hepatitis (patient no. 2) showed a microbiota that was significantly different from",4,ALD patent background + target paper.pdf,109,True
6e607ff4fcf96493e90864e165d30e92,"that of the other mouse groups after ethanol administration (Extended Data Fig. 3f). Non-cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorp- tion or hepatic metabolism of ethanol between mice colonized with faeces from cytolysin-positive versus cytolysin-negative patients (Extended Data Fig. 3h, i). Together, these results provide further evi- dence that cytolysin promotes",4,ALD patent background + target paper.pdf,110,True
cb929dc98c74ac74c28ad9529a28b4cf,ethanol-induced liver disease.,4,ALD patent background + target paper.pdf,111,False
1bbc7f86cfc32ba44f7dac2f2d8d82d5,a,5,ALD patent background + target paper.pdf,112,False
383cee10961937c5afdc15f5acbb5323,Ef6.1 Ef6.2 Ef6.3 Ef 6.4 Ef7.1 Ef7.2 Ef7.3 Ef 7.4,5,ALD patent background + target paper.pdf,113,False
52bcd86abf9c2f61c1d784d2ff65b6fa,"b

s l e v e l m u r e S",5,ALD patent background + target paper.pdf,114,False
be40cae9c914b69cc8cd0e49fe2f680c,400 300 200 100 0 Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,115,False
b09b7ce249e243b678124f200663978e,"– l U ( T L A

( T L A f",5,ALD patent background + target paper.pdf,116,False
6789bce27839360628aab58049480251,) r e v i l g r e p g m ( t n e t n o c 50 40 30 20 10 0 Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,117,False
efbb08dca037aa8e54161673e370adef,d,5,ALD patent background + target paper.pdf,118,False
4f22338333d83811d471321d21d3b805,Control Ethanol C. crescentus phages Cytolysin-negative E. faecalis phages C. crescentus phages Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,119,False
8a8610bbbb54402ef5460ae36aee6225,"Patient no. 6

Patient no. 7",5,ALD patent background + target paper.pdf,120,False
5129f03594b9fc237f688c34d4d59c2d,"e g n a h c d l o F

N w A O

1",5,ALD patent background + target paper.pdf,121,False
7e87bbb008cec09987c1d6b39ef8ad10,0,5,ALD patent background + target paper.pdf,122,False
36dc816028d9552fae039cc23294e45e,Patient no. 6,5,ALD patent background + target paper.pdf,123,False
b5fb7716d0a145a2b3a91596dc28eee6,Cxcl1,5,ALD patent background + target paper.pdf,124,False
735ca87b2aa81ac8acd8ddd635277c22,"Patient

&6 - - Patient 6",5,ALD patent background + target paper.pdf,125,False
b7b8b0ecdbe70429538bedca18f789dd,g Col1a1 h 6 4 2 0 Patient Patient Patient Patient no. 6 no. 7 no. 6 no. 7 Control Ethanol,5,ALD patent background + target paper.pdf,126,False
e8dbb6b01412ed16ce50e36beae12bba,Control,5,ALD patent background + target paper.pdf,127,False
a5aefcd9aedee04c76c7ba4cbb7343c5,Ethanol,5,ALD patent background + target paper.pdf,128,False
d35c8dba98b33b6e78d0a7232c987eb5,m,5,ALD patent background + target paper.pdf,129,False
2cdedb2f03b8b1cf6d1b11bd060e5c50,C. crescentus phages,5,ALD patent background + target paper.pdf,130,False
0ead233afeb0a0af67b724ad29d3ca27,=,5,ALD patent background + target paper.pdf,131,False
3cb66aa8d757e14e3901ccd8308abe1f,Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,132,False
de27be43736a88de29e968fb59320629,m,5,ALD patent background + target paper.pdf,133,False
58f045e5569d88f5b890fd0c15518c3e,C. crescentus phages,5,ALD patent background + target paper.pdf,134,False
a43e6cc10507c26dffcf888900f3bc36,m,5,ALD patent background + target paper.pdf,135,False
9dd149b05fa9bf83da4eba2433c4d5eb,Cytolysin-negative E. faecalis phages,5,ALD patent background + target paper.pdf,136,False
005fe674c7a4688d1607fd0eb9c322ad,"e g n a h c d l o F 5 4 3 2 1 0 Il1b Patient no. 6 Patient no. 7 Patient no. 6 Patient no. 7 Control Ethanol

s u c 1010 * * c o c o r e t n E l a c ) 1 – g U F C ( 109 108 107 106 e a F 105 Patient Patient Patient Patient no. 6 no. 7 no. 6 no. 7",5,ALD patent background + target paper.pdf,137,False
c6cbc043cc897fa415b8dea12e72b77c,"Fig. 4 | Phages that target non-cytolytic E. faecalis do not reduce ethanol- induced liver disease in gnotobiotic mice. a, Transmission electron microscopy revealed that the phages we isolated were either podophages (Ef6.2, Ef6.3, Ef7.2, Ef7.3 and Ef7.4) or siphophages (Ef6.1, Ef6.4 and Ef7.1). Scale bar, 50 nm. b–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis and subjected to the chronic–binge feeding model, gavaged with",5,ALD patent background + target paper.pdf,138,False
7973d2ef1c740959423bfdf593030801,control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target non-,5,ALD patent background + target paper.pdf,139,False
f4e427a72049170a6628d99269b98ce6,"To determine the mechanism by which cytolysin increases liver dis- ease, we isolated hepatocytes from mice fed ethanol or control diets, and stimulated them with pure bioactive cytolysin peptides (CylLL′′ and CylLS′′)6. Incubation of the primary mouse hepatocytes with the two cytolysin subunits caused a dose-dependent increase in cell death compared to hepatocytes that were incubated with vehicle or with one subunit only (Fig. 2h). When we isolated hepatocytes from ethanol-fed mice and then",5,ALD patent background + target paper.pdf,140,True
214ae1e568b34b33b939e97c1f233f1c,"incubated these hepatocytes with ethanol, we did not observe increased levels of cytolysin-induced cell death compared to hepatocytes isolated from mice on the control diet, which indicates that cytolysin-induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are possibly mediated by pore forma- tion, resulting in cell lysis14.",5,ALD patent background + target paper.pdf,141,True
a5f9ef32e8010a9e78b4bca3dbba2b1d,Bacteriophage treatment in liver disease,5,ALD patent background + target paper.pdf,142,False
135daf9ff022901479d21fc883ecc263,"To further demonstrate the potential causative role of cytolytic E. faecalis for the development of ethanol-induced steatohepatitis,",5,ALD patent background + target paper.pdf,143,False
04d57626eebd065a9b2a19bf645f8cf1,"cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. b, Serum levels of ALT. c, Hepatic triglyceride content. d, Representative H & E-stained liver sections. Scale bar, 100 μm. e–g, Hepatic levels of mRNAs that encode Il1b, Cxcl1 and Col1a1. h, Faecal colony-forming units (CFUs) of Enterococcus. Results are expressed as mean ± s.e.m. (b, c, e–h). P values are determined by two-way ANOVA with Tukey’s post hoc test (b, c, e–h). All results were generated from at least three",5,ALD patent background + target paper.pdf,144,False
e2d7ecc53be51c1878e654a054f9085e,independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05.,5,ALD patent background + target paper.pdf,145,False
20fc8211be2207f7ebbc1f9da4b90d6b,"we investigated the effects of treatment with bacteriophages (here- after, phages). Phages are ubiquitous in bacteria-rich environments, including the gut16. E. faecalis phages that are highly strain-specific can be isolated17, which potentially makes the direct editing of gut microbiota feasible. It has previously been shown that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, which is associated with increased susceptibility to alcohol-induced",5,ALD patent background + target paper.pdf,146,True
f783833317fcda1d67fae16824103ca1,steatohepatitis11. The gavaging of wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice led to increased ethanol-induced steatohepatitis11. We found that this same E. faecalis strain expressed cytolysin. We then isolated four distinct phages from sewage water. These phages lyse the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type littermates,5,ALD patent background + target paper.pdf,147,True
c1196772abedcc34d482006821ba0b99,"were then placed on the chronic–binge ethanol diet and gavaged with the lytic phage cocktail. Phages directed against Caulobacter crescen- tus, a bacterium that is present in freshwater lakes and streams18 but that does not colonize humans or rodents19,20, were used as controls.",5,ALD patent background + target paper.pdf,148,False
e9bb6864c408924f4c8ff606770fd9f9,Nature | www.nature.com | 5,5,ALD patent background + target paper.pdf,149,False
fcd14ba7efbd76de57339e49d31a7130,Article,6,ALD patent background + target paper.pdf,150,False
d9ac1b615fdd2bf5e600d7df13fec8de,"Compared to Atp4aSl/Sl mice gavaged with control phages or vehicle, Atp4aSl/Sl mice gavaged with phages that target cytolytic E. faecalis had less severe liver injury, steatosis and inflammation after chronic ethanol feeding (Extended Data Fig. 5a–f). Administration of E. faecalis phages significantly reduced levels of cytolysin in the liver (Extended Data Fig. 5g) as well as faecal amounts of Enterococcus (Extended Data Fig. 5h). Phage administration did not affect the overall composition of",6,ALD patent background + target paper.pdf,151,True
6f0543ddeb923b7f7262b240d5b70aef,"the faecal microbiome, intestinal absorption or hepatic metabolism of ethanol (Extended Data Fig. 5i–k).",6,ALD patent background + target paper.pdf,152,False
fcaf8ee93aa30caad09e40b224cb1dc1,"To develop a therapeutic approach to precisely edit the intestinal microbiota, we cultured cytolytic E. faecalis strains from the faecal samples of patients with alcoholic hepatitis. We then isolated lytic phages from sewage water against these cytolytic E. faecalis strains; these phages had siphophage or myophage morphology (Fig. 3a, Extended Data Fig. 6). Gnotobiotic mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (Sup- plementary Table 8) and",6,ALD patent background + target paper.pdf,153,True
baf51e181775b4dcfa74544228c84273,"given three or four different—but patient- specific—lytic phages against cytolytic E. faecalis. The phages against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, as shown by lower levels of ALT, lower percentages of hepatic cells positive for terminal deoxynucleotide transferase-mediated dUTP nick-end labelling, and lower levels of hepatic triglycerides and oil red O-staining (Fig. 3b–d, Extended Data Fig. 7a, b), as well as by decreased hepatic levels of Il1b,",6,ALD patent background + target paper.pdf,154,True
10f2c121251e7865f10e7f5043ac0bc3,"Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLS, as compared with mice given control phages (against C. crescentus) (Fig. 3e–h, Extended Data Fig. 7c, d). Treatment with phages against cytolytic E. faecalis also reduced faecal amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were similar in all groups (Extended Data Fig. 7g, h).",6,ALD patent background + target paper.pdf,155,True
da9fd7f19241044c965123053eb42f33,"To demonstrate that the effect of phage treatment occurs via the targeting of cytolysin-positive E. faecalis, rather than a reduction in cytolysin-negative E. faecalis, we colonized gnotobiotic mice with faeces from cytolysin-negative patients with alcoholic hepatitis (Sup- plementary Table 8). Phages against non-cytolytic E. faecalis from patients were isolated from sewage water; they had siphophage or podophage morphology (Fig. 4a, Extended Data Fig. 8). These phages did not reduce features of",6,ALD patent background + target paper.pdf,156,True
60dd9e4ba9b6783c14557df1602b62e3,"ethanol-induced liver disease compared with control phages (Fig. 4b–g, Extended Data Fig. 9a–h), despite the reduc- tion of faecal Enterococcus (Fig. 4h). Our findings indicate that treat- ment with lytic phages can selectively attenuate the ethanol-induced liver disease caused by cytolysin-positive E. faecalis in humanized mice.",6,ALD patent background + target paper.pdf,157,True
834c2b5f1d22d4592d170d5436e54e4e,Discussion,6,ALD patent background + target paper.pdf,158,False
498f1d8b3a437ae999e672b742edacb6,"Phage-based therapies have predominantly been studied in patients with bacterial infections in the gastrointestinal tract21–23, urinary tract24,25 and other organ systems26–28. The results of these studies— although mixed in terms of efficacy—strongly suggest that phage treat- ment offers a safe alternative to antibiotics26,27. However, safety studies are required for complex populations (such as patients with alcoholic hepatitis), because phages can induce a strong immune reaction29. Further",6,ALD patent background + target paper.pdf,159,True
a7f4dd56d870f83786e1ded97b09e6de,"work is required to determine whether phages that target cyto- lytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening disease that at present has no effective treatment. Eradication of this specific bacterial strain might produce better out- comes than current treatments, and environmental sources can be used to easily isolate phages that target cytolysin-positive E. faecalis. Here we provide an example of the efficacy of approaches based on phages in mice",6,ALD patent background + target paper.pdf,160,True
c04244d11660c52310810cb9c64c925b,"for a disease that is not considered a classic infectious disease. Our data also suggest that cytolysin may be used as a predictive biomarker of severe alcoholic hepatitis; an independent, prospective",6,ALD patent background + target paper.pdf,161,True
44116a8025c84603062367c53a71cf79,"cohort is therefore needed to validate cytolysin as a biomarker, and to extend the phage findings in mice to human patients.",6,ALD patent background + target paper.pdf,162,False
c97e080f7535538b4bcff1b87fb53e01,Online content,6,ALD patent background + target paper.pdf,163,False
5bfd218ef4ad46d119866b15d45abca4,"Any methods, additional references, Nature Research reporting sum- maries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author con- tributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-019-1742-x.",6,ALD patent background + target paper.pdf,164,False
a13137949463911e54e84eb212a85ed1,"1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).",6,ALD patent background + target paper.pdf,165,False
b96f16ecb80f86600d7387df3acab991,"2. Lee, B. P., Vittinghoff, E., Dodge, J. L., Cullaro, G. & Terrault, N. A. National trends and long- term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern. Med. 179, 340–348 (2019).

3. Rehm, J. et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol. Clin. Exp. Res. 38, 1068–1077 (2014).",6,ALD patent background + target paper.pdf,166,False
82409951aa1ec6660c7df35caf176cdc,"4. Llopis, M. et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65, 830–839 (2016).",6,ALD patent background + target paper.pdf,167,False
8ad887d9a34433be7b2c84cc21aad66c,"5. Ike, Y., Clewell, D. B., Segarra, R. A. & Gilmore, M. S. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: Tn917 insertional mutagenesis and cloning. J. Bacteriol. 172, 155–163 (1990).",6,ALD patent background + target paper.pdf,168,False
059dccc7c46ff77f92ca0e43336a1e78,"6. Tang, W. & van der Donk, W. A. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat. Chem. Biol. 9, 157–159 (2013).",6,ALD patent background + target paper.pdf,169,False
dc5e40d76e0eab42204f6a8153750a98,"7. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193–199 (1978).

8. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747–2756 (2008).

9. Thursz, M. R. et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 372, 1619–1628 (2015).

10. Mathurin, P. & Lucey, M. R. Management of alcoholic hepatitis. J. Hepatol. 56, S39–S45 (2012).",6,ALD patent background + target paper.pdf,170,True
6ab480a65fa21c7c89c54c7f244a5b0c,"11. Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).",6,ALD patent background + target paper.pdf,171,True
65cd9e8cb8b25d0a55dd5d3a1f9ec361,"12. Gilmore, M. S. et al. Genetic structure of the Enterococcus faecalis plasmid pAD1- encoded cytolytic toxin system and its relationship to lantibiotic determinants. J. Bacteriol. 176, 7335–7344 (1994).

13. Cox, C. R., Coburn, P. S. & Gilmore, M. S. Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. 6, 77–84 (2005).",6,ALD patent background + target paper.pdf,172,False
9348fff1a52bba85dab00911391bd466,"14. Van Tyne, D., Martin, M. J. & Gilmore, M. S. Structure, function, and biology of the Enterococcus faecalis cytolysin. Toxins 5, 895–911 (2013).",6,ALD patent background + target paper.pdf,173,False
e56d385bac9407a71ba08add86f592f6,"15. Bertola, A., Mathews, S., Ki, S. H., Wang, H. & Gao, B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat. Protoc. 8, 627–637 (2013).",6,ALD patent background + target paper.pdf,174,False
c6e4e2d9d828f548f06c801ded0ca222,"16. Ogilvie, L. A. & Jones, B. V. The human gut virome: a multifaceted majority. Front. Microbiol. 6, 918 (2015).",6,ALD patent background + target paper.pdf,175,False
1f85cd3532b36ff333188aea9f8c0510,"17. Chatterjee, A. et al. Bacteriophage resistance alters antibiotic-mediated intestinal expansion of enterococci. Infect. Immun. 87, e00085-19 (2019).

18. Poindexter, J. S. Biological properties and classification of the Caulobacter group. Bacteriol. Rev. 28, 231–295 (1964).",6,ALD patent background + target paper.pdf,176,False
fc5d76be23e8678fcc32d6e3607ca7c8,"19. Shin, J. et al. Analysis of the mouse gut microbiome using full-length 16S rRNA amplicon sequencing. Sci. Rep. 6, 29681 (2016).",6,ALD patent background + target paper.pdf,177,False
5581ec145e2a45c07955f8ffad2a80f3,"20. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).",6,ALD patent background + target paper.pdf,178,False
778e402178c920ded3d8c65b5d62b3f6,"21. Marcuk, L. M. et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull. World Health Organ. 45, 77–83 (1971).

22. Sarker, S. A. et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137 (2016).",6,ALD patent background + target paper.pdf,179,False
7f248353e778ded2845b2b968204f4ff,"23. Dalmasso, M., Hill, C. & Ross, R. P. Exploiting gut bacteriophages for human health. Trends Microbiol. 22, 399–405 (2014).

24. Ujmajuridze, A. et al. Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9, 1832 (2018).

25. Khawaldeh, A. et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60, 1697–1700 (2011).",6,ALD patent background + target paper.pdf,180,False
b62ee0946460fd95485be49a96d8b1d4,"26. Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).

27. Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).",6,ALD patent background + target paper.pdf,181,False
fdb11bf0baf4b0acf722b950cc9a19b1,"28. Fish, R. et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).",6,ALD patent background + target paper.pdf,182,False
21f5cb7458898691beb95969a4e12c00,"effective step for moving toward clinical trials. Methods Mol. Biol. 1693, 159–170 (2018).

29. Górski, A. et al. Phages and immunomodulation. Future Microbiol. 12, 905–914 (2017).",6,ALD patent background + target paper.pdf,183,False
151fcb89fa1bcbcb5a1930ca15732069,"Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2019",6,ALD patent background + target paper.pdf,184,False
c62045f8a89cc5fbb4a2d00ddfadea7d,6 | Nature | www.nature.com,6,ALD patent background + target paper.pdf,185,False
0011ab476f6353191b3beacfd474df93,"1Department of Medicine, University of California San Diego, La Jolla, CA, USA. 2Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. 3Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. 4J. Craig Venter Institute, Rockville, MD, USA. 5J. Craig Venter Institute, La Jolla, CA, USA. 6Host–Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, UK. 7Division of Biostatistics and Bioinformatics,",7,ALD patent background + target paper.pdf,186,False
e60cf796821269f7923ccfa105761bc6,"Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 8Department of Biochemistry and Biophysics, Texas A & M University, College Station, TX, USA. 9Center for Phage Technology, Texas A & M AgriLife Research and Texas A & M University, College Station, TX, USA. 10Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 11Department of Pathology, University of California San Diego, La Jolla, CA, USA. 12Division of",7,ALD patent background + target paper.pdf,187,False
85c417fbd8b4c4b44e79142080b5ba39,"Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, PA, USA. 13Hospital Universitario, Departamento de Gastroenterología, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. 14Division of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 15Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.",7,ALD patent background + target paper.pdf,188,False
2039ee0dc36f927e1b17ff801da5693b,"16Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA. 17Liver Unit, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 18Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 19Liver Unit, Hospital Clinic, Barcelona, Spain. 20Liver Sciences, Department of Inflammation Biology, School of Infectious Diseases and Microbial Sciences, King’s College London, London, UK.",7,ALD patent background + target paper.pdf,189,False
82694c65a7b3d543d8151acdaeb20ae3,"21Service des Maladies de L’appareil Digestif et Unité INSERM, Hôpital Huriez, Lille, France. 22Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 23Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA. 24Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, CT, USA. 25Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana,",7,ALD patent background + target paper.pdf,190,False
4e56e2dcd0f0fe84746b4fe239b575b2,"IL, USA. 26Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 27St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 28Center for Innovative Phage Applications and Therapeutics, University of California San Diego, La Jolla, CA, USA. 29These authors contributed equally: Yi Duan, Cristina Llorente. *e-mail: beschnabl@ucsd.edu",7,ALD patent background + target paper.pdf,191,False
88867e5d9938c13a860b7250399c1d90,"Nature | www.nature.com | 7

7",7,ALD patent background + target paper.pdf,192,False
8c0b9249635e257a90e03cbf897611a3,"Methods

Methods",8,ALD patent background + target paper.pdf,193,False
58b63f2ac1b1120161190d90537f9369,No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.,8,ALD patent background + target paper.pdf,194,True
610827890350f0b935d3e1c4f21b7ca9,"Patient cohorts

Patient cohorts have previously been described* 2, We evaluated",8,ALD patent background + target paper.pdf,195,False
e042944def6cf71eb330b21b17b93bb3,"26 subjects without alcohol-use disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol-use disorder and 88 patients with alcoholic hepatitis. Patients with alcohol-use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption (self-reported >60 g/day) presented with various stages of liver disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index) (Supplementary Table 1). Patients with alcohol-use disorder",8,ALD patent background + target paper.pdf,196,True
c0ca7b327033c0e6165379376b8c68ba,"were recruited from an alcohol withdrawal unit in San Diego and Brussels, where they followed a detoxification and rehabilitation programme. At admission to the hospital, a complete medication and medical history was taken, and a complete physical examination was performed, including collection of bio-specimens, basic demographic data (such as age, gender, weight and height) and self-reported daily alcohol consumption. Patients were actively drink- ing until the day of admission. Controls or",8,ALD patent background + target paper.pdf,197,True
817fee613af66d171c4e3576ae0dc3dd,"patients with alcohol-use disorder did not take antibiotics or immunosuppressive medication during the two months preceding enrolment. Other exclusion criteria were diabetes, inflammatory bowel disease, known liver disease of any other aetiology, and clinically important cardiovascular, pulmonary or renal co-morbidities. Patients with alcoholic hepatitis were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centres in the USA, Mexico, UK, France and",8,ALD patent background + target paper.pdf,198,False
0f976c0e660004200f04da06431ab779,"Spain. Inclusion criteria for this study were active alcohol abuse (>50 g/day for men and >40 g/day for women) in the past 3 months, aspartate aminotransferase (AST) > ALT and total bilirubin >3 mg/dl in the past 3 months, and a liver biopsy and/or clinical picture consistent with alco- holic hepatitis. Exclusion criteria were autoimmune liver disease (ANA >1/320), chronic viral hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, pregnancy and a",8,ALD patent background + target paper.pdf,199,True
cd245ece245b24fa43712674060a852e,"lack of signed informed consent. In all patients, the clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology was consistent with the diagnosis of alco- holic hepatitis. Liver biopsies were only done if clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic hepatitis. Bio-specimens were collected during their admission to the hospital. The median time of specimen collection was 4 days fol- lowing",8,ALD patent background + target paper.pdf,200,True
38ce4f336a6096a4e0eb4efc385c6884,"admission to the hospital (range 0–24, n = 82). For one patient who underwent liver transplantation, the transplantation date was considered as date of death. Patients were censored at the time point at which they were last seen alive. The baseline characteristics are shown in Supplementary Tables 1, 2. Faecal 16S rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, ABIC score and discriminant function were calculated from all alcoholic hepatitis patients from whom",8,ALD patent background + target paper.pdf,201,True
d816fd6f4542d1b8eb4f77190745d144,"respective laboratory values were avail- able. The protocol was approved by the Ethics Committee of Hôpital Huriez, Universidad Autonoma de Nuevo Leon, Hospital Universitari Vall d’Hebron, King’s College London, Yale University, University of North Carolina at Chapel Hill, Weill Cornell Medical College, Columbia University, University of Wisconsin, VA San Diego Healthcare System, University of California San Diego (UCSD) and Université Catholique de Louvain. Patients were enrolled after written",8,ALD patent background + target paper.pdf,202,False
077ff414cee1eb0193dbc2ca6bd1badb,informed consent was obtained from each patient.,8,ALD patent background + target paper.pdf,203,False
8c2cd087d7482ec1cc860453e9de31fb,"Mice

C57BL/6 mice were purchased from Charles River and used in Fig. 2h and Extended Data Fig. 2. C57BL/6 germ-free mice were bred at UCSD and used in Figs. 2a–g, 3, 4, Extended Data Figs. 3, 7 and 9. Sublytic Atp4aSl/Sl",8,ALD patent background + target paper.pdf,204,True
43d130fb7cbac4d01b6a808303dff089,8 | Nature | www.nature.com,8,ALD patent background + target paper.pdf,205,False
0acac659a7a3f3c83930f1adf07c902d,"mice on a C57BL/6 background have previously been described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their wild-type littermates were used in Extended Data Fig. 5.",8,ALD patent background + target paper.pdf,206,True
db0feac9cc609c82c55d0c628caf10f8,"Female and male mice (age of 9–12 weeks) were placed on a chronic– binge ethanol diet (NIAAA model) as previously described15. Mice were fed with Lieber–DeCarli diet and the caloric intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in the early morning and killed 9 h later. Pair-fed control mice received a diet with an isocaloric substitution of dextrose.",8,ALD patent background + target paper.pdf,207,True
cb20161a2564d2d7216e477505fcbb8f,"Stool samples from patients with alcoholic hepatitis (Fig. 1) were used for faecal transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g stool dissolved in 30 ml Luria–Bertani (LB) medium containing 15% glycerol under anaerobic conditions), starting at an age of 5–6 weeks and repeated 2 weeks later. Two weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.",8,ALD patent background + target paper.pdf,208,True
8a6d17a0e3f64443f3390d86dca1c328,"In studies of the effects of cytolysin, 5 × 108 CFUs of a cytolytic E. fae- calis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2- 2(pAM771))5 (E. faecalis Δcytolysin) (kindly provided by M. S. Gilmore), or PBS (vehicle control) were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol feeding. Administration every third day was necessary, given that E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of phage",8,ALD patent background + target paper.pdf,209,True
f9d7bfe2eedac9500d5b3cdb1d356f97,"treat- ment, 1010 PFUs of E. faecalis phages (or C. crescentus phage phiCbK as control)35 were gavaged to the mice 1 day before the ethanol binge (at day 16). All animal studies were reviewed and approved by the Institu- tional Animal Care and Use Committee of UCSD.",8,ALD patent background + target paper.pdf,210,True
5a2bbaec774f4d4dc98598a1cefca12a,Bacteriophage isolation and amplification,8,ALD patent background + target paper.pdf,211,False
92ef1fa99dff370a9149c2961a1ed388,"The E. faecalis strain from Atp4aSl/Sl mice faeces has previously been isolated11 and was used to isolate phages Efmus1, Efmus2, Efmus3 and Efmus4 (phages specific to the E. faecalis strain isolated from mouse faeces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). E. faecalis strains from human stool samples were isolated using methods described below, and the cor- responding phages were named as Ef with patient number plus a digit (Ef for E.",8,ALD patent background + target paper.pdf,212,True
4f0069590b39e0075cc29c89eb86b6d8,"faecalis, last digit for isolation order). All E. faecalis strains were grown statically in brain–heart infusion (BHI) broth or on BHI agar at 37 °C. C. crescentus phage phiCbK was purified as previously described35.",8,ALD patent background + target paper.pdf,213,False
d3e8d3246d66c688354723e9dbcdf290,"E. faecalis phages were isolated from untreated raw sewage water obtained from North City Water Reclamation Plant in San Diego. Fifty millilitres of raw sewage water was centrifuged at 8,000g for 1 min at room temperature to pellet large particles. The supernatant was passed through a 0.45-μm and then a 0.2-μm syringe filter (Whatman, PES membrane). One hundred microlitres of the clarified sewage was mixed with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar)",8,ALD patent background + target paper.pdf,214,True
5a2ecb20b98679abe9ec4e7d4685525a,"and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, the resulting plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more times to ensure that the phages were clonal isolates.",8,ALD patent background + target paper.pdf,215,True
8aeb5a7c4f1f437cad055f2f2da16aae,"High-titre phage stocks were propagated by infecting 200 ml of expo- nentially growing E. faecalis at a multiplicity of infection of 0.1 in BHI broth containing 10 mM MgSO4. Lysis was allowed to proceed for up to six hours at 37 °C with shaking. The lysates were centrifuged at 10,000g for 20 min at room temperature to remove the remaining bacterial cells and debris. Supernatant was then vacuum-filtered through a 0.2-μm membrane filter and kept at 4 °C until use.",8,ALD patent background + target paper.pdf,216,True
b05d19fa5af188c7b8e5420e7cabc173,"Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF Concentrators with 100,000-molecular weight cutoff (MWCO) to a volume of approximately 1 ml. Following concen- tration, the culture medium was replaced with PBS via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml and adjusted to the required PFUs.",8,ALD patent background + target paper.pdf,217,True
127006a3bdcfa8ba2f6dd414c0e18a32,Whole-genome sequencing for phages,9,ALD patent background + target paper.pdf,218,False
a8bae4416c18abf2cac155e38c37d73a,"For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase and RNase at 37 °C for 1 h and phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4 °C overnight. Precipitated phages were then pel- leted by centrifugation at 10,000g for 10 min at 4 °C and resuspended in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA Clean-up kit (Promega). Phage genomes were",9,ALD patent background + target paper.pdf,219,True
59099ab5d3446bade1b274c1a33f5170,sequenced using a combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-based size selection before loading onto Illumina flow cells. Sequencing was performed with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) and loaded onto,9,ALD patent background + target paper.pdf,220,True
8bdbccea6236b8bbfd96fd480201388c,"MinION R9.4 flow cells. ONT reads were basecalled with Albacore v.2.3.4 (ONT). The sequence reads were demultiplexed and adapters trimmed from ONT reads using Porechop v.0.2.336. A hybrid Illumina-ONT de novo assembly was performed using the Unicycler v.0.4.7 pipeline37. Subsequently, Pilon v.1.2238 was used iteratively to polish the assemblies with Illumina reads until no addi- tional corrections could be made.",9,ALD patent background + target paper.pdf,221,True
ca35435b8ec55078f0a01c7a808831ea,"For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45-μm and 0.2-μm filters (VWR) and purified on a caesium chloride (CsCl) density gradient39. One millilitre of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qia- gen), amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a Bioruptor (Diagenode). Libraries were created using the Ion",9,ALD patent background + target paper.pdf,222,True
d2a1059394870487841ec6518e2f9ca7,"Plus fragment library kit and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 × coverage).",9,ALD patent background + target paper.pdf,223,True
1c53bab920a70926e09c18f7f7a39263,"Mapping of ONT reads to the hybrid assemblies was used to deter- mine the orientation and terminal ends of linear phage genomes, and reference genomes served as guides to orient circular phage genomes. Phage genome assemblies were annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.",9,ALD patent background + target paper.pdf,224,True
91576a226a9cce9c84181d3e0cda5481,"Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3",9,ALD patent background + target paper.pdf,225,True
04cf83af215edc1f24728bc57e7b8a48,(MK721184) and Ef7.4 (MK721198).,9,ALD patent background + target paper.pdf,226,False
d23dd11e0d7d9d85c2aea1a91db70f28,"Genetic maps of phage genomes were generated by LinearDisplay. pl (https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://sourceforge.net/projects/mcj/) to render high- quality images. Preliminary annotation of genes was derived from the automated annotation and from Phage_Finder42, which uses curated hidden Markov models and databases of core phage gene to annotate core gene functions. Annotation was then manually reviewed to assign the final colours.",9,ALD patent background + target paper.pdf,227,True
a43d823c09b324b791bcb8beae797bac,"Phage phylogenetic tree

A phage whole-genome phylogeny tree was generated from a pairwise distance matrix calculated with the MASH program, which approxi- mates average nucleotide identity (ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated and sequenced in",9,ALD patent background + target paper.pdf,228,True
4e90311181576034039a159db8836df1,"this study plus 54 Enterococcus phage genomes obtained from Gen- Bank, with 5,000 12-mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial phage genome sequences to generate the ANI matrix using the mash distance command using default settings. The GGRaSP R package was used to calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI >99.985) were removed using the GGRaSP R package with a user",9,ALD patent background + target paper.pdf,229,True
006235dedb8b656ba8cae88658b1c5c8,"defined cutoff of 0.015 (ggrasp. cluster (threshold = 0.015)). The resulting dendrogram was translated into newick format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with taxonomic information and manually entered clade identification.",9,ALD patent background + target paper.pdf,230,True
400fe72e41345fd626b019a2b0c5eada,"Electron microscopy

Phage morphology was examined by transmission electron microscopy of negatively stained grids, prepared using the valentine method46 with either 2% uranyl-acetate or 2% phosphotungstic acid, and examined at an acceleration voltage of 100 kV in the JEOL 1200 EX transmission electron microscope.",9,ALD patent background + target paper.pdf,231,False
61a089e1c2d3c159c43d979a9a92e0f4,Bacterial DNA extraction and 16S rRNA sequencing,9,ALD patent background + target paper.pdf,232,False
26e716086b8135b36384ee83044eabb2,"DNA from human stool samples, mouse liver sections or bacterial cul- ture was extracted as previously described11, and DNA from mouse faeces was extracted using QIAamp Fast DNA Stool kit (Qiagen). 16S rRNA PCR was completed using Illumina adaptor and barcode-ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified using the Qiaquick PCR purification kit (Qiagen) using manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay",9,ALD patent background + target paper.pdf,233,True
702d4caabd5158cd933d728c9bc2cccf,"(Tecan), normalized and pooled in preparation for 16S rRNA sequencing. Pooled library was quantified and checked for qual- ity using Agilent 2100 Bioanalyzer (Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 cycles, 2 × 250-bp format using manufacturer’s specifications. 16S sequence reads were processed and operational taxonomic units were determined using our MOTHUR-based 16S rDNA analysis workflow as previously described11,49. Raw 16S",9,ALD patent background + target paper.pdf,234,True
3d18fea7254ecef51090d7c0a9695384,sequence reads can be found in the NCBI Sequence Read Archive (SRA) associated with Bioproject PRJNA525701.,9,ALD patent background + target paper.pdf,235,False
ed093f2bf7a85e0a56302918ccc7d1c7,Real-time qPCR,9,ALD patent background + target paper.pdf,236,False
ac97f219012f3111e9b6704302dea360,"Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and cylLL genes have previously been described50,51. All primers used in this study are listed in Supplementary Table 9. Mouse gene expression and amplification of bacterial genes were determined with Sybr Green",9,ALD patent background + target paper.pdf,237,True
bc267b0deb89a2c59e96f85c67de5eba,(Bio-Rad Laboratories) using ABI Ste- pOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 18S.,9,ALD patent background + target paper.pdf,238,True
e122346f051da594e24eff2597a12e74,E. faecalis isolation and whole-genome sequencing,9,ALD patent background + target paper.pdf,239,False
a9f464facaa1cbf817a9c2422eaf8e4e,"To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial dilutions were made and 100 μl was placed on plates with selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the production of dark brown or black colour, generated by hydrolysis of esculin to esculetin (which reacts with ferric ammonium citrate). Each Enterococcus colony was then picked, and qPCR was performed to identify E.",9,ALD patent background + target paper.pdf,240,True
89cc95f4a0731b39a24a6b54c5a6ab46,"faecalis, using specific primers against the E. faecalis 16S rRNA gene50. For each subject, between 1 and 6 E. faecalis colonies were analysed and bacterial genomic DNA was then extracted as described in ‘Bacterial DNA extraction and 16S rRNA sequencing’.",9,ALD patent background + target paper.pdf,241,True
36cb8e6b2ee7ecc23a2b9f5175b6d079,DNA sequencing was performed on the Illumina HiSeq Ten X generat- ing paired-end reads (2 × 151 bp). Bacterial genomes were assembled,9,ALD patent background + target paper.pdf,242,True
94978dc872b00f7e28f8ad3ffb09e08c,Article,10,ALD patent background + target paper.pdf,243,False
099b7dfd205c297ccfd990d3aa6e41c5,"and annotated using the previously described pipeline52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes carried by E. faecalis isolates were identified by comparing individual genome assemblies against the CARD and VFDB databases, respectively, using abricate v0.8.10 (https://github.com/tseemann/abricate)53,54.",10,ALD patent background + target paper.pdf,244,True
4cd207c672357b22bc736d7265606756,"For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cutoff was used, and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this study have been deposited in the European",10,ALD patent background + target paper.pdf,245,True
9d9bc99597f92ac870ed6fc92f396f4b,Nucleotide Archive (ENA) under the accession number PRJEB25007. Sequence reads are available at ENA under run acces- sion identifiers ERR3200171–ERR3200263.,10,ALD patent background + target paper.pdf,246,False
160b9572e75fc7f21313c5b6fe72b406,"E. faecalis culture

All E. faecalis strains were grown statically in BHI broth or on BHI agar plate at 37 °C. Fifty micrograms per millilitre erythromycin was added when cytolytic and non-cytolytic E. faecalis strains were grown (Extended Data Fig. 2).",10,ALD patent background + target paper.pdf,247,True
acdd7e01fb2c54d8d623c5224e27ffa7,Determination of levels of faecal Enterococcus,10,ALD patent background + target paper.pdf,248,False
0b3f87f0128253ff5d4a35973c23662d,"To determine levels of faecal enterococci in mice, 10–30 mg of mouse faeces was resuspended into 500 μl PBS and serial dilutions were made. Five microlitres of each dilution from each sample was spotted onto a plate with a selective medium, BBL enterococcosel broth (Becton Dickinson) and the plates were then incubated at 37 °C overnight. For Extended Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were identified by the production of a dark brown or black colour.",10,ALD patent background + target paper.pdf,249,True
ce9b9a313e1c7d2f80a952a7f3bdfd5d,"Colony numbers of each sample were then counted, and CFUs were calculated.",10,ALD patent background + target paper.pdf,250,False
1f879305f24c8f4a42df1b4bf9cf9d0e,Cytolysin expression and purification,10,ALD patent background + target paper.pdf,251,False
6fbc1965b9031eac7d8fe0a1f15c0b0e,"To purify bioactive CylLL′′ and CylLS′′, an Escherichia coli heterologous expression system was used. In brief, either 6×His–CylLL or 6×His–CylLS were co-expressed with CylM (the enzyme that performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. The His tag and leader peptide were then removed using recombinant CylA (27–412), the soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive",10,ALD patent background + target paper.pdf,252,True
5aa1494873b653edbf3376e5eda334ee,CylLL′′ or CylLS′′. The resulting core peptides were further purified by reversed-phase high-performance liquid chromatography (HPLC).,10,ALD patent background + target paper.pdf,253,True
b31c744b5081aaac404dd88ef2fddd09,"The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 backbone vector that contained the cylM gene in MCSII6. The cylA (27–412) gene was previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star (DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, cylLS_cylM:pRSFDuet or cylA (27–412):pRSFDuet plasmids via KCM chemical transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 μg/ml) and",10,ALD patent background + target paper.pdf,254,True
409aae3f1eba8cc017c19167bc703e6f,grown at 37 °C overnight. One colony was picked to inoculate 15 ml of LB broth supplemented with kanamycin overnight at 37 °C. The culture was used to inoculate 1.5 l of terrific broth supple- mented with kanamycin. Cultures were grown with shaking at 37 °C to an optical density at 600 nm (OD600) of 0.8. The temperature of the incu- bator was lowered to 18 °C and expression was induced with the addi- tion of 0.3 mM final concentration of isopropyl β-d-thiogalactoside. The cultures were allowed,10,ALD patent background + target paper.pdf,255,True
8e5b87a0a6d982b36d840a001ad89e9e,"to incubate at 18 °C for 18 h. The cells were collected by centrifugation at 5,000g for 12 min. The cell paste was collected and frozen at -70 °C.",10,ALD patent background + target paper.pdf,256,True
95b7fab4c3c4954353259b85595a6288,"For the purification of the protease CylA (27–412), the cell paste was thawed and resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension was lysed by homogenization. The lysate was clarified by centrifugation at 13,000g for 45 min and filtered through a 0.45-μm centrifugal filter (Thermo Scientific). The clarified",10,ALD patent background + target paper.pdf,257,True
34a8543d6f0ed82dc1b09027480afb04,"lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a peristaltic pump. The loaded column was con- nected to an ÄKTA pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as determined by 4–20% SDS–PAGE, were combined, concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into",10,ALD patent background + target paper.pdf,258,True
caeefdcf1084e77ff5e6857cc445e3ff,"storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). Protein concentration was determined by absorbance at 280 nm.",10,ALD patent background + target paper.pdf,259,True
dca8b89b3f4eba96883fe6595de92729,"For the purification of CylLL′′ and CylLS′′ peptides, the cell paste was thawed and resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2-s pulse on, 5-s pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation at 13,000g for 45 min. The clarified cell lysate was filtered through a 0.45-μm centrifugal filter and applied via gravity flow to a pre-equili-",10,ALD patent background + target paper.pdf,260,True
c0fe84d533b3c2dc3baec429d45bd71d,"brated, 2 ml bed volume of His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The peptides were eluted with 10 ml of LanA elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final",10,ALD patent background + target paper.pdf,261,True
c5c35ee95bdcc35de798b9a11aa9ed68,concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.,10,ALD patent background + target paper.pdf,262,True
e23a4d1755011379bc6eca0c3bce3bfa,"The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. The solution was centrifuged at 4,500g for 10 min and filtered through a 0.45-μm syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse-phase HPLC using a Phenomenex Jupiter Proteo column (10 mm × 250 mm, 4 μm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were separated using a linear gradient of 3% (v/v) solvent B",10,ALD patent background + target paper.pdf,263,True
e7b6e4f32f22069121b573fc9ad95185,"(acetonitrile + 0.1% trifluoroacetic acid) in solvent A (water + 0.1% trif- luoroacetic acid). The fractions were spotted on a matrix-assisted laser desorption/ionization (MALDI) target plate by mixing 1 μl of sample with 1 μl of a 25 mg/ml solution of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were analysed by MALDI–time of flight (TOF) mass spectrometry on a Bruker UltrafleXtreme MALDI–TOF/ TOF operating in positive ionization, reflector mode.",10,ALD patent background + target paper.pdf,264,True
8f7b943cd1c07dffb42ef78bb3ada19c,Primary mouse hepatocytes,10,ALD patent background + target paper.pdf,265,False
3a9f17d58ca5c1ed985aa20b6572a3e5,Hepatocytes were isolated from C57BL/6 female mice fed the chronic– binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced and filtered using a 70-μm nylon cell strainer. Hepatocytes were centrifuged at 50g for 1 min after 3 washes. Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher,10,ALD patent background + target paper.pdf,266,True
5507af1caa99c80bdb1e3ffd8d38a71b,"Scientific). Hepatocytes (1.5 × 105) were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin–transferrin–selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics. After 4 h, the culture was washed with DMEM-F12 medium and changed to the same complemented medium without FBS58. Then 16 h later, hepato- cytes were cultured with",10,ALD patent background + target paper.pdf,267,True
1292a03a6d1e4234fb6c3a8ac7031c7a,"0 or 25 mM ethanol and stimulated with 0, 200 or 400 nM CylLS′′ and/or CylLL′′ in the same culture medium without FBS. After 3 h stimulation, hepatocyte cytotoxicity was assessed using Pierce LDH cytotoxicity detection kit (Thermo Fisher Scientific).",10,ALD patent background + target paper.pdf,268,False
ca53f71f2c8fcfc0f706ae94f8767245,Biochemical analysis,10,ALD patent background + target paper.pdf,269,False
a7c38a89a8698c16dd863b474932e67e,Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride,10,ALD patent background + target paper.pdf,270,True
526871f039a3574903a419da5dbe52cd,"Liquid Reagents kit (Pointe Scientific). Levels of serum lipopolysac- charide and faecal albumin were determined by enzyme-linked immu- nosorbent kits (Lifeome Biolabs and Bethyl Labs, respectively). Serum levels of ethanol were measured using ethanol assay kit (BioVision).",11,ALD patent background + target paper.pdf,271,False
3feedfdcf36c414c3f83ef80ceecc03e,Staining procedures,11,ALD patent background + target paper.pdf,272,False
d49b5f36c647dff9812e57563fc16120,"Formalin-fixed tissue samples were embedded in paraffin and stained with H & E. To determine lipid accumulation, liver sections were embed- ded in OCT compound. Eight-micrometre frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). Representative images from each group of mice are shown in each figure. The terminal deoxynucleo- tide transferase-mediated dUTP nick-end labelling (TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly",11,ALD patent background + target paper.pdf,273,True
95e1be95a5fc12714d11ba3fba2e3456,selected five high-power fields for counting TUNEL-positive cells and normalized numbers to total cells.,11,ALD patent background + target paper.pdf,274,False
d39206785cc747d4e6b9e368bd61fd38,Statistical analysis,11,ALD patent background + target paper.pdf,275,False
266821d571654b9cf819491e7ad4f506,"Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and multivariate Cox regression analysis was used to detect associations of cytolysin with overall mortality. The multivariate model was adjusted for geographical origin of the patients, antibiotic treat- ment, platelet count, and creatinine, bilirubin and INR as components of the MELD score. Univariate logistic regression analysis of laboratory and clinical parameters associated with the detection of cytolysin and",11,ALD patent background + target paper.pdf,276,True
49a403ab85cf1287247d0dee3c6104d2,"E. faecalis was performed. Univariate linear regression analysis of labo- ratory and clinical parameters associated with the log-transformed total amount of faecal E. faecalis measured with qPCR was performed. To associate log-transformed total E. faecalis and E. faecalis positiv- ity with mortality, univariate Cox regression was used. P values from univariate and multivariate Cox regression, univariate logistic regres- sion and univariate linear regression were determined by Wald test.",11,ALD patent background + target paper.pdf,277,True
8d804e9fc95ed2db69557c927cb77778,"Multicollinearity was examined using the variance inflation factor. Kaplan–Meier curves were used to compare survival between cytolysin- positive and cytolysin-negative patients with alcoholic hepatitis. Faecal E. faecalis, bacterial diversity and richness from controls and patients were compared using Kruskal–Wallis test with Dunn’s post hoc test. Region- and/or centre-specific clinical characteristics of patients with alcoholic hepatitis were compared with Kruskal–Wallis test for continu- ous",11,ALD patent background + target paper.pdf,278,True
7b8dbc9af15bbcc3e361831b11ca9cb8,"and Fisher’s exact test for categorical variables. Faecal E. faecalis in patients with alcoholic hepatitis with or without cytolysin, and with or without cirrhosis, were compared with Mann–Whitney-Wilcoxon rank-sum test. Faecal E. faecalis in patients with alcoholic hepatitis from different region and/or centres were compared with the Kruskal– Wallis test. The percentage of subjects with faecal samples that were positive for E. faecalis and cytolysin was compared using Fisher’s exact test,",11,ALD patent background + target paper.pdf,279,True
f76e2fd0575907e2393cf2e9bac23226,"followed by FDR procedures for multiple group comparisons. Jaccard dissimilarity matrices were used for PCoA, and P values were determined by PERMANOVA followed by FDR procedures to correct for multiple comparisons.",11,ALD patent background + target paper.pdf,280,True
14e86a0ecd10b0bdc033d9707701e4ea,"For mouse and cell culture studies, the significance of multiple groups was evaluated using one-way or two-way ANOVA with Tukey’s post hoc test. Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for multiple comparisons. Kaplan–Meier curves were used to compare survival between experi- mental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed between experimental mouse groups and the P values were determined by PERMANOVA",11,ALD patent background + target paper.pdf,281,True
c050356c803ef939e49dfdec8c6a021d,followed by FDR procedures to cor- rect for multiple comparisons.,11,ALD patent background + target paper.pdf,282,False
32c2ea73902ed3c942e714bd6eee2331,"Exact P values for all comparisons, together with group size for each group, were listed in Supplementary Table 10. Statistical analyses were performed using R statistical software, R v.3.5.1 (R Foundation for Sta- tistical Computing) and GraphPad Prism v.6.01. A value of P < 0.05 was considered to be statistically significant (adjusted for multiple comparisons when performing multiple tests).",11,ALD patent background + target paper.pdf,283,True
20895efe9efe890b2b9c587c948f1fe3,Reporting summary,11,ALD patent background + target paper.pdf,284,False
413a85d9454a030f8e01ab89a18c5b53,Further information on research design is available in the Nature Research Reporting Summary linked to this paper.,11,ALD patent background + target paper.pdf,285,False
538ce29f229eacf5622b5aef07e0b1a8,Data availability,11,ALD patent background + target paper.pdf,286,False
1bea2d99c1de3a43e7eef19cff96d941,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Phage raw sequence reads and annotated genomes are available at NCBI under the following consecutive BioSa- mple identifiers (SAMN11089809–SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at the ENA under study PRJEB25007.,11,ALD patent background + target paper.pdf,287,True
5da732bbf729e12797d9c8075e604ed5,Code availability,11,ALD patent background + target paper.pdf,288,False
0b827e4a9d34b276bf03e7156d0e8bbb,The PERL script for making the genetic maps of phage genomes can be found at https://github.com/JCVenterInstitute/LinearDisplay.,11,ALD patent background + target paper.pdf,289,False
baedfe40e4f269fca25eb42d92f10ef7,"30. Brandl, K. et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 69, 396–405 (2018).

31. Gao, B. et al. Serum and fecal oxylipins in patients with alcohol-related liver disease. Dig. Dis. Sci. 64, 1878–1892 (2019).

32. Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology (2019).",11,ALD patent background + target paper.pdf,290,False
38d13c6e9eec5033ef302b04ff0e5be2,"33. Ball, S. A., Tennen, H., Poling, J. C., Kranzler, H. R. & Rounsaville, B. J. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers. J. Abnorm. Psychol. 106, 545–553 (1997).",11,ALD patent background + target paper.pdf,291,False
5394a8c018c88ac0536804b7b2d6477f,"34. Krieg, L. et al. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood 118, 6418–6425 (2011).",11,ALD patent background + target paper.pdf,292,True
6f0fd3c395dada604d8ef5bb6ef5505d,"35. Gill, J. J. et al. The Caulobacter crescentus phage phiCbK: genomics of a canonical phage. BMC Genomics 13, 542 (2012).

36. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Completing bacterial genome assemblies with multiplex MinION sequencing. Microb. Genom. 3, e000132 (2017).

37. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLOS Comput. Biol. 13, e1005595 (2017).",11,ALD patent background + target paper.pdf,293,False
e35095589a38bb2d1ad40d1db0694bcd,"38. Walker, B. J. et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS ONE 9, e112963 (2014).",11,ALD patent background + target paper.pdf,294,False
6a088455c3d71db852d725bb45e9824b,"39. Santiago-Rodriguez, T. M. et al. Transcriptome analysis of bacteriophage communities in periodontal health and disease. BMC Genomics 16, 549 (2015).

40. Haft, D. H. et al. RefSeq: an update on prokaryotic genome annotation and curation. Nucleic Acids Res. 46, D851–D860 (2018).

41. Tatusova, T. et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 44, 6614–6624 (2016).",11,ALD patent background + target paper.pdf,295,False
754ab1e19f0033df93026c1210264067,"42. Fouts, D. E. Phage_Finder: automated identification and classification of prophage regions in complete bacterial genome sequences. Nucleic Acids Res. 34, 5839–5851 (2006).",11,ALD patent background + target paper.pdf,296,False
70fd2c91de5297438cf2c55d5a859454,"43. Ondov, B. D. et al. Mash: fast genome and metagenome distance estimation using MinHash. Genome Biol. 17, 132 (2016).",11,ALD patent background + target paper.pdf,297,False
3f17dba3585624b45708b6cdb2c1a58d,"44. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

45. Letunic, I. & Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242–W245 (2016).",11,ALD patent background + target paper.pdf,298,True
231bf0b3d610160fac5aa0581eb990db,"46. Valentine, R. C., Shapiro, B. M. & Stadtman, E. R. Regulation of glutamine synthetase. XII. Electron microscopy of the enzyme from Escherichia coli. Biochemistry 7, 2143–2152 (1968).",11,ALD patent background + target paper.pdf,299,False
ddd068bd6053537d2ab93629d00d2a75,"47. Haas, B. J. et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504 (2011).

48. Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc. Natl Acad. Sci. USA 108 (Suppl 1), 4516–4522 (2011).",11,ALD patent background + target paper.pdf,300,False
f4bb22faef5daa08533bf8dfbc9d210b,"49. Chen, P. et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203–214.e16 (2015).",11,ALD patent background + target paper.pdf,301,True
223f1fe9a83970a249e8e22ff65b69ca,"50. Ryu, H. et al. Development of quantitative PCR assays targeting the 16S rRNA genes of Enterococcus spp. and their application to the identification of enterococcus species in environmental samples. Appl. Environ. Microbiol. 79, 196–204 (2013).",11,ALD patent background + target paper.pdf,302,False
f3ca9cab4c8781f6a8d08e2ca546e7f5,"51. Haas, W., Shepard, B. D. & Gilmore, M. S. Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature 415, 84–87 (2002).",11,ALD patent background + target paper.pdf,303,False
835210699cb70f748cd752e3269d7eb5,"52. Page, A. J. et al. Robust high-throughput prokaryote de novo assembly and improvement pipeline for Illumina data. Microb. Genom. 2, e000083 (2016).",11,ALD patent background + target paper.pdf,304,False
e8b73b89a0e6cec54141fc9ebc2c1e82,"53. Chen, L. et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 33, D325–D328 (2005).

54. Jia, B. et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 45, D566–D573 (2017)",11,ALD patent background + target paper.pdf,305,False
1b0a633a64879c41d24bc0f8ff0d2b37,"55. Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068–2069 (2014).

56. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312–1313 (2014).",11,ALD patent background + target paper.pdf,306,False
74ddde87e79bc8420281120ba97dfa07,Article,12,ALD patent background + target paper.pdf,307,False
f124b103101de64fc996b147c774e243,"57. Tang, W., Bobeica, S. C., Wang, L. & van der Donk, W. A. CylA is a sequence-specific protease involved in toxin biosynthesis. J. Ind. Microbiol. Biotechnol. 46, 537–549 (2019).",12,ALD patent background + target paper.pdf,308,True
4b69bb9281dd161172990165d96744ee,"58. Iwaisako, K. et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc. Natl Acad. Sci. USA 109, E1369–E1376 (2012).",12,ALD patent background + target paper.pdf,309,False
a5745eb642d7583c5c59426d5a6b7625,"59. Clarke, T. H., Brinkac, L. M., Sutton, G. & Fouts, D. E. GGRaSP: a R-package for selecting representative genomes using Gaussian mixture models. Bioinformatics 34, 3032–3034 (2018).",12,ALD patent background + target paper.pdf,310,False
728722f46f7c405bc25df62602aec8b5,"Acknowledgements S. Lang was supported by a DFG fellowship (LA 4286/1-1), C.L. was supported by an AASLD Pinnacle Research Award in Liver Disease and a pilot project award from Southern California Research Center for Alcoholic Liver and Pancreatic Disease (ALPD) and Cirrhosis (P50 AA011999), Y.S. was supported by a Wellcome Trust PhD studentship and I.R.R. was supported by National Institute of General Medical Sciences (NIGMS)–NIH Chemistry–Biology Interface Training Grant (T32-GM070421). This",12,ALD patent background + target paper.pdf,311,False
9c6ab862bc0fba078df83ec34d84e2df,"study was supported in part by a Biocodex Microbiota Foundation Grant, NIH grants R01 AA24726, U01 AA026939, by Award Number BX004594 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.), the Wellcome Trust (WT098051) (to T.D.L.), NIH grant U01AA021908 (to R.B.) and services provided by P30 DK120515 and P50 AA011999.",12,ALD patent background + target paper.pdf,312,False
87cd1514dd382222eaa9679135af1cec,"Author contributions Y.D. was responsible for acquisition, analysis and interpretation of data, and drafting of the manuscript; C.L. was responsible for study concept and design, acquisition,",12,ALD patent background + target paper.pdf,313,False
185b9ea67d68e949dd1a9b4978ad85c7,"analysis and interpretation of data and key preliminary experiments; S. Lang, K.B., J.L. and X.M.T. provided assistance with statistical analysis; H.C., L.J., B.G., W.S., R.K., F.H. and S. Lee provided assistance with data acquisition; R.C.W., T.H.C., K.N., M.T. and D.E.F. were responsible for 16S rRNA sequencing, phage genome sequencing and data analysis; Y.S. and T.D.L. were responsible for bacterial genome sequencing and data analysis; A.H.-M., L.L. and R.Y. provided assistance with phage",12,ALD patent background + target paper.pdf,314,True
92213ec4a7e96cd9bf6d19f09ab9c4d3,"studies and were responsible for electron microscopy data; R.Y. provided critical revision of the manuscript; I.R.R. and W.A.v.d.D. were responsible for cytolysin expression and purification; Y.M. and L.E. provided assistance with the design and conduct of the gnotobiotic mouse studies; M.L. and D.P. provided assistance with phage isolation; M.V.-C., F.B.-P., E.C.V., J.G.A., R.S.B. Jr, V.V., J.A., J.C., D.L.S., S.B.H., A.L., M.R.L., P.M., G.G.-T., R.B. and P.S. were responsible for collection of",12,ALD patent background + target paper.pdf,315,False
d0a90c4eded56b73265a47a840d38b92,"human samples; D.E.F. and B.S. were responsible for the study concept and design, and editing the manuscript; B.S. was responsible for study supervision.",12,ALD patent background + target paper.pdf,316,False
87fd9ef724034ebf3b7aab3789cd5ee0,"Competing interests B.S. consults for the Ferring Research Institute; however, there is no competing interest with regard to this study. All other authors declare no competing interests.",12,ALD patent background + target paper.pdf,317,False
c5b479abffcc520e53c53aa65f1b58eb,Additional information,12,ALD patent background + target paper.pdf,318,False
8c985f7329343cae9d62f8921757e702,Supplementary information is available for this paper at https://doi.org/10.1038/s41586-019- 1742-x.,12,ALD patent background + target paper.pdf,319,False
f080cbbd727dd8670cfbba040cf60182,Correspondence and requests for materials should be addressed to B.S.,12,ALD patent background + target paper.pdf,320,False
801fc86f4206d87d1dea2d19265ca464,Reprints and permissions information is available at http://www.nature.com/reprints.,12,ALD patent background + target paper.pdf,321,False
46c705e16cd763c9771436ac18f81264,[ - 00 Bacterial Genera Bacteroides Unclassified Lachnospiraceae Unclassified Ruminococcaceae 80 Veelllonella Akkermansia 70 Prevotella Blautia 60 Rosebuna Escherichia/Shigella Streptococcus 50 Unclassified Clostndiales 40 Dialister Faecalibacterium Clostndium_XiVa 30 Ruminococcus Enterococcus 20 Megasphaera Mogamonas Ruminococcus2 Relative sequence abundance (%) 10 Bifidobacterium | | = B Q=) = = - B: B ... [remaining 309 | Alcoholic Controls AUD hepatitis,13,ALD patent background + target paper.pdf,322,True
2b2c7cde73a85089f619ad212239dd0b,o Jede X % % % = N Shannon diversity Controls AUD Alcoholic hepatitis,13,ALD patent background + target paper.pdf,323,False
053164ae9a555b8ddb5d2e5630834386,Simpson diversity,13,ALD patent background + target paper.pdf,324,False
30b17e3b17bd5b4484846b4685a31a06,5,13,ALD patent background + target paper.pdf,325,False
540e250dc00a308fd985843148ea2c61,"o

o o",13,ALD patent background + target paper.pdf,326,False
2891f844a90e0847ee3d1f76367ba192,(=] »,13,ALD patent background + target paper.pdf,327,False
3d1f14a43c599c4245d9d7c44e2eb71c,"o N

o",13,ALD patent background + target paper.pdf,328,False
414ebf526d0852de3a5389f930face87,Controls,13,ALD patent background + target paper.pdf,329,False
474dd4794b96bb0b816dbf1558b4b2b1,k x,13,ALD patent background + target paper.pdf,330,False
f72a2b087bddbdfd6c9d5444c6e857bf,AUD,13,ALD patent background + target paper.pdf,331,False
44779d1e41e6f07b9121599a3659ec6b,"%

%",13,ALD patent background + target paper.pdf,332,False
1f2b2471e2c6e31ae783f50099c13f78,Alcoholic hepatitis,13,ALD patent background + target paper.pdf,333,False
1a272df7744d04e39ac25f18e319c1d6,Chao richness,13,ALD patent background + target paper.pdf,334,False
7311cf9e11c513d4d02eb5a562d8bdac,— de kK —,13,ALD patent background + target paper.pdf,335,False
906a73ded42dfb91bf804c6bcaeb6935,"10,000",13,ALD patent background + target paper.pdf,336,False
c091b8fe56de0ca64aed7171564d17a7,"& 8 oo =34

H» , =34 00",13,ALD patent background + target paper.pdf,337,False
4664825036a85ec110643dcc3fc108ff,w &,13,ALD patent background + target paper.pdf,338,False
8b77a40e9c6a234afca2f72ddf500331,"2,000

1,000",13,ALD patent background + target paper.pdf,339,False
48d049e77b772bcb849770102e4ec7c7,Controls,13,ALD patent background + target paper.pdf,340,False
8b0ecf7bfd2b062f25b8681d862de4bd,AUD,13,ALD patent background + target paper.pdf,341,False
17f02b7eb90fbe3ecb39d7b5fcbf4e2a,Ll ],13,ALD patent background + target paper.pdf,342,False
bf17fcd184fe9afb37dcc598d1f2058d,Alcoholic hepatitis,13,ALD patent background + target paper.pdf,343,False
8a0491b100ebdf74802992a9a7447ba4,"1.0 0.8 -] » -Cytolysin, AUC=0.81 Sensitivity -MELD, AUC=0.70 0.2 -ABIC, AUC=0.66 -DF, AUC=0.63 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1 - Specificity",13,ALD patent background + target paper.pdf,344,False
9d76049faf77396566f91e0d4907f9ff,"Enterococcus faecalis ek e K 150,000 * % 100,000 50,000 "" - 300 300 Relative abundance 100 100 . Controls AUD Alcoholic hepatitis

@@ E. faecalis negative [ E. faecalis positive 100 80 60 40 20 Percent subjects (%) Controls AUD Alcoholic hepatitis",13,ALD patent background + target paper.pdf,345,False
fea9cf9b896e4e67a30ddd8ae4c34c83,@@,13,ALD patent background + target paper.pdf,346,False
bc86e6842e9d05e4fdd6efb7c14907d3,[,13,ALD patent background + target paper.pdf,347,False
b1d7bfe620abf6007ff6464f429bde29,"0.50 France Mexico 0.25 Spain 0.00 UK { USA East PC2 (16.74%) USA Midwest 0.25 L 0000 USA West -0.4 -0.2 0.4 PC1 A%)

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) P & « ¥",13,ALD patent background + target paper.pdf,348,False
31ac83d1cd9cee0fcc651709f115bd33,@@,13,ALD patent background + target paper.pdf,349,False
fba65d6a6c9a5dab581897e73d0dc980,3,13,ALD patent background + target paper.pdf,350,False
8f52a72387708e40619f305a4187a09a,mm Cytolysin negative Bl Cytolysin positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis,13,ALD patent background + target paper.pdf,351,False
9ec064b1ee321d8b644d379916677d3d,mm,13,ALD patent background + target paper.pdf,352,False
c1c4a0b2cf913e2752e9c0b3b4dfeb52,Bl,13,ALD patent background + target paper.pdf,353,False
b4ddbdca2b1f073d23e39d2818537122,Extended Data Fig. 1 | See next page for caption.,13,ALD patent background + target paper.pdf,354,False
44b6d23e5a06d05eb660143d15fde751,"Enterococcus faecalis 150,000 100,000 - 50,000 - - —— — Relative abundance 1,000 0007 | | Cytolysin Cytolysin negative positive

Enterococcus faecalis 150,000 100,000 8 < g Relative abundance _ I - s & & Sl & R & o

@@ E. faecalis negative 3 E. faecalis positive 100 80 60 40 20 Percent subjects (%) Cirrhosis Non- cirrhosis",13,ALD patent background + target paper.pdf,355,False
f883fa5aa7a9a601d7d35f4dfd6cbb5c,@@,13,ALD patent background + target paper.pdf,356,False
6e68c847369e703f76904cfa8543c972,3,13,ALD patent background + target paper.pdf,357,False
8a68ae2eae6b154052ee904f7596fb84,Em Cytolysin negative Cytolysin positive s [ o =2 o o Percent subjects (%) S 2 & & W & X,13,ALD patent background + target paper.pdf,358,False
5d51aa9472407a0b4f1ea73bbbc9f495,Em,13,ALD patent background + target paper.pdf,359,False
fb6211b92146e08800e98f2ee8f0bd49,Enterococcus faecalis,13,ALD patent background + target paper.pdf,360,False
f7a6e8a30c4dc8ea3962054de350c70e,"80,000",13,ALD patent background + target paper.pdf,361,False
010b4fac6be7259184351cb5a4d08455,Relative abundance,13,ALD patent background + target paper.pdf,362,False
8630c085d2ed446de326cb8dce2149e3,"60,000

40,000

20,000",13,ALD patent background + target paper.pdf,363,False
8c9d213a5cb176e3d7bb32008b437d87,),13,ALD patent background + target paper.pdf,364,False
9d3615216d3d6a22d2fa5ea37faf334c,"Cirrhosis

Non- cirrhosis",13,ALD patent background + target paper.pdf,365,False
65aabf0d31484033f4407ab7f34b7cc0,Article,14,ALD patent background + target paper.pdf,366,False
3919263ca56eb9cac86f7a0ab5ec3306,"Extended Data Fig. 1 | Intestinal dysbiosis in patients with alcoholic hepatitis. a, 16S rRNA sequencing of faecal samples from controls (n = 14), patients with alcohol-use disorder (n = 43), or alcoholic hepatitis (n = 75). The graph demonstrates the relative abundance of sequence reads in each genus. b, Bacterial diversity (Shannon index and Simpson index) and richness (Chao richness) was calculated in controls (n = 14), patients with alcohol-use disorder (n = 43) or alcoholic hepatitis (n =",14,ALD patent background + target paper.pdf,367,False
13c2eda700daeea7cfac4eeb693fd871,"75). c, E. faecalis in faecal samples from controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. d, Percentage of faecal samples positive for E. faecalis in controls (n = 25), patients with alcohol-use disorder (n = 38) or alcoholic hepatitis (n = 82), assessed by qPCR. E. faecalis was detected in faeces from 80% of patients with alcoholic hepatitis, versus 36% of controls (P < 0.001). There was also a significant difference between",14,ALD patent background + target paper.pdf,368,True
5a8966cb66560b2cf24e21445cc8fdc9,"patients with alcohol-use disorder and patients with alcoholic hepatitis (P < 0.01). e, Receiver operating characteristic curves and area under the curve (AUC) for the comparison of 90-day mortality and cytolysin positivity (red; n = 57), MELD score (blue; n = 56), ABIC score (yellow; n = 57) and discriminant function (green; n = 42) in patients with alcoholic hepatitis. f, E. faecalis in faecal samples from patients with alcoholic hepatitis whose faecal samples were cytolysin- positive (n = 25)",14,ALD patent background + target paper.pdf,369,False
c6c794005ed2c243b6b65bc3dfd034cf,"or cytolysin-negative (n = 54), assessed by qPCR (P = 0.8174). g, 16S rRNA sequencing of faecal samples from patients with alcoholic hepatitis from different centres (France, n = 9; Mexico, n = 6; Spain, n = 5; UK, n = 11; USA (east), n = 16; USA (Midwest), n = 12; USA (west), n = 16 patients). We used PCoA based on Jaccard dissimilarity matrices to show β-diversity among groups at the genus level. The composition of faecal microbiota was significantly different between patients from different",14,ALD patent background + target paper.pdf,370,True
04f8e25335c7c097cf73a9f4a4bbef35,"regions (P < 0.01). h, Percentage of faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin- positive), in patients with alcoholic hepatitis from different centres (France,",14,ALD patent background + target paper.pdf,371,True
7da79d03ad17fe213d7c088ae389b3ef,"n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest), n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.6094). i, E. faecalis in faecal samples from patients with alcoholic hepatitis from different centres, assessed by qPCR (P = 0.5648). j, Percentage of faecal samples that were positive for E. faecalis in patients with alcoholic hepatitis from different centres (France, n = 16; Mexico, n = 6; Spain, n = 6; UK, n = 10; USA (east), n = 16; USA (Midwest),",14,ALD patent background + target paper.pdf,372,False
b5ef9926d10662dcfece05cb8ad1f403,"n = 13; USA (west), n = 15 patients), assessed by qPCR (P = 0.0529). k, Percentage of subjects with faecal samples that were positive for cylLL and cylLS DNA sequences (cytolysin-positive), in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.3431). l, E. faecalis in faecal samples from patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.5736). m, Percentage of faecal samples that were",14,ALD patent background + target paper.pdf,373,False
110198f4cecac26794a2b9b07553eeb2,"positive for E. faecalis in patients with alcoholic hepatitis and with (n = 30) or without (n = 18) cirrhosis, assessed by qPCR (P = 0.2878). Results are expressed as mean ± s.e.m. (c, f, i, l). For the box and whisker plots in b, the box extends from the 25th to 75th percentiles, and the centre line represents the median; for all three groups, the bottom whiskers show the minimum values; for the control group (black), the top whisker shows the maximum value; for the other two groups, the top",14,ALD patent background + target paper.pdf,374,True
fce98a9079b5963ef312b9f85de722b8,"whiskers represent the 75th percentile plus 1.5× the inter-quartile distance (the distance between the 25th and 75th percentiles); all values greater than this are plotted as individual dots. P values were determined by Kruskal– Wallis test (i) with Dunn’s post hoc test (b, c), two-sided Fisher’s exact test (h, j, k, m) followed by FDR procedures (d), two-sided Mann–Whitney Wilcoxon rank-sum test (f, l) or PERMANOVA (g). The exact group size (n) and P values for each comparison are listed in",14,ALD patent background + target paper.pdf,375,True
a17407200028b60545284e2af3f2a3f2,"Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",14,ALD patent background + target paper.pdf,376,False
b4f6b083e9349a260a261dfd4f715f31,"Serum ALT 400 k 300 200 100 o1 A o Control Ethanol

b u Fold change oo H Fod Control Ethanol",15,ALD patent background + target paper.pdf,377,False
b42b9c48b0d45b28a90e59f6d7ea0c3a,«,15,ALD patent background + target paper.pdf,378,False
904df34fb50d9bd36ee8572bac8991e7,« ~ E. faecalis Acytolysin —— E. faecalis 100 920 80 70 Log-rank test 60 (Mantel-Cox) Percent survival (%) P<0.05 50 10 Days,15,ALD patent background + target paper.pdf,379,False
58701960095396c4827c93bca3c0e44b,"~

——",15,ALD patent background + target paper.pdf,380,False
8ddd7cee2d820f53fbae639a503ff763,"Fecal albumin

Fecal albumin 400 30 - l ~ 200 10 [ [a] il Control Ethanol",15,ALD patent background + target paper.pdf,381,False
6005b7683a92ff10f921f03b8bd7eb2f,"Serum ethanol 1,000 [T} 800 ] S 600 g —— 400 200 Ethanol",15,ALD patent background + target paper.pdf,382,False
ad224e4d1872659c439a67fc228d56fa,Extended Data Fig. 2 | See next page for caption.,15,ALD patent background + target paper.pdf,383,False
7958a66d5675689df66c12035d590729,") Control 3 Y Ethanol PBS E. faecalis E. faecalis Acytolysin

Hepatic triglycerides PBS 40 W E. faecalis u B E. faecalis Acytolysin 30 L 20 10 oo [ =] i i Control Ethanol",15,ALD patent background + target paper.pdf,384,False
8e6ee81d15ad03b8dd6a9bdccc58f120,"Cxcl1 — Fold change oo e 18 [ o Control Ethanol

Liver cyLg 100 k k k, 80 60 40 Percent mice (%) 20 nd nd nd Control Ethanol

Serum LPS 60 k —— 40 [N (ng/ml) 20 Qo l 2 [on] Control Ethanol

Adht & S . P oo 1] 5 Fold change i S Control Ethanol

Cxcl2 x 10 L] Fold change [al Control Ethanol",15,ALD patent background + target paper.pdf,385,False
5675c304cff0c3865658e4041d913e4b,"Liver E. faecalis 100 © = = S = Percent mice (%) = nd Control Ethanol

Liver Enterococcus",15,ALD patent background + target paper.pdf,386,False
0eedbd1d2ecc10515fe6443e965dd3c8,"1,500",15,ALD patent background + target paper.pdf,387,False
865b04eafaf086a71881f006d7ded3f2,L],15,ALD patent background + target paper.pdf,388,False
4343c3bbe5e58502abe102d81cb902ba,"1,000

500",15,ALD patent background + target paper.pdf,389,False
0ee636ef9844e4e1d78f578ebf5efc2d,"Ethanol

0.50 PBS E. faecalis Control 0.25 ' E. faecalis Acytolysin PBS B E. faecalis Ethanol 0.00 ‘& B E. faecalis Acytolysin -0.25: -0.4 0.4 PC1 .)

Cyp2e1 25 2.0 - o - = Fold change 1F 0.0 Control Ethanol",15,ALD patent background + target paper.pdf,390,False
3f5f8ebe0b5190b981eb01bec6499a63,Fecal Enterococcus 1010 108 1 104 102 24 48 72 Time (hrs),15,ALD patent background + target paper.pdf,391,False
244639aae3fecfe62518d29f2ab3e9b1,Article,16,ALD patent background + target paper.pdf,392,False
0e2785b2ea6bb8fcf61be2758e65dd64,"Extended Data Fig. 2 | Cytolytic E. faecalis causes the progression of ethanol-induced liver disease in mice. a–n, C57BL/6 mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with vehicle (PBS), a cytolytic E. faecalis strain (FA2-2(pAM714)) (denoted E. faecalis) (5 × 108 CFUs) or a non-cytolytic E. faecalis strain (FA2-2(pAM771))5 (denoted E. faecalis Δcytolysin) (5 × 108 CFUs) every third day. a, Serum levels of ALT. b, Hepatic triglyceride content. c,",16,ALD patent background + target paper.pdf,393,False
a25ffe06483580a9c9d97d5e48597abb,"Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding). Mice gavaged with PBS all survived, and are not included in the figure. A higher proportion of mice (n = 15) gavaged with non-cytolytic E. faecalis survived than did mice (n = 25) gavaged with cytolytic E. faecalis. h, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR",16,ALD patent background + target paper.pdf,394,False
20f6fe0bca9889708ae041a56576eaac,"for cylLS (the gene that encodes cytolysin subunit CylLS′′). i, Proportions of mice that were positive for E. faecalis in the liver, measured by qPCR. About 80% of mice colonized with cytolytic E. faecalis, as well as those colonized with non- cytolytic E. faecalis, were positive for E. faecalis in their livers. j, Liver CFUs of Enterococcus in mice on a chronic–binge ethanol diet. k, Paracellular intestinal permeability was evaluated by measuring faecal albumin content and serum levels of",16,ALD patent background + target paper.pdf,395,False
550684485674072abafcf4f167f8b82d,"lipopolysaccharide (LPS) by enzyme-linked immunosorbent assays. l, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices showed no significant differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following",16,ALD patent background + target paper.pdf,396,True
064f217c6f689fd99666e16faa4d30e3,"feeding with the control and ethanol diets. Compared to mice fed with a control diet, mice fed with an ethanol diet had significantly different faecal microbiomes after gavaging with E. faecalis (P < 0.05). m, n, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis after ethanol feeding. o, Mice were gavaged with cytolytic or non- cytolytic E. faecalis strains (carrying the",16,ALD patent background + target paper.pdf,397,True
f3de804e37dd92a77be6a081d904b203,"erythromycin resistance gene; 5 × 108 CFUs) at time 0, and faeces were collected 0, 8, 24, 48 and 72 h later. Faecal CFUs of Enterococcus were determined by culturing faecal samples on BBL enterococcosel broth agar plate with 50 μg ml-1 erythromycin. At time 0 and 72 h, five out of five and four out of five mice, respectively, had no detectable erythromycin-resistant Enterococcus in their faeces. These points are not shown on the graph, but have been included in the calculation of mean ± s.e.m.",16,ALD patent background + target paper.pdf,398,True
678fd25842a32d15af88e49a916e3396,"Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, j, k, m–o). P values among groups of mice fed with the control or ethanol diet were determined by one-way ANOVA with Tukey’s post hoc test (a, b, d–f, j, k, m, n), two-sided log-rank (Mantel–Cox) test (g), two-sided Fisher’s exact test followed by FDR procedures (h, i) or PERMANOVA followed by FDR procedures (l). All results were generated from at least three independent replicates. The exact group size (n) and P values for",16,ALD patent background + target paper.pdf,399,False
cc1254c2ed66b0763812d016ff8c63ca,"each comparison are listed in Supplementary Table 10. P values between mice fed with a control diet and mice fed with an ethanol diet were determined by two-way ANOVA (k). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",16,ALD patent background + target paper.pdf,400,False
66a5c17e414f00a8c6cbd4f18aef4db9,"TUNEL AH cytolysin positive #1 r AH cytolysin positive #2 AH cytolysin negative #3 [N AH cytolysin negative #4 Percent positive (%) i il l 1l Control Ethanol

R Control . 3 /3% ¥ Ethanol F R o Ve, AH cytolysin AH cytolysin AH cytolysin AH cytolysin positive #1 positive #2 negative #3 negative #4

Cxcl2 Fold change - o oo 3 i Control Ethanol

Acta2 10 Fold change Control Ethanol",17,ALD patent background + target paper.pdf,401,True
3223f30ed37315d8a4b20a1212176138,"AH Cytolysin negative AH Cytolysin positive "" 0 90; 80; 70 Log-rank test 60; (Mantel-Cox) Percent survival (%) P<0.05 50 2 10 Days

AH cytolysin positive #1 AH cytolysin positive #2 Control | AH cytolysin negative #3 ] AH cytolysin negative #4 H PC2 (24.13%) & 05 '..",17,ALD patent background + target paper.pdf,402,False
b5a5cdda47a2a098ee1b520b1c9c9729,"|

]",17,ALD patent background + target paper.pdf,403,False
d2bbabd87e48ba7675f3327f1659544a,"0.4- AH cytolysin pos ive #1 AH cytolysin posi #2 I Ethanol AH cytolysin negative #3 AH cytolysin negative #4 g [mmm|m i PC2 (22.82%) 1 A S | | y/ y 0. 02 0. Be (51%)

Cytolysin positive E. faecalis a 8 3 2 8 8 Percent colonies (%) nd nd o Patient Patient Patient Patient #1 # #3 # AH ¢y lysin AH cytolysin po: negative",17,ALD patent background + target paper.pdf,404,False
324c6381659d7efd354d8809231fdf2c,"Serum ethanol 1,000 800 600 400 - 200 Ethanol",17,ALD patent background + target paper.pdf,405,False
e5615af7c2c89de057ba25226f47e397,"Extended Data Fig. 3 | Transplantation of cytolysin-positive faeces increases ethanol-induced liver disease in gnotobiotic mice. a–f, h, i, C57BL/6 germ- free mice were colonized with faeces from two cytolysin-positive and two cytolysin-negative patients with alcoholic hepatitis, and then fed isocaloric (control) or chronic–binge ethanol diets. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the",17,ALD patent background + target paper.pdf,406,False
af5a1aaba0134c1579fbfd8b1ba4b214,"inflammatory cytokine Cxcl2 and Acta2 (a marker of activated hepatic stellate cells). e, Kaplan–Meier curve of survival of mice on chronic–binge ethanol diets (day 0 denotes the start of ethanol feeding), gavaged with faeces from cytolysin-positive (n = 48 mice) or cytolysin-negative (n = 32 mice) patients with alcoholic hepatitis. f, Faecal samples were collected and 16S rRNA genes were sequenced. The graph shows PCoA of faecal microbiomes. No significant difference was observed between mice",17,ALD patent background + target paper.pdf,407,False
ff9d64831d16a0ded96ff2e6dbab66ca,"colonized with faeces from cytolysin-positive or cytolysin-negative donors with alcoholic hepatitis, following the control diet. Mice transplanted with faeces from a cytolysin-positive patient with alcoholic hepatitis (patient",17,ALD patent background + target paper.pdf,408,True
b36c1b741488ef2643a6003250c15651,Ad1 Cyp2et 2.5 2.0 2.0 - 1.5 o 15 e o - % . 1.0{ H - 1.0 H Fold change Fold change 0.5: = W 0.5: 0.0 il 0.0 Control Ethanol Control Ethanol,17,ALD patent background + target paper.pdf,409,False
8a092a9fc4f0f2e603dc4aec6e5ebda3,"no. 2) showed a microbiota that was significantly different to that of the other mouse groups following ethanol administration (P < 0.01). g, Percentage of cytolysin-positive E. faecalis in four patients with alcoholic hepatitis. Stool samples from the four patients were placed on plates with selective medium, and Enterococcus colonies were identified by the production of a dark brown or black colour. Enterococcus colonies were confirmed to be E. faecalis by qPCR. The cytolysin status of each E.",17,ALD patent background + target paper.pdf,410,True
9583ee1332d78f68cfb6cb2efb9030b1,"faecalis colony was determined by qPCR. h, Serum levels of ethanol were comparable among colonized mice after ethanol feeding. i, Hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice on control or ethanol diets. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, h, i). P values were determined by one-way ANOVA with Tukey’s post hoc test (a, c, d, h, i), two- sided log-rank (Mantel–Cox) test (e) or PERMANOVA followed by FDR procedures (f). All",17,ALD patent background + target paper.pdf,411,False
4a5bb1e756991a1edd43066e311c2280,"results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001.",17,ALD patent background + target paper.pdf,412,True
92b53e4a0604ff8f5eb56bdcc57efe3c,Article,18,ALD patent background + target paper.pdf,413,False
7685edd1a6f2798486848d3a1a0c112f,"a Head s v % | . 2 | % o . Tail Siphophage Myophage Podophage (long, flexible, (contractile tail) (short, noncontractile tail) noncontractile tail) S5 or ¥ @ ¥ % Efmus1 Efmus2 Efmus3 Efm us4 Efmus1 (17,927 bp) y b Efmus2 (18,366 bp) Efmus3 (18,286 bp) T SN Efmus4 (18,186 bp) D ol | encapsidation/terminase [ tail fiber DNA polymerase | [l endolysin/lysin | I hypothetical protein - major capsid [ tail components [ DNA binding intron/intein [ holin Il ortal",18,ALD patent background + target paper.pdf,414,True
5ba2c443e670dc5f792737949c3768f3,"Head

Tail",18,ALD patent background + target paper.pdf,415,False
fc00eabbdfe3a5d28e64ed2c6348661c,major capsid,18,ALD patent background + target paper.pdf,416,False
0a471dd183faa7287d48fc6647cb111d,"[

[

[",18,ALD patent background + target paper.pdf,417,False
fff155ad52d6712e2b72101c54253fbc,Il,18,ALD patent background + target paper.pdf,418,False
99d5b137eee6472c133aea06d6e0d470,ortal,18,ALD patent background + target paper.pdf,419,False
cff5e75f554195cd18cc432c1f904e6a,"Extended Data Fig. 4 | Isolation and amplification of phages against cytolytic E. faecalis isolated from mice. a, BHI agar plate showing phage plaque morphology. The phage cocktail (100 μl) (102–103 PFUs) was mixed with overnight-grown E. faecalis culture (100 μl) and then added to BHI broth top agar (0.5% agar) and poured over a BHI plate (1.5% agar). After overnight growth at 37 °C, images were captured on an Epson Perfection 4990 Photo scanner. b, Simplified illustration of the morphologies",18,ALD patent background + target paper.pdf,420,False
ea3deba3d301bf8a6784ed14a0631485,"of different phages. Siphophages have long, flexible noncontractile tails (left); myophages have contractile tails",18,ALD patent background + target paper.pdf,421,False
ba18e429ca55ff5b56d134b2a7f065b3,"(middle); and podophages have short noncontractile tails (right). c, Transmission electron microscopy revealed that phages we isolated were all podophages (Efmus1, Efmus2, Efmus3 and Efmus4). d, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories.",18,ALD patent background + target paper.pdf,422,False
dec71488ac36d4808c0933a8cb6c22a7,"Scale bar, 50 nm. All results were generated from at least three independent replicates.",18,ALD patent background + target paper.pdf,423,False
07050f0ff43493f216963888170f3067,"Serum ALT 500 — 400 ~300 200 - 100 ll WT II WT Atpas Control Ethanol

Hepatic triglycerides PBS C. crescentus phages 60 E. faecalis phages PBS C. crescentus phages EEEE E. faecalis phages '. i WT WT I/I Control Ethanol

S =y 5 Control "" | ey 3 - 3 Ethanol > R - 2 e PBS C. crescentus phages E. faecalis phages PBS C. crescentus phages E. faecalis phages WT Atp4ass

Cxcl1 15 es — e, 10 .- ""~ Fold change - o M | i WT WT /I Control Ethanol",19,ALD patent background + target paper.pdf,424,True
cfd6f71d41302ad17e0349d23f3478de,"Cxcl2 pes 3 — i - o - =3 Fold change ] . H - _ B L & WT I/ WT Control Ethanol

Liver cylLg 100 — s i 8 3 ] Percent mice (%) 8 2 nd o 3 /I WT / Control Ethanol

b S — e - o - o Fold change 5 SUs WT Atpda WT A Control Ethanol

Fecal Enterococcus 1010 10° 2108 108 10% il | 104 WT / WT / Control Ethanol

PBS a C. crescentus phages o8 E. faecalis phages o o & > Control PBS (10.08%) ] C. crescentus phages Atpdassi PC2 E. faecalis phages -1.0 4 17.1) 0",19,ALD patent background + target paper.pdf,425,True
d1e5b319b3409afe9fe7a57832c18e62,Serum ethanol,19,ALD patent background + target paper.pdf,426,False
6a9b53066605475f1336cf851dacdfe8,Adh1,19,ALD patent background + target paper.pdf,427,False
20abf38e55008d68044fd40473feb3b7,"800

600

400",19,ALD patent background + target paper.pdf,428,False
63df6a1f3c90137cb9c173df706ea4ea,20,19,ALD patent background + target paper.pdf,429,False
ae5b7428da71c892c4661ae8ddfa7ece,o S il i,19,ALD patent background + target paper.pdf,430,False
f03c7a7a1cf49350b3dcdac8910093f8,Fold change,19,ALD patent background + target paper.pdf,431,False
22315b4230922fa690c75b970c31d648,H,19,ALD patent background + target paper.pdf,432,False
a2979c91536f7440bf1a001ead675600,"I I

|

:",19,ALD patent background + target paper.pdf,433,False
942c826ff6d10f79e15829a1b934b577,WT,19,ALD patent background + target paper.pdf,434,False
8e919d0c66136a2fe604771856bef652,II,19,ALD patent background + target paper.pdf,435,False
59d17cdef09e5f2ff2b2c8cf0826b0c1,"WT

WT",19,ALD patent background + target paper.pdf,436,False
344ad24dbf5fb114282cb57d44ce1de3,/s,19,ALD patent background + target paper.pdf,437,False
52dfa4d0288b74906fba364b1c88347e,Ethanol,19,ALD patent background + target paper.pdf,438,False
69602007880a5e3baab9541e1906b935,Control,19,ALD patent background + target paper.pdf,439,False
c93657badc3fd11f19631e74fba44d37,Ethanol,19,ALD patent background + target paper.pdf,440,False
d320f1de19ea599a044cbc89feef8edd,Extended Data Fig. 5 | See next page for caption.,19,ALD patent background + target paper.pdf,441,False
5fd879f6cfb7204a19e24ed00a15d34f,"2 PBS C. crescentus phages WT 5 E. faecalis phages Ethanol PBS g (17.92%) C. crescentus phages Atpdasus PC2 E. faecalis phages B 0.4 0 5 PC1 'z.

Cyp2e1 S = - S P = 1.0 B Fold change 0.5 il I i 0.0 WT wT I I/I Control Ethanol",19,ALD patent background + target paper.pdf,442,False
8529d78db4cfda8acfe9f6d5a801f281,Article,20,ALD patent background + target paper.pdf,443,False
251a57bd201671dfa7051e175f12a942,"Extended Data Fig. 5 | Phages reduce translocation of cytolysin to the liver and reduce ethanol-induced liver disease in Atp4aSl/Sl mice. a–k, Wild-type (WT) and Atp4aSl/Sl littermates were fed oral isocaloric (control) or chronic– binge ethanol diets, and gavaged with vehicle (PBS), control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages that target cytolytic E. faecalis (1010 PFUs), 1 day before an ethanol binge. a, Serum levels of ALT. b, Hepatic triglyceride",20,ALD patent background + target paper.pdf,444,False
9a8375ca91f81ed22aee38162e8e3aea,"content. c, Representative oil red O-stained liver sections. d–f, Hepatic levels of mRNAs. g, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. h, Faecal CFUs of Enterococcus. i, Faecal samples were collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant",20,ALD patent background + target paper.pdf,445,False
de00ac12aa0e7be4da5736f4f59ef571,"difference in faecal microbiota among mice given PBS, control phage or phages that target cytolytic E. faecalis in each group. j, k, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, b, d–f, h, j, k). P values were determined by two-way ANOVA with Tukey’s post hoc test (a, b, d–f, h, j, k), two-sided Fisher’s exact test followed by FDR",20,ALD patent background + target paper.pdf,446,False
97eea067db56287109cd9915c89a6f7c,"procedures (g) or PERMANOVA followed by FDR procedures (i). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.",20,ALD patent background + target paper.pdf,447,True
6f3e50c4b9906a218faf67bacc81e5f5,<. 2. - 8s °s - Ef5 Ef2,21,ALD patent background + target paper.pdf,448,False
6732d98ddb71f08ec4cdd648f47f85a9,Ef2.1,21,ALD patent background + target paper.pdf,449,False
cb06323014af01f332d7889709d322e4,Ef2.3,21,ALD patent background + target paper.pdf,450,False
d9d851e2342951de959914430e46830b,"Ef5.1 F)- ) ) o l ) ) o (41,141 bp) Ef5.2 (41,418 bp) ) b o s i D Ef5.3 F)- b ) o ol e ) ) (39,115 bp) Ef5.4 (41,141 bp) W) e om Ef2.1 (140,938 bp) PP o ) ) s o ) ) o D DO O OO 0 0 ¢ Ef2.2 ( W W (58,400 bp) L Ef2.3 i oo ) ) o (147,289 bp) ) ) m) m) o m m Capsid structural components Tail and baseplate and assembly assembly [ encapsidation/terminase [ tail fibers - DNA polymerase - endolysin/lysin - hypothetical protein (] major capsid - tail component [ DNA binding I holin intron/intein I rortal",21,ALD patent background + target paper.pdf,451,True
632d7112d59fbbb3227bd5a9ba56d5c5,[ tail measure DNA recombination | regulatory [ protease (scaffold protein) I salvage of [ transcription factor nucleosides and Il other nucleotides | other known functions ] DNA restriction/ modification e tRNA || nucleotide degradation,21,ALD patent background + target paper.pdf,452,False
ca2ff0493a7859cbf26c64fc7c83a7b6,"Extended Data Fig. 6 | Isolation and amplification of phages against cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Transmission electron microscopy graphs of myophages Ef2.1 and Ef2.3, stained with phosphotungstic acid showing contracted tails. c, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage",21,ALD patent background + target paper.pdf,453,False
14fc8bbb7f38a8f10590590030b2c092,"genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. Scale bar, 50 nm. All results were generated from at least three independent replicates.",21,ALD patent background + target paper.pdf,454,False
ec8c9e5d7db71cc96bd36acda0ce8b90,"Article

a",22,ALD patent background + target paper.pdf,455,False
cd3bd91d5a5ca35c7291b3382fc225fc,"TUNEL C. crescentus phages Cytolysin-positive E. faecalis phages K k C. crescentus phages EE Cytolysin-positive E. faecalis phages Percent positive (%) Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

o e Control e A o ] Ethanol C. crescentus phages Cytolysin-positive C. crescentus phages ylin- ive E. faecalis phages E. faecalis phages Patient #5 Patient #2",22,ALD patent background + target paper.pdf,456,False
60625ff8a0b5576570aa2d313d373046,"Patient #2

Cxcl2 [T "" Fold change o H al Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,ALD patent background + target paper.pdf,457,False
db6af0b67489cfe3893bf1a5c56fe40b,"Acta2 10 I Fold change y B o H ¥ Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Fecal Enterococcus 1010 10° 2108 O 107 108 108 | Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol

Control C. crescentus phages 5 Cytolysin-positive E. faecalis phages | Patient #5 =) o C. crescentus phages Cytolysin-positive E. faecalis phages I Patient #2 =] o PC2 (7.13%) -0.5 -1.0 -0.5 c (80.98%) 0",22,ALD patent background + target paper.pdf,458,False
d7bafceb9012693c07d5bacb83e3fc01,"Ethanol C. crescentus phages 0.25 Cytolysin-positive E. faecalis phages Patient #5 C. crescentus phages Patient #2 LILILIL Cytolysin-positive E. faecalis phages PC2 (16.3%) -0.25 0.25 1.)

Serum ethanol 800 60 = 400 20 Patient Patient #5 #2 Ethanol

Adh1 2.0 - o oo o - ] Fold change 0.5 . 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol",22,ALD patent background + target paper.pdf,459,False
d5687c084a4f242b36fdbdc997e9c530,"Extended Data Fig. 7 | Phages that target cytolytic E. faecalis reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-positive patients with alcoholic hepatitis (faeces from one patient were also used in Fig. 2). The mice were then fed oral isocaloric (control) or chronic–binge ethanol diets, and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of 3 or 4 different phages that target cytolytic",22,ALD patent background + target paper.pdf,460,False
bfb42bb260db14eb789fdd8600f0885d,"E. faecalis (1010 PFUs), one day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Faecal CFUs of Enterococcus. f, Faecal samples were",22,ALD patent background + target paper.pdf,461,False
990f5abd435071845b4a5bb7f9a1ae4d,Cyp2e1 s = o Oo T - = o Fold change 0.5 | 0.0 Patient Patient Patient Patient #5 #2 #5 #2 Control Ethanol,22,ALD patent background + target paper.pdf,462,False
5e65bb528a0462abbeb41d6fda397cb8,"collected and 16S rRNA genes were sequenced. PCoA based on Jaccard dissimilarity matrices shows no significant differences in the faecal microbiota of mice gavaged with control phage and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c–e, g, h). P values were determined by two-way",22,ALD patent background + target paper.pdf,463,True
3dcba7887dc4bafcba4fee83e5039e68,"ANOVA with Tukey’s post hoc test (a, c–e, g, h) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10. *P < 0.05, ***P < 0.001.",22,ALD patent background + target paper.pdf,464,True
e56821eab81d0fc071508d7c191c7b80,"%, H % % 84 S X %3 s y 3 3 g H £ S & X3 2 & F o %, 8% , o o Yo, s, 5 2. & e, & B, By ® N ) S <1 G %, A 2. g5eC f54 PhiM1E, fal Ef6 VB-EfaM-£f23 vB-EfaSEf PhiEF17H. PMBT2 B-EfaM-Ef2.1 -vB-EfaS-Ef5.2 iEF24C P2 Si r , EfaP_igg KA s A S S, 103 & 253 o o, 62 ¥ & S, S, - kN N & %, G [ Siphoviridae P ne 5 % & § N N g3 & N % Podoviridae k) Ef7 B Myoviridae Tree scale: 1",23,ALD patent background + target paper.pdf,465,False
36746146626a68c1869d333cae1ffd69,"Ef6.1 ) b e o 4 (40,429 bp) Ef6.2 (17,966 bp) ) o Ef6.3 ) o (18,136 bp) Ef6.4 s ) o (41,133 bp) Ef7.1 D ) | (58,018 bp) - Ef7.2 1 ) o s (18,737 bp) Ef7.3 oo (18,818 bp) Ef7.4 (18,415 bp) C apsid structural components Other N and assembly || encapsidation/terminase [ tail fibers - DNA polymerase [ endolysin/ysin | [ hypothetical protein - tail component I intron/intein major capsid [ DNA binding [ holin I portal [ tail measure [ regulatory DNA recombination [l protease (scaffold protein) I",23,ALD patent background + target paper.pdf,466,True
d303711fd5e54e319fbbb615871757a0,salvage of RNA l other nucleosides and nucleotides [ DNA restriction/ modification (| nucleotide degradation,23,ALD patent background + target paper.pdf,467,False
bd5b3e2ba159f02832aaf7e04052ac13,Extended Data Fig. 8 | See next page for caption.,23,ALD patent background + target paper.pdf,468,False
15c686ef219e640d44797543b729ca56,Article,24,ALD patent background + target paper.pdf,469,False
7734dffb61c7174f1d28546501855c34,"Extended Data Fig. 8 | Isolation and amplification of phages against non- cytolytic E. faecalis strains isolated from patients with alcoholic hepatitis. a, BHI agar plates showing phage plaque morphology. b, Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the phage genomes and predicted open reading frames. The name and length (in bp) of each genome are indicated to the left of each phage map. Protein-coding sequences are coloured on the basis of functional",24,ALD patent background + target paper.pdf,470,False
9684cf995def83f21282c53411f39630,"role categories. Sequences that encode tRNA genes are indicated by a cloverleaf structure. c, Phylogenetic tree of Enterococcus phages. A whole-genome average nucleotide distance tree was constructed for 73 available Enterococcus phage genomes: 54 of these were",24,ALD patent background + target paper.pdf,471,False
045bb667bb02c256e39972e6453647d8,from GenBank (denoted by black letters) and 19 were from this study (4 phages against cytolysin-positive E. faecalis isolated from mice (shown in blue letters); 7 phages against cytolysin-positive E. faecalis isolated from patients with alcoholic hepatitis (shown in pink letters); and 8 phages against cytolysin- negative E. faecalis isolated from patients with alcoholic hepatitis (shown in green letters)) with Mash43 using a sketch size of s = 5000 and a k-mer size of k = 12 and GGRaSP59,24,ALD patent background + target paper.pdf,472,True
8f3bc226826ffa26427dd375d96dbf81,"(Methods). Coloured branches denote specific phage genera or subfamily: Sap6virus, P68virus and Spounavirinae. The scale bar represents per cent average nucleotide divergence. All results were generated from at least three independent replicates.",24,ALD patent background + target paper.pdf,473,False
cbdef8a8f27333dcc05547a3f2e39985,TUNEL C. crescentus phages Cytolysin-negative E. faecalis phages C. crescentus phages L B | Cytolysin-negative E. faecalis phages Percent positive (%) | Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,474,False
1368e7b41b26d7f7a990555a69d20095,|,25,ALD patent background + target paper.pdf,475,False
4cfd00ef0efa5bdc27497da63c2557c4,"o o Control 2 . “ . L ‘ ok - -4 & l Ethanol 3 4 C. crescentus phages lyioiv C. crescentus phages lyin- ve E. faecalis phages E. faecalis phages Patient #6 Patient #7

Cxcl2 L] L oo Fold change 0 ] i Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol

Acta2 Ll Fold change T l ] g i Patient Patient Patient Patient #6 H#7 #6 H7 Control Ethanol

Liver cylLg 100 =3 =3 o o B o Percent mice (%) =3 nd nd nd nd nd nd nd nd [ Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol",25,ALD patent background + target paper.pdf,476,False
f8ab596b0e4d1fad49ecc15a595e4570,Control,25,ALD patent background + target paper.pdf,477,False
87eb08b389fe482e1c2c91f83d1b7139,Ethanol,25,ALD patent background + target paper.pdf,478,False
3339a5608a94dffc480710212d1278bb,"Control 1.0 C. crescentus phages g Cytolysin-positive E. faecalis phages | Patient #6 2 C. crescentus phages Cytolysin-positive E. faecalis phages | Patient #7 g ] PC2 (19.54%) -0.5 -1.0 -1.0 1.0 PC1

Ethanol . - C. crescentus phages Cytolysin-positive E. faecalis phages Patient #6 0. C. crescentus phages u|| Cytolysin-positive E. faecalis phages Patient #7 0.0 PC2 (15.2%) -0.3 -0.2 0.2 0.50 (.)

Serum ethanol 1,000 800 (1] 600 I (mg/dl) 400 200 Patient Patient #6 #7 Ethanol",25,ALD patent background + target paper.pdf,479,True
332df11e6b212d3035a69c71ea0865cf,Adh1 25 20 - LT - Fold change & S Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,480,False
e082f2210f85b74bb74f09ffc7ad7d30,"Extended Data Fig. 9 | Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease in gnotobiotic mice. a–h, C57BL/6 germ-free mice were colonized with faeces from two cytolysin-negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against C. crescentus (1010 PFUs) or a cocktail of four different phages targeting non-cytolytic E. faecalis (1010 PFUs),",25,ALD patent background + target paper.pdf,481,True
7685b742c8dacbe399d857540289a192,"1 day before an ethanol binge. a, Percentage of TUNEL-positive hepatic cells. b, Representative oil red O-stained liver sections. c, d, Hepatic levels of mRNAs that encode the inflammatory cytokine Cxcl2, and Acta2 (a marker of activated hepatic stellate cells). e, Proportions of mice that were positive for cytolysin in the liver, measured by qPCR for cylLS. f, Faecal samples were collected and 16S rRNA",25,ALD patent background + target paper.pdf,482,False
c3f99829b15e4a01973877a3f5b78a8f,Cyp2e1 25 2.0 O - e - o Fold change = o Patient Patient Patient Patient #6 #7 #6 #7 Control Ethanol,25,ALD patent background + target paper.pdf,483,False
1d7af732e5a50753c3d4a4b86ee5665e,"genes were sequenced. PCoA based on Jaccard dissimilarity matrices found no significant difference in faecal microbiota among mice gavaged with control phages and phages that target cytolytic E. faecalis in each group. g, h, Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale bar, 100 μm. Results are expressed as mean ± s.e.m. (a, c, d, g, h). P values were determined by two-way ANOVA with Tukey’s post",25,ALD patent background + target paper.pdf,484,True
b9bbd412a629bc8d0ed6fbdbc73d0fb3,"hoc test (a, c, d, g, h), two-sided Fisher’s exact test followed by FDR procedures (e) or PERMANOVA followed by FDR procedures (f). All results were generated from at least three independent replicates. The exact group size (n) and P values for each comparison are listed in Supplementary Table 10.",25,ALD patent background + target paper.pdf,485,False
fe77b74c0db0141a1b726159c1df4f62,natureresearch,26,ALD patent background + target paper.pdf,486,False
d2b0adfb1e59aca0688bb9c981ee8c71,Reporting Summary,26,ALD patent background + target paper.pdf,487,False
77b2051064438668626de2b377d56c79,"Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.",26,ALD patent background + target paper.pdf,488,False
7f043129783e9ebdd43415f9e8d44ef9,Statistics,26,ALD patent background + target paper.pdf,489,False
a59fceee82250b70b476ce79598c3840,"For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described",26,ALD patent background + target paper.pdf,490,True
7283176899e9359a7761c62c0e8578cd,"solely by name; describe more complex techniques in the Methods section. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis",26,ALD patent background + target paper.pdf,491,True
744b1ea1b50d5157015a0ccb020f44ff,"testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated",26,ALD patent background + target paper.pdf,492,True
1143ba3a1f4b39452ffb4a1874006eb0,Our web collection on statistics for biologists contains articles on many of the points above.,26,ALD patent background + target paper.pdf,493,False
3b67389966c555e3abe89f45bab1e931,"Software and code

Policy information about availability of computer code",26,ALD patent background + target paper.pdf,494,False
dac4bbe82e53ce41122430ac09e2b09f,Data collection All biochemical assays were measured using SoftMax Pro 7.0.3; gPCRs were run with StepOnePlus real-time PCR system; Liver histological pictures were taken with DP Controller and DP Manager (Olympus); Phage electronic microscopy pictures were taken using Maxim DL5; Plates were scanned using EPSON 4990 Photo; All pictures were viewed using Image,26,ALD patent background + target paper.pdf,495,False
1935a40d230fed96831e2809d1db8109,Data analysis,26,ALD patent background + target paper.pdf,496,False
59cb227458d0170c095d9a964b471e9c,"Bacteriophage sequencing and phage tree: Albacore v2.3.4 (ONT), Porechop v0.2.3, Unicycler v0.4.7 pipeline, Pilon v1.22, CLC Genomics Workbench 4.9, NCBI Prokaryotic Genome Annotation Pipeline, in-house PERL script using Xfig, Phage_Finder, MASH program, GGRaSP and APE R-package, iTOL tree viewer 16S sequencing: MOTHUR-based 16S rDNA analysis workflow E. faecalis genome sequencing and tree: abricate v0.8.10 , Prokka, Roary, RAXML, iTOL Statistical analyses: R",26,ALD patent background + target paper.pdf,497,True
3fce177312421169ff9ea853c344b69b,"statistical software 3.5.1, GraphPad Prism v6.01",26,ALD patent background + target paper.pdf,498,False
db919547ce2b2fb8114099bdb5949cb6,"For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",26,ALD patent background + target paper.pdf,499,True
4598ab42b4ffa38be6d03c1bd3be18c9,"Data

Policy information about availability of data",26,ALD patent background + target paper.pdf,500,False
02eed19603761eb3a5a1bfcd12f13125,"All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets",26,ALD patent background + target paper.pdf,501,True
cf22d75f60f3dee1281945fdc0c21bb4,- A list of figures that have associated raw data,26,ALD patent background + target paper.pdf,502,False
39043b7d94c31ef62236577d78eca663,- A description of any restrictions on data availability,26,ALD patent background + target paper.pdf,503,False
da692ddd31c3de12249645eb02db0c94,Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject PRJNA525701. Bacteriophage raw sequence reads and annotated genomes are,26,ALD patent background + target paper.pdf,504,False
242d1f5339cab833978c9ac28f94bfd5,Corresponding author(s): Bernd Schnabl,26,ALD patent background + target paper.pdf,505,False
c6c3f3441c9dcda5311237650ede6039,"Last updated by author(s): Sep 5, 2019",26,ALD patent background + target paper.pdf,506,False
1c8f855b4911e63523887baa395996ad,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 1,26,ALD patent background + target paper.pdf,507,False
83791a2c67b42e2b3d1b1394bc0f3a9d,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 2,27,ALD patent background + target paper.pdf,508,False
a45bda3b81483a87565a5c5d14f72869,available at NCBI under the following consecutive BioSample IDs (SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were registered at ENA under Study PRJEB25007.,27,ALD patent background + target paper.pdf,509,True
6cfd21a395bcd6e3f4eaba77ae4b5df3,Field-specific reporting,27,ALD patent background + target paper.pdf,510,False
6ea03404d04de76df42adba19a97d1f7,"Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf",27,ALD patent background + target paper.pdf,511,False
fb8346b41da7b2783265e16ff7670267,Life sciences study design,27,ALD patent background + target paper.pdf,512,False
e191f760ebd1bb86366aaf5274f6b401,All studies must disclose on these points even when the disclosure is negative.,27,ALD patent background + target paper.pdf,513,False
1782d002a5db530f4f0491d834b12409,"Sample size No power analyses or other calculations were used to predetermine sample sizes. Sample sizes were chosen based on prior literature using similar experimental paradigms (Nat Commun. 2017;8:2137; Gut. 2019;68:1504-1515) Data exclusions No data were excluded Replication In vivo experiments: more than two technical replicates (from different cohorts, on different dates), as well as biological replicates were performed to ensure data reproducibility; In vitro experiments: three",27,ALD patent background + target paper.pdf,514,True
31287eec58409495d16539420bfe7d0f,independent experiments and also replicates were performed on different dates to ensure data reproducibility. All replications were successful. Randomization Mice of similar age and weight were randomly assigned to experimental and control groups. Blinding The investigators were not blinded during cell and animal experiment assays.,27,ALD patent background + target paper.pdf,515,True
dbe3dc6363295054617f7cb56083d632,"Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.",27,ALD patent background + target paper.pdf,516,False
6b81c4664da8790749e844ead5ba05fc,Methods n/a Involved in the study Antibodies ChIP-seq Eukaryotic cell lines Flow cytometry Palaeontology MRI-based neuroimaging Animals and other organisms Human research participants Clinical data,27,ALD patent background + target paper.pdf,517,False
3de50d4ad769fe5bd196c54c4f7b069f,Animals and other organisms,27,ALD patent background + target paper.pdf,518,False
ad97ec75cb11f35e0af9b99afc5d73bc,"Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Female and male C57BL/6 mice (age, 9-12 weeks) (strain: wild type, Atpdasl/sl) Wild animals No wild animals were involved in the study. Field-collected samples No field-collected samples were involved in the study",27,ALD patent background + target paper.pdf,519,False
2a5b0b192987cbbcb213e79f0f5b91fc,"Ethics oversight All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.",27,ALD patent background + target paper.pdf,520,True
881e496cb267d9dc466d9f995ce715a1,Note that full information on the approval of the study protocol must also be provided in the manuscript.,27,ALD patent background + target paper.pdf,521,False
ef18784ff9b04a25c832c1a5de2f55b7,"Human research participants

Policy information about studies involving human research participants",27,ALD patent background + target paper.pdf,522,False
de087d79e22d382901fd3edcd24e8e90,Population characteristics,27,ALD patent background + target paper.pdf,523,False
330a1d172ffee2071b3606d297971db3,"Alcoholic hepatitis patients were from multiple centers from United States, Mexico and Europe, with the age ranged from 30 to",27,ALD patent background + target paper.pdf,524,False
9dbd38caba28b3366151e6a1001bd66d,"Population characteristics 75. Alcohol use disorder patients and non-alcoholic controls were from United States and Europe, with the age ranged from 27 to 74. Both genders were included in all populations. Detailed descriptions in Methods, Extended Data Tables 1 and 2",28,ALD patent background + target paper.pdf,525,False
c512aa2d465bb297896f4d8cd043a614,Recruitment,28,ALD patent background + target paper.pdf,526,False
60bb3c1268359bab70329f41a916b08e,"Patients with alcohol use disorder fulfilling the DSM IV criteria (J Abnorm Psychol. 1997;106:545-553) were recruited from an alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a detoxification and rehabilitation program. Alcoholic hepatitis patients were enrolled from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers in the USA, Mexico, United Kingdom, France and Spain. Detailed inclusion and",28,ALD patent background + target paper.pdf,527,True
a36dcf5b60089e8b129d10b0b75d06be,exclusion criteria are listed in Methods,28,ALD patent background + target paper.pdf,528,False
51e997308e3cbe402b516987a27fdce5,Ethics oversight,28,ALD patent background + target paper.pdf,529,False
9f978083d35ae2daa32d7ef55673dd5b,"The protocol was approved by the Ethics Committee of Hopital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San Diego",28,ALD patent background + target paper.pdf,530,True
a09eac428bc3c834f53b07f29fea2432,"Healthcare System (San Diego, USA) and Université Catholique de Louvain (Brussels, Belgium).",28,ALD patent background + target paper.pdf,531,False
78136cb738ed122039139ea7fa9bafff,Note that full information on the approval of the study protocol must also be provided in the manuscript.,28,ALD patent background + target paper.pdf,532,False
01accb07fb2d6eb3aa370e0559ac6a11,n a t u r e r e s e a r c h | r e p o r t i n g s u m m a r y O c t o b e r 2 0 1 8 3,28,ALD patent background + target paper.pdf,533,False
bde5947c3aa128a08aa3bcc7e187ed42,RES EARCH,1,GvHD-paper.pdf,534,False
20d1dc3add40542e9cd01b4cc74b68cb,MICROBIOME,1,GvHD-paper.pdf,535,False
2f47343d09539d18cbccd39f8e7ea358,Lactose drives Enterococcus expansion to promote graft-versus-host disease,1,GvHD-paper.pdf,536,False
331d5ae435ddb18fbe20eb92cad90f4d,"C. K. Stein-Thoeringer1,2,3, K. B. Nichols1,2, A. Lazrak1,2, M. D. Docampo1,2, A. E. Slingerland1,2, J. B. Slingerland1,2, A. G. Clurman4, G. Armijo1,2, A. L. C. Gomes1,2, Y. Shono1,2, A. Staffas1,2, M. Burgos da Silva1,2, S. M. Devlin5, K. A. Markey1,2,4, D. Bajic6, R. Pinedo7, A. Tsakmaklis8,9, E. R. Littmann1,10, A. Pastore1, Y. Taur11, S. Monette12, M. E. Arcila13, A. J. Pickard14, M. Maloy4, R. J. Wright1, L. A. Amoretti1, E. Fontana1, D. Pham15, M. A. Jamal15, D. Weber16, A. D. Sung17, D.",1,GvHD-paper.pdf,537,False
c847c58771cb21f8867b40c841c1c7d6,"Hashimoto18, C. Scheid8, J. B. Xavier19, J. A. Messina20, K. Romero21, M. Lew17, A. Bush17, L. Bohannon17, K. Hayasaka22, Y. Hasegawa18, M. J. G. T. Vehreschild8,9,23, J. R. Cross14, D. M. Ponce2,4, M. A. Perales2,4, S. A. Giralt2,4, R. R. Jenq15, T. Teshima18,22, E. Holler16, N. J. Chao17, E. G. Pamer1,2,10, J. U. Peled1,2,4*†, M. R. M. van den Brink1,2,4*†",1,GvHD-paper.pdf,538,False
3dff5bf0dd3d987610c819245891f764,"Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and",1,GvHD-paper.pdf,539,True
aaa0885b0f55e841fb07099e59cf25f8,"exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.",1,GvHD-paper.pdf,540,True
97816344e044637e689d1a6574cab252,"community of mostly anaerobic bacteria, and a hallmark of microbial imbalance (dysbiosis) observed in many disease states involves the expansion of facul- tative anaerobic bacteria (1). Enterococci are facultative anaerobes that colonize the intes- tines of almost every species, from insects to mammals (2), and make up a very small proportion (<0.1%) of the gut microbiota in healthy humans (3). However, enterococci are also pathogens; the species Enterococcus faecium and Enterococcus faecalis",1,GvHD-paper.pdf,541,False
43c6d0fc9904d9d1a853af41520f416c,"are impor- tant causes of multidrug-resistant infections in patients (4). In single-center studies, E. faecium has been observed to dominate the fecal microbiota of immunocompromised patients after allogeneic hematopoietic cell transplantation (allo-HCT), a curative-intent therapy for hematological malignancies (5–7). Moreover, fecal domination with vancomycin- resistant enterococci increases the risk of",1,GvHD-paper.pdf,542,True
1b22244d9546e48c7c6e6d5783287762,"bloodstream infection in allo-HCT patients (5, 8). Patients with severe graft-versus-host disease (GVHD) after allo-HCT have poor outcomes with only ~30% long-term survival (9). Gut microbiota perturbations caused by broad-spectrum antibiotics and a reduction in microbial diversity are associated with in- creased transplant-related mortality and lethal GVHD in humans and mice (10–13). Besides causing infections, experimental studies in gno- tobiotic mice have revealed that enterococci play an",1,GvHD-paper.pdf,543,True
f61465198e6440e5f43238f30249cc80,"important role in colitis (14) by stimulat- ing antigen-presenting cells and CD4+RORg+ T cell infiltration, causing intestinal inflam- mation (15). In this study, we investigated the role of enterococci in the development of acute GVHD, both in allo-HCT patients and preclinical allo-HCT mouse models.",1,GvHD-paper.pdf,544,True
e4f3a612c5044eda5f3f1695a85bc930,We used 16S ribosomal RNA (rRNA) gene sequencing to study the fecal microbiota of 1325 adult allo-HCT recipients at four HCT centers: Memorial Sloan Kettering Cancer,1,GvHD-paper.pdf,545,True
b59c3859e6f00b6fade6679a559fc46d,"Center (MSKCC) (United States), Duke Uni- versity (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). Patient characteristics are shown in table S1. We observed high abundance of enterococci soon after transplantation in samples from all four transplant centers (Fig. 1B and fig. S1B). We defined Enterococcus domination as relative genus abundance ≥0.3 (≥30%) in any fecal sample, following a thresh- old we have used previously (5) (materials and methods and",1,GvHD-paper.pdf,546,True
ba5a7cd89a0dd0e1e025134ac812d2fa,"fig. S2C). The incidence of domination rose comparably across cen- ters, with up to 65% of patients exhibiting a domination event after allo-HCT (Fig. 1A). E. faecium was the dominant species in both the MSKCC and the multicenter-validation cohort (Duke, Hokkaido, and Regensburg) (Fig. 1B, fig. S1, and table S2), where 40.1% of MSKCC patients (441 of 1101 patients) and 46.0% of multicenter-validation patients (103 of 224 patients) met criteria for domination at any time point between day −20 and",1,GvHD-paper.pdf,547,True
6eccc4e5d3edefb82d95c98ac3129fa8,"day +80 relative to the date of allo-HCT, in which cells are infused on day 0.",1,GvHD-paper.pdf,548,False
07dfeaf72aaa01606b402fc242d17978,"early posttransplant period (day 0 to +21) was associated with significantly reduced overall survival and increased GVHD-related mortality in both the MSKCC and multicenter- validation cohort, as well as an increased risk of moderate-to-severe acute GVHD in the MSKCC cohort (Fig. 1, C and D, fig. S2, A and B, and table S3). The risk of relapse or disease progression was not associated with enterococcal domination in either cohort. The association of domination by genus Enterococcus with clinical",1,GvHD-paper.pdf,549,True
0b3f9ba03bbc4a8ad978c5a6129cefeb,"outcomes in the MSKCC cohort remained significant in a multivariate analysis adjusted for graft source, disease, conditioning intensity, gender, and age (table S4). In a subset of MSKCC patients, the vanA operon was found in 152 (37.4%) of 406 patients that had samples available for analysis, indicating the presence of vancomycin-resistant enterococci (VRE) (fig. S2E). Notably, expansions of several different taxa were detected in fecal samples in this study, but the Enterococcus genus was the",1,GvHD-paper.pdf,550,True
6037f488f5b1672e4f9895b7d56806b7,one most commonly observed dominating the microbiota in all four transplant centers (fig. S3 and tables S5 and S6).,1,GvHD-paper.pdf,551,False
ec48ff5348e8f896d4fa3940c0a3d20f,"1Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2Weill Cornell Medical College, New York, NY, USA. 3German Cancer Research Center (DKFZ), Heidelberg, Germany. 4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Department of Internal Medicine II, Technical University",1,GvHD-paper.pdf,552,False
4a7e36bf8a772cba2e6fa481b9acb93a,"of Munich, Munich, Germany. 7Gnotobiotic Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. 9German Center for Infection Research, Partner site Bonn-Cologne, Cologne, Germany. 10Department of Medicine, Section of Infectious Medicine and Global Health, University of Chicago, Chicago, IL, USA. 11Infectious Disease Service, Department of",1,GvHD-paper.pdf,553,False
764e2196e70d7470591cd5dbdb538f5c,"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY, USA. 13Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15Department of Genomic Medicine, The University of",1,GvHD-paper.pdf,554,False
ac4505a946b43b3ec8b7aa5bf2465df9,"Texas MD Anderson Cancer Center, Houston, TX, USA. 16Internal Medicine III, University Clinic Regensburg, Regensburg, Germany. 17Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA. 18Department of Hematology, Hokkaido University, Faculty of Medicine, Sapporo, Japan. 19Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 20Division of Infectious Diseases, Department of",1,GvHD-paper.pdf,555,False
d35d0ae01aa2bf19a227b3c1a314657c,"Medicine, Duke University, Durham, NC, USA. 21Office of Clinical Research, Duke University School of Medicine, Durham, NC, USA. 22Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan. 23Department of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.",1,GvHD-paper.pdf,556,False
fa6f57dbeba09163cd5d009e6df48d30,"*These authors contributed equally to this work.

†Corresponding author. Email: peledj@mskcc.org (J.U.P.); vandenbm@mskcc.org (M.R.M.v.d.B.)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",1,GvHD-paper.pdf,557,False
009d44f00d27142ab787cdd968d8f68b,29 November 2019,1,GvHD-paper.pdf,558,False
9fdf714d2dd986f360093fee4dc16178,"1 of 7

D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",1,GvHD-paper.pdf,559,False
0e95ffef31a285d4f3613b1a065c9426,RES EARCH | R E P O R T,2,GvHD-paper.pdf,560,False
7167bbe87dc96d8199e21579ac3e08d9,"To further investigate these clinical obser- vations, we examined the fecal microbiota of mice early after transplantation using well- established mouse models of allo-HCT. In a major histocompatibility complex (MHC)– matched, minor-antigen-mismatched allo-HCT model [C57BL/6-to-129S1/Sv transplant (C57BL/ 6→129S1/Sv)], we performed 16S rRNA gene sequencing of fecal samples and found that E. faecalis dominated the fecal microbiota at posttransplant day +8 in mice who re- ceived T cell–replete",2,GvHD-paper.pdf,561,True
43839c87eb8aace015e7723f9fa7f14a,"grafts and developed lethal, acute GVHD (Fig. 2A and fig. S4A). In contrast to the patients who had pro- longed antibiotic exposures, this expansion of E. faecalis was independent of antibiotic administration and dependent upon GVHD, as it was not observed in control recipients of T cell–depleted allografts in which GVHD did",2,GvHD-paper.pdf,562,True
7684a55062ee8af4fdf8d0c77304a56f,"not develop. This posttransplant expansion of enterococci was consistently found in two additional lethal GVHD models: C57BL/6→ BALB/c mice (MHC-disparate model after ir- radiation conditioning) (Fig. 2B) and LP/ J→C57BL/6 mice [MHC-matched, minor- antigen–mismatched after busulfan and cyclophosphamide conditioning (16)] (Fig. 2C). The expansion of enterococci in murine allo- HCT recipients with GVHD was accompanied by an increase in Enterococcus colony–forming units recovered from mesenteric",2,GvHD-paper.pdf,563,True
a70530c67f9017ad9e3c21664b10aa87,"lymph nodes, consistent with increased bacterial translo- cation (Fig. 2B).",2,GvHD-paper.pdf,564,False
aee0e1b81e7d3b79483c65310b022827,"Although we observed E. faecium domina- tion in patients and a transient expansion of E. faecalis in GVHD mice, we hypothesized that both members of this genus might be associated with GVHD. Of note, E. faecium",2,GvHD-paper.pdf,565,True
89027271151d4580fc1e3ab5a68f82c5,"only recently became recognized as a major human pathogen; before the 1990s it was E. faecalis that caused >90% of clinical in- fections (17). Because E. faecalis expands in mice with GVHD and is the major Enterococcus species in laboratory mice, we next investigated whether E. faecalis contributes to GVHD. We colonized germ-free C57BL/6 mice with a com- munity of six bacterial strains (Akkermansia muciniphila, Lactobacillus johnsonii, Blautia producta, Bacteroides sartorii, Clostridium bolteae,",2,GvHD-paper.pdf,566,True
0196242abc12beb7b4005908f58cc2d7,"and Parabacteroides diastonis; see materials and methods) (10, 18, 19) 21 days prior to allo-HCT (LP/J→gnotobiotic C57BL/6). One group of mice was cocolonized on day −21 with E. faecalis OG1RF, which remained detectable in mouse feces on days 0 and +7 (Fig. 2D, right panel, and fig. S4E). GVHD was exacerbated in E. faecalis–harboring mice",2,GvHD-paper.pdf,567,True
7e720d9cd1cdd9de337d2fede74d5355,A,2,GvHD-paper.pdf,568,False
f611ec9449d36eac76f849197793cf43,Incidence of domination,2,GvHD-paper.pdf,569,False
7662d7986d070968e094b451b5815018,"0.75 n f o o i e t a c 0.50 n n i e m d o i c d n i s u e c v c i t o a 0.25 c l o u m r e t u n c E 0 20 0 -20 day relative to HCT

Prevalence of domination MSKCC 0.6 Duke s e Hokkaido l p Regensburg m a s d 0.4 e t f o a n n i m o i t o c d a r s 0.2 f u c c o c o r e t n E 0 -20 20 0 day relative to HCT",2,GvHD-paper.pdf,570,False
840f24b6c5851f9c7d2e4caff4882a83,"«

=

«",2,GvHD-paper.pdf,571,False
c12163a6c434cb30622db48554235e05,B,2,GvHD-paper.pdf,572,False
2e02651b2bf34489c2fbb4d5d62e9e86,E. faecium other E. spp. 1.00 E. faecium 0.60 E. cecorum M S E. durans 0.30 K C E. mundtii C 0.10 e c E. rivorum n a d E. moraviensis 0.01 n u E. gallinarum b a v 1.00 a E. lactis e l v i i d t E. malodoratus a a 0.60 l t e i r o E. ureasiticus n 0.30 c E. faecalis o h o 0.10 r t 0.01 20 60 80 −20 0 60 40 20 40 0 −20 80 day relative to HCT,2,GvHD-paper.pdf,573,True
771d951b168958fce453b78d5759e6af,"®

®

®",2,GvHD-paper.pdf,574,False
9318c4f48cac82762cc552b298742c10,%,2,GvHD-paper.pdf,575,False
47eba74ad1a65abd402727a9e8d23f61,"Fig. 1. Enterococcus domination occurs globally and increases risk of GVHD and mortality after allo-HCT. Fecal microbiota were profiled using 16S rRNA gene sequencing of 1325 adult allo-HCT recipients. The patients attended one of four HCT centers in different countries: MSKCC (United States), Duke University (United States), Hokkaido University (Japan), and University Hospital Regensburg (Germany). (A) (Left) Cumulative incidence of patients who experienced at least one instance of genus",2,GvHD-paper.pdf,576,False
d570fef3b0c8b7a841f6aa39ed31f5a9,Enterococcus domination of the gut microbiota [domination defined as a genus relative abundance of ≥0.3 (on a unitless scale from 0 to 1) over the course of allo-HCT (day −20 to +24 relative to HCT; using 7-day sliding windows) at different transplant centers]. (Right) Fraction of fecal specimens with enterococcal domination of the gut microbiota. (B) Relative abundance of different Enterococcus spp. in the microbiota of allo-HCT patients from the MSKCC and multicenter-validation cohort over the,2,GvHD-paper.pdf,577,True
669f418279ec6c04ef4e954c90d01136,"course of HCT, determined by 16S rRNA gene sequencing of fecal samples. Each",2,GvHD-paper.pdf,578,False
f2110261ad3895a598ff0fea631fe0e8,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019

29 November 2019",2,GvHD-paper.pdf,579,False
1f850bdbbceffe30694af9d537ca7965,spp.,2,GvHD-paper.pdf,580,False
8a3cdbeeeaf7707926528f0b90493512,"C

D",2,GvHD-paper.pdf,581,False
9e19d279e6827f592f18b6b5d4434fdd,"Overall survival 1.0 0.8 g n i v i v 0.6 r u s n o i t 0.4 r o p o Enterococcus ≥ 0.3 (n=149) r p < 0.3 (n=389) Enterococcus 0.2 HR, 1.97; p < 0.001 0 15 10 5 0 20 months after HCT

1.0 0.8 g n i v i 0.6 v r u s n o i 0.4 t r o p Enterococcus ≥ 0.3 (n=54) o r p Enterococcus < 0.3 (n=113) 0.2 HR, 1.95; p = 0.03 0 0 5 15 20 10 months after HCT",2,GvHD-paper.pdf,582,False
b6694168b8e0a0d433134651d8af0e54,GVHD-related mortality,2,GvHD-paper.pdf,583,False
c6a7ce5b5e771466d28650523b34315a,Enterococcus ≥ 0.3 (n=148),2,GvHD-paper.pdf,584,False
644e1dd36c2c23c371aa6d875eacd52e,—,2,GvHD-paper.pdf,585,False
188d429f62d558277df0959b0ed2d50f,Enterococcus < 0.3 (n=389),2,GvHD-paper.pdf,586,False
caeee2db1da23fbb7b8fdf3b449c838e,---,2,GvHD-paper.pdf,587,False
9f7a5883365a80434689195880507b58,"0.2

HR, 2.04; p = 0.01",2,GvHD-paper.pdf,588,False
e7ddd9965a66baf74cc3fcf7130e431b,"e c n e d i c n i e v i t a l u m u c

4",2,GvHD-paper.pdf,589,False
2bf747180263d2bf8df2f86bad8ec7a7,"0.15

0.1",2,GvHD-paper.pdf,590,False
7ce294b47f48f9e343236968db89270a,4,2,GvHD-paper.pdf,591,False
fdb6520fb39ef05445edc2f667ef806f,"0.05

0",2,GvHD-paper.pdf,592,False
f669bbd52ede6757c0206e4031759f87,o1,2,GvHD-paper.pdf,593,False
2284770f81988712a8dc1372a9ec2246,"10

5

15

20",2,GvHD-paper.pdf,594,False
5949162eb34b6aa3376934230477c478,months after HCT,2,GvHD-paper.pdf,595,False
828e3d7554e59588cca8ddf4d1db363a,"GVHD-related mortality Enterococcus ≥ 0.3 (n=53) < 0.3 (n=111) Enterococcus 0.2 HR, 5.8; p = 0.002 e c n e 0.15 d i c n i e 0.1 v i t a l u m 0.05 u c 0 20 5 15 10 0",2,GvHD-paper.pdf,596,False
9699d347d90b3ff6d6ed7bf145b4b245,"point represents a fecal sample, and color indicates the different Enterococcus spp.; the red dotted line indicates the threshold for domination set at a relative abundance ≥0.3. (C) Overall survival (left) and cumulative incidence of GVHD- related mortality (right) in the T cell replete graft recipients in the MSKCC patient cohort (see table S3), stratified into nondominated and Enterococcus- dominated groups (domination is defined as the relative genus abundance ≥0.3 in at least one sample",2,GvHD-paper.pdf,597,True
10ac17b617ed6906ffae7f3f788f203e,"between day 0 and +21). n, number of individuals. (D) Overall survival (left) and cumulative incidence of GVHD-related mortality (right) in Enterococcus-dominated (at genus level) versus nondominated allo-HCT patients in the combined multicenter-validation cohort (table S3). Clinical outcomes in (C) and (D) were analyzed using the R packages survival and cmprsk. Wald values of P <0.05 signify higher risks (HR, hazard ratios) of mortality among patients with Enterococcus domination as compared",2,GvHD-paper.pdf,598,False
ba25ff6c46b5bba6c5e2795bfcda92d4,with those without domination.,2,GvHD-paper.pdf,599,False
f73b871ed5f104c18f8b1bc12bee8eaf,2 of 7,2,GvHD-paper.pdf,600,False
101071406f97f6417944961f850945d5,D,2,GvHD-paper.pdf,601,False
4269271d1a465a36ede8905f3f219876,o,2,GvHD-paper.pdf,602,False
4b0c1520e75f2344e78e0ebc6bae2704,"n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",2,GvHD-paper.pdf,603,False
9cbea3c6c29a18e938744d190bda5b26,RES EARCH | R E P O R T,3,GvHD-paper.pdf,604,False
bc3eb75a3b4aaa789f00ed47f8e2a3c1,A,3,GvHD-paper.pdf,605,False
89c55bab1365ea269e589eee2ddbdcf0,C57BL/6 = 12951/Sv Survival Enterococcus Akkermansia 100 0.5 M Bacteroides M Blautia x50 rel. abundance 0 Pl i Clostridium 0 10 20 30 0 10 20 30 0O 10 20 30 0 10 20 30 0 10 20 30 [ Lactobacillus 1.0 Oscillospira A p=0013 W Roseburia 0 20 40 60 80 100 days after HCT 0.5 — BM (n=5) — BM+T (n=5) rel. abundance 0 0 10 20 30 10 20 30 O 10 20 30 0 10 20 30 0 10 days after HCT C57BL/6 — BALB/c 16S rRNA feces o before HCT Enterococcus feces Enterococcus mLN Survival e BM -~ 4x10* e BM 10°% e BM+T 8 ®,3,GvHD-paper.pdf,606,False
51c5aab43d05e63127bbe42b6cc4ad68,"BM+T 100 10"" ° 1 3x10* — BM (n=20) 102 107 2x10* — BM+T ® 50 102 10¢ g Enterococcus el.abundance 10+ A 19 o CFUs/g stool CFUs/mLN 1x10* 10° ° ) 10° o p<0.001 10 -1 4 7 10 10 7 10 0 5 10 15 20 days after HCT days after HCT days after HCT days after HCT c LP/J C57BL/6 16S rRNA feces Survival 14 days rel. to HCT o before bu/cy-cond 100 @ before HCT VVVYVYY v 1074 e BM ® BM+T — BM (n=9) AAA 1074 ¥ 50 g — BM+T (n=10) V busulfan g 'V cyclophosphamide Enterococcus rel. abundance 10° o 8 HCT p<0.01 10",3,GvHD-paper.pdf,607,True
f3a76bd4695117cb149ee21a0a841256,-7 -1 10 0 20 40 60 80 100 days after HCT days after HCT D LP/ - C57BL/6 Survival 16S rRNA feces -7 days rel. to HCT B 0 m -21 100 EF] (n=4) - day 0 day 7 v \AAAA v > o AAA BM [+ EF] (n=5) BM+T [- EF] (n=10) Se 'V colonization V busulfan 50 | BM+T [+ EF] (n=12) o e -1+ EF g WV cyclophosphamide WV HCT p<0.001 Enterococcus rel. abundance 0 0 20 40 60 80 HCT: - BM BM+T days after HCT,3,GvHD-paper.pdf,608,False
8ad0dc96c7ec8df463110cf7d83f9653,(n=32),3,GvHD-paper.pdf,609,False
381c9819218574db461b7056242abde4,"Fig. 2. Enterococcus dominates mouse gut microbiota after HCT and can exacerbate GVHD. (A) (Left) High-density sampling and 16S rRNA gene sequencing of fecal microbiota from 129S1/Sv mice (1 box = 1 mouse) receiving bone marrow (BM; upper row) or T cell–replete bone marrow [BM+T (2 × 106 T cells); lower row]. (Right) BM+T transplanted mice develop lethal GVHD as shown by survival analysis. rel., relative. (B) (Left) Relative abundance of the genus Enterococcus in BALB/c host mice transplanted",3,GvHD-paper.pdf,610,False
75c46e2a2d726c9af9fdafd73add297b,with C57BL/6 BM or BM+T (1 × 106 T cells) at different time points relative to HCT. (Middle) Colony-forming units (CFUs) of enterococci in fecal samples and in mesenteric lymph nodes (mLN). Scatter plot data show means ± SEM. (Right) Survival of BALB/c recipient mice after HCT [BM versus BM+T (1 × 106 T cells)]. (C) (Left) Schematic showing HCT of LP/J BM versus BM+T (4 × 106 T cells) into C57BL/6 mice after chemotherapy conditioning. (Middle) Relative abundance of the genus Enterococcus in the,3,GvHD-paper.pdf,611,False
bcca109caaf96cad56eaaaac7fb94925,feces of,3,GvHD-paper.pdf,612,False
aa574ba6864efdddc6fcac48649f613e,"transplanted mice at different time points relative to HCT. (Right) Comparison of overall survival between BM and BM+T mice. bu/cy-cond., busulfan/ cyclophosphamide conditioning. (D) (Left) Schematic showing colonization of germ-free C57BL/6 mice with a 6-strain minimal microbiota with (+EF) or without (-EF) E. faecalis OG1RF (2 × 107 CFUs per mouse); after 14 days, colonized mice received chemotherapy conditioning with busulfan and cyclophosphamide and, subsequently, an HCT of LP/J BM versus",3,GvHD-paper.pdf,613,False
e354dcc9d7acc85fe3682f03625fa994,"BM+T (4 × 106 T cells). (Middle) Comparison of overall survival. (Right) Relative abundances of E. faecalis spiked to the minimal microbiota in the EF+ group with samples collected at the day of HCT (day 0) and 7 days later (n = 4 to 11 mice per group; P = 0.09, paired testing of relative abundances of enterococci of day 0 versus BM+T day +7). Scatter plot data are presented as means ± SEM **P < 0.01, ***P < 0.001 (independent t test for BM versus BM+T); survival data were statistically analyzed",3,GvHD-paper.pdf,614,False
0f9556dd72bd9f83510d8771a5639c2b,using Mantel-Cox log-rank test.,3,GvHD-paper.pdf,615,False
f31404c860fb71941ecd4699114f6cba,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

29 November 2019",3,GvHD-paper.pdf,616,False
da8a97e4819b4e1abbe09ed96baa2a52,"3 of 7

o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",3,GvHD-paper.pdf,617,False
0265cd329e927e508b2fc02709affa74,RES EARCH | R E P O R T,4,GvHD-paper.pdf,618,False
6464d42cbded84d95353460653a01e18,"A allo HCTin AML patients == pre HCT/ non-dom. (i == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ Superpath. alanine biosyn. ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Calvin-Banson-Bassham cycld GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. Glycolysis IV P-diacylglycerol biosyn. | CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. N -2denosyl-L-methionine cycte | I",4,GvHD-paper.pdf,619,True
2ca4b4e6da6075fe38c0c8e3228ebcb5,Chorismate biosyn. 2ch degradataion V i hoshote | 3 E B 0 1 2 3 LDA score (log 10),4,GvHD-paper.pdf,620,False
31cddea802aa517fb42fe13a7a3f3d9b,"A allo HCTin AML patients pre HCT (diverse) == pre HCT/ non-dom. (i M Enterococcus == post HCT/ domin. { . . . Pyrimidine déoxyriboncl. salvage [ B Akkermansia Superpath. alanine biosyn. W Blautia ‘Guarlosine ribancl. denovo biosyn. Adenosine riboncl. denovo biosyn. [ W Clostridium Pyuvate feri. to acetate actate N Lactose and galctose degradation [N Dorea Calvin-Banson-Bassham cycld Eubacterium GDP-mannose biosyn. Superpath. Lysine, Lhreon, Lmeth. biosyn. ost HCT Glycolysis IV (E. F. domin.) I",4,GvHD-paper.pdf,621,True
8059ee5dd393fe36945a19e491ac9594,Lactobacillus P-diacylglycerol biosyn. | Faecalibacterium CDP-diacylglycerol biosyn. Il Superpath. aromatic AA biosyn. 1| Oscillospira N -2denosyl-L-methionine cycte | I Chorismate biosyn. Ruminococcus 2ch degradataion V i hoshote | [ Streptococcus 3 E B 0 1 2 3 W Veillonella LDA score (log 10) I Other,4,GvHD-paper.pdf,622,False
b7aa4d5eebc77e9b42e03d9e7b1cce0c,pre HCT (diverse) M Enterococcus B Akkermansia W Blautia W Clostridium Dorea Eubacterium Lmeth. biosyn. ost HCT (E. F. domin.) I Lactobacillus Faecalibacterium 1| Oscillospira | Ruminococcus | [ Streptococcus W Veillonella I Other,4,GvHD-paper.pdf,623,False
08e34909941fd39f8cd66b0b3125b8a7,B C57BL/6 — 12951/Sv,4,GvHD-paper.pdf,624,False
d380954f6cbddb4b0ed01875994c6e25,"M

B",4,GvHD-paper.pdf,625,False
f6522bb511f6a4e511334e575aa7e4db,"W

W",4,GvHD-paper.pdf,626,False
5b5ac51ebda17acc4a44aed8374f3af3,"I

1|",4,GvHD-paper.pdf,627,False
e178c0bfbb1cf01e5c5bf1d88dda2593,day 7 after HCT = BM (n=5) == BM+T (n=5) Lactose and galactose degradation — Thiamine formation from pyrithiamine Pyrimidin deoxyriboncl. salvage Lysine iosynthesis hamnose degradation | ! s-aminoiidazole ribdncl. biosyn supepath 5+ aminoimid. fiboncl.biosyn. Inogine- Inosine- phosph biosyn. | — Peptifloglycanbigsynthesis || hosph biosyn. I I scrine and ycne biosyn. | S-adenosyL-methionne cycle | -1 0 i 2 LDA score (log 10),4,GvHD-paper.pdf,628,False
71d32ec9bc9b10583d0ad558ab6278bc,"=

==

[",4,GvHD-paper.pdf,629,False
9bb0ade00488a9fd42667098449dfe48,W,4,GvHD-paper.pdf,630,False
737106136865f574ebf96e4c6f211d33,I,4,GvHD-paper.pdf,631,False
ac3c9ee44b3deaeb087c6f32e0cc4ac7,D,4,GvHD-paper.pdf,632,False
08904f8b0be8c01df88fa56ba02d3739,invitro Enterococcus growth,4,GvHD-paper.pdf,633,False
3c7f9970f5fcd292852b68baada1ca50,E. faecalis - ° & Incubation in 0D600 nm regular BHI 02462810 hours < Regular BHI -+ Lactase pretreatment,4,GvHD-paper.pdf,634,False
b84aeb7cac022466f433fb978bdf2aad,15 0.0 —— = 024681 hours,4,GvHD-paper.pdf,635,False
7654b27289fe4e1e15bda9b08e675333,"E. faecium - Regular BHI -+ Lactase pretreatment 15 - - ° 10 Incubation in 0D600 nm o 0D600 nm 05 regular BHI | [= 0.0 0246 810 024 8 10 hours hours

- Regular BHI -+ Lactase pretreatment 15 - 10 0D600 nm 05 0.0 024 8 10 hours

- ° Incubation in 0D600 nm o regular BHI | [= 0246 810 hours",4,GvHD-paper.pdf,636,False
851447f60b5755773ad526b4c7b664ba,F Clostridum vs. Enterococcus (genera) in allo-HCT patients Kendall tau =-0.21; p<0.001 1 3 o = 3 2 B o Clostridium 3 2 rel. abundance - 0 107 107 1 Enterococcus rel. abundance,4,GvHD-paper.pdf,637,True
3df53188854786cb5fad48654920483c,"Butyrate in C57BL/6 — BALB/c

cecal content . 100- * BM BM+T 50- B butyrate pm/mg",4,GvHD-paper.pdf,638,False
f033f8fe9746c75496976e1bbf1abb9d,"or in BHI broth pretreated with lactase. (Right) E. faecalis or E. faecium incubated in lactase-pretreated BHI were put into regular BHI broth after 8 hours to assess growth dynamics in regular BHI (gray symbols). Data are results of four experiments combined; values represent means ± SEM. (E) (Left) Fecal butyrate concentrations (means ± SEM) from pre- and posttransplant fecal samples from AML patients from MSKCC, who received allo-HCT and were selected based on a highly diverse pre-HCT",4,GvHD-paper.pdf,639,False
cd0db599eafc0f07ee61881be7c11af3,"microbiota and a posttransplant E. faecium domination [by 16S rRNA gene sequencing; 6 (out of 8) patients are presented in (A)]. (Right) Correlation of butyrate concentrations with relative abundances of the genus Enterococcus (n = 139 patients; 8 patients from left panel), and 131 allo-HCT patients from a dataset published by Haak et al. (28); statistical analysis was performed using Kendall’s tau rank correlation coefficient. (F) Stool samples were collected at the time of engraftment (~24",4,GvHD-paper.pdf,640,False
cc17c894eef552ae475edbff3d286a62,days after allo-HCT). Data show Kendall’s tau rank correlation of relative abundances of the genera Clostridium and Enterococcus from the dataset of Haak et al. (G) Butyrate concentration (mean ± SEM) in cecal contents of BALB/c mice transplanted with C57BL/6 BM or BM+T (1 × 106 T cells) at day +7 after HCT. Statistical analysis: *P < 0.05 [paired t test (E) or independent t test (F)].,4,GvHD-paper.pdf,641,False
7116f204bf4de77f75b214d0c26f826f,4 of 7,4,GvHD-paper.pdf,642,False
fa8d86e3ebcb9d88d4f620fb3b77c718,"==

==",4,GvHD-paper.pdf,643,False
2e942ac9918d59671f6e34957851bade,C,4,GvHD-paper.pdf,644,False
d4babf903a390e3ec4ecfc4095195909,"Metagenomic metabolic pathways Enterococcus isolates

Amino sugar and nucleotide Pyrimidine metabolism sugar metabolism Purine metabolism Lactose and ‘metabolism alactose AminoacytRNA meta Glycolysis/ gluconeogenesis Pyruvate metabolism Arginine proline metab. Methane metabolism Cysteine methionine metab. Glycine serine threonine metab. Other pathways Oxidative phosphorilation E. faecalis (BALB/c mice, GVHD) Pentose phosphate pathway Fructose mannose metabolism",4,GvHD-paper.pdf,645,False
8b27ed067d7311d05479c96733fbfee1,E. faecium (human isolate),4,GvHD-paper.pdf,646,False
f42452bc77880df1abd9db2a1d69d953,Amino sugar and nucleotide sugar metabolism Pyrimidine metabolism Glycolysis/ Purine metabolism gluconeogenesis Sucrose metabolism Methane metabolism Fructose mannose metabolism l Pentose pathway Pyruvate metabolism AminoacyHRNA metab. Other pathways Pentose glucuronate interconversions Glycine serine threonine metabolism,4,GvHD-paper.pdf,647,False
64bac0311ed85a3d6add58446c81e362,E Butyrate in allo-HCT patients,4,GvHD-paper.pdf,648,False
e5a69dbd3810b89dfb77dbbd0a262bb5,feces 15 —_— © preHCT postHCT 10 butyrate mM,4,GvHD-paper.pdf,649,False
c67041e3bab0318d51fe098303530d13,©,4,GvHD-paper.pdf,650,False
2498ac75135d91cdb2352300d0b9073f,Kendall tau =-0.15; p = 0.008 20 0o butyrate mM oo 3 - orts o 0 107 10 _I- Enterococcus rel. abundance,4,GvHD-paper.pdf,651,True
0a0ff0d0e84af95d79bc7242c1dce9c3,"Fig. 3. Metagenomic and metabolomic analyses of Enterococcus-dominated fecal specimens in human HCT patients and mice. (A) (Left) Differential abundances of shotgun-sequenced and HUMAnN2-annotated bacterial metabolic pathways between paired pre- and post-HCT fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia (AML) analyzed by linear discriminant analysis (LDA) coupled with effect size measurements (LEfSe). pre HCT, day −8 to −1 before allo-HCT; post HCT, day +3 to",4,GvHD-paper.pdf,652,False
e7ff5cec6b91c12c303d21db094b002b,"+25 after allo-HCT. (Right) Pie chart showing mean relative abundances of bacterial genera (analyzed by MetaPhlAn2) found in patient fecal samples pre- and post-HCT; data are aggregated across all patients. non-dom., nondominated; domin., dominated. (B) LEfSe analysis of bacterial metabolic pathway abundances in HCT day +7 fecal samples of 129S1/SV mice transplanted with C57BL/6 BM versus BM+T (2 × 106 T cells) (see Fig. 2A). (C) Pie charts with metabolic pathway abundances determined by",4,GvHD-paper.pdf,653,False
3a37b7dd7b78501e39fe8ad058c1dc5a,"whole-genome sequencing of E. faecalis (isolated from feces of a BALB/c GVHD mouse, day +7 after HCT; upper panel) and E. faecium (human isolate; ATCC #700221; lower panel); only pathways with an abundance ≥2% are shown in both panels. (D) (Left) In vitro growth of E. faecalis (mouse GVHD isolate; upper panel) and E. faecium (ATCC #700221; lower panel) in nontreated BHI broth",4,GvHD-paper.pdf,654,False
892262af77036211776a4afcd2c3a3a2,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

29 November 2019",4,GvHD-paper.pdf,655,False
e1bcf685f93c39db31e3f369be79bd25,"D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",4,GvHD-paper.pdf,656,False
b1809ff96ac474bf7e4dcc6c03ede0cc,RES EARCH | R E P O R T,5,GvHD-paper.pdf,657,False
cffa761b3293f1bad8dc1fd8805a8bb6,"vated and proliferating CD4+ T cells (fig. S4D; CD4+CD25+; CD4+Ki67+), and an increased number and percentage of CD4+RORg+ T helper 17 (TH17) cells in colon lamina propria (fig. S4D). Posttransplant administration of E. faecalis",5,GvHD-paper.pdf,658,True
800978a75dc4064315cc89df1820b2ab,Survival 100 += ' - BM [ctr] (n=10) ' - BM [LF] (n=10) — BM+T [ctr] (n=20) 50 — BM+T [LF] (n=20) survival [%] p<0.05 %020 40 60 80 100 days after HCT,5,GvHD-paper.pdf,659,False
e3893d2315b78cc679d42a41d25739f7,"' -

' -

—",5,GvHD-paper.pdf,660,False
30b8556340e413cdacd92bde63e02948,Survival 100 BM [ctr] (n=8) BM [LF] (n=10) BM+T [ctr] (n=19) 50 BM+T [LF] (n=13) survival [%] p<0.01 0 20 40 60 80 100 days after HCT,5,GvHD-paper.pdf,661,False
5930457a87d4904bdfc3b4f0d64f227a,day-7to 0 1.0 0.5 Enterococcus rel. abundance day 25 1.0 N 05 Enterococcus rel. abundance TT+ / T/C,5,GvHD-paper.pdf,662,False
6c18a965da23926ebf5cb44ff4b5e423,T/C,5,GvHD-paper.pdf,663,False
dcee265dde1662d9b5135c2a51aa3aa4,"OG1RF to conventionally housed, T cell–replete bone marrow (BM+T)–transplanted BALB/c mice also aggravated GVHD (fig. S5A). These findings indicate that E. faecalis can aggravate GVHD severity.",5,GvHD-paper.pdf,664,True
44a50777888f491ce95b360b3871c681,"16S rRNA feces

16S rRNA feces o BM [ctr] © BMI[LF] ¥ 107 © BM+T [ctr] © BM+T[LF] 102 Enterococcus rel. abundance 10° days r HCT",5,GvHD-paper.pdf,665,False
501bedc5154e146ecba8da94eb442ba6,o,5,GvHD-paper.pdf,666,False
9ee37b786701642ccd238ffd14bf3ce0,"©

©

©",5,GvHD-paper.pdf,667,False
9853613213f9c9ceafe2b4ff001198d5,"165 rRNA feces 107! o BM [ctr] o BM[LF] 102 © BM+T [ctr] 10, . © BM+T [LF] Enterococcus 10 2, .1 rel. abundance 10 14 days after HCT",5,GvHD-paper.pdf,668,False
5088c76be19dbad3bec3ebc842538154,"o

o",5,GvHD-paper.pdf,669,False
f8c7312886c2decb3cc33a74f13c8574,"Acute GVHD (grade 2-4) 06 — — T/T+T 04 0.2 cumulative incidence HR, 1.08; p=0.62 20 40 60 80 100 days after HCT",5,GvHD-paper.pdf,670,False
fbc2cf194eb750e2130cb674e5bf2141,—,5,GvHD-paper.pdf,671,False
ad6d880433115eb1b7fde6a73abfcf22,"SEM; *P < 0.05 (independent t test). (C) (Left) Relative abundance (log10) of Enterococcus (genus) by days relative to the day of antibiotic cessation (broad- spectrum antibiotics for neutropenic fever: intravenous piperacillin-tazobactam, intravenous imipenem-cilastatin, or intravenous meropenem). Box plot inserts display the median relative abundances of the genus Enterococcus of time binned in the indicated day ranges relative to antibiotic cessation; whiskers represent maximum and minimum.",5,GvHD-paper.pdf,672,False
0e59ef689baac0d6e83daed3d3dc10b2,"Statistical analysis of box plot data: *P < 0.05 (Wilcoxon rank test). (D) Cumulative incidence of acute GVHD grade 2 to 4 in rs4988235 SNP-genotyped MSKCC patients (T cell–depleted grafts excluded; graft source: BM/PBSC unmodified = 213 patients; cord blood = 102 patients; C/C = 175, T/C+T/T = 140). The cumulative incidence of grade 2 to 4 acute GVHD was compared between genotype groups using the R package cmprsk.",5,GvHD-paper.pdf,673,True
339a4b3c9b60bd865932458df8bfbf6d,5 of 7,5,GvHD-paper.pdf,674,False
04bb720ca1a632416a49b40bcc919b42,"(Fig. 2D and fig. S4B). Serum interferon-g con- centrations were significantly elevated in E. faecalis–colonized mice (fig. S4C), and we observed a significantly increased num- ber of donor T cells, an increase of acti-",5,GvHD-paper.pdf,675,False
8f85b4202fdbe2d88ef1f91bcfdc91aa,A,5,GvHD-paper.pdf,676,False
d6ef5338cf897ab2a0626724b531c2f3,C57BL/6 — BALB/c days rel. to HCT -7 0 14 v W HCT ctr vs. LF chow,5,GvHD-paper.pdf,677,False
b32f0d0436dfc5f18c7aa6c1d659d30b,W,5,GvHD-paper.pdf,678,False
bef59d3d2616e16e3dc49c915668985a,B LP/J = C57BL/6,5,GvHD-paper.pdf,679,False
5fda4236bb5f93d1bf4a036e38159bf9,days rel. to HCT -7 -3 14 YVVYV V AAA W busulfan W HT W cyclophosphamide ctrvs. LF chow,5,GvHD-paper.pdf,680,False
9a42fdfe6f58042b867c231189558435,"W

W",5,GvHD-paper.pdf,681,False
86cecbe80d68e11b01c260c53ec29e05,"C Allo HCT patients: Enterococcus abundance by lactase genotype

0 o { - 153 -1 ’ -2 Enterococcus log10 rel. abundance -4 -20 -10 0 10 20 days relative to antibiotic termination T/T+T/C ~ C/C lactose absorber non-absorber

day-7to 0 1.0 0.5 Enterococcus rel. abundance day 25 1.0 N 05 Enterococcus rel. abundance TT+ / T/C",5,GvHD-paper.pdf,682,False
49eae528833a329259a3a015b2ae1380,~,5,GvHD-paper.pdf,683,False
39fe7053aa26c34f2a9149f4bbb04748,Fig. 4. Lactose-free diet reduces experimental GVHD and lactase genotypes associated with microbiota dynamics after allo-HCT in humans. (A) (Left) Schematic showing that BALB/c recipient mice received C57BL/6 BM or BM+T (5 × 105 T cells) and were fed control chow (ctr) versus lactose-free chow (LF) from day −7 to +14 relative to transplant. Comparison of survival between BM and BM+T mice (middle) and relative abundance of the genus Enterococcus in mouse feces (right) are shown. Scatter plot data,5,GvHD-paper.pdf,684,False
b82aa2a05ff20906c201f935bbbcddc5,presented as means ± SEM; *P < 0.05 (independent t test). (B) (Left) Schematic showing HCT of LP/J BM versus BM+T (4 × 106 T cells) into C57BL/6 mice after chemotherapy conditioning. Comparison of survival between BM and BM+T mice (middle) and relative abundance of the genus Enterococcus at different time points relative to HCT (right) are shown. Scatter plot data presented as means ±,5,GvHD-paper.pdf,685,False
962cffefddce35078e33625401e464ce,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)

Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",5,GvHD-paper.pdf,686,False
f8037f069cd3f1e745427a6c11106b29,"o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",5,GvHD-paper.pdf,687,False
e4a432928794f03e7ed4f8ce295caf8c,RES EARCH | R E P O R T,6,GvHD-paper.pdf,688,False
5a6c1e16a3e36906a3e2d3a8a327fc54,"We next considered whether posttransplant defects of mucosal defense mechanisms facil- itate enterococcal expansion. Immunoglobulin A (IgA) coating of intestinal bacteria can be protective in colitis and is important for maintaining mucosal integrity (20). How- ever, we did not observe members of the genus Enterococcus to be enriched in either IgA- negative or IgA-positive fecal fractions, even though total fecal IgA was significantly re- duced in allo-HCT recipients with GVHD (fig. S5, B to D).",6,GvHD-paper.pdf,689,True
d2fd496bdfe0b7e7b6ce33f463067ead,"Reduction of IgA by transplant- ing IgA-deficient bone marrow (BM) from activation-induced cytidine deaminase knock- out mice did not further increase enterococcal expansion (fig. S5E). Intestinal antimicrobial peptides of the Reg3 family can suppress the growth of VRE (21) and are reported to play a major role in GVHD (22). Accordingly, we found that both Reg3B/G transcripts and interleukin-22 protein, which regulates Reg3 expression (23), were reduced in the ileum of GVHD mice (fig. S5F).",6,GvHD-paper.pdf,690,True
f437430e0d1cd83772d368fde5605c8c,"Next, we analyzed microbiota-intrinsic fac- tors and used shotgun metagenomic sequenc- ing to characterize the metabolic potential of the Enterococcus-dominated fecal microbiota. Pre- and posttransplant fecal samples from MSKCC patients who received allo-HCT for acute myeloid leukemia were selected for sequencing on the basis of having a highly diverse pre-HCT microbiota and posttrans- plant E. faecium domination (by 16S rRNA gene sequencing). We focused on microbial metabolic pathways that",6,GvHD-paper.pdf,691,True
954c9a9e57f11308dd3b33e7774937ff,"specifically charac- terize domination by comparing them with the highly diverse pretransplant microbiota from the same patients. Pathways involved in DNA synthesis and, notably, in lactose and galactose degradation were enriched in the E. faecium–dominated, posttransplant micro- biota. In contrast, amino acid synthesis and starch-degradation pathways were more prev- alent in pretransplant specimens (Fig. 3A). The lactose-and-galactose degradation path- way was also significantly enriched in the",6,GvHD-paper.pdf,692,True
1763b36f0e868d4f3f751a78c1fadc47,posttransplant E. faecalis–dominated samples of mice with GVHD (Fig. 3B). Comparison of whole-genome sequencing from isolates of E. faecium (from a human allo-HCT patient) and of E. faecalis (from a mouse with GVHD) revealed that genes encoding lactose and galactose metabolism accounted for ~3% of their genomes (Fig. 3C). In silico analysis of these Enterococcus genomes and publicly available genomes of other members of the gnotobiotic six-strain consortium revealed that enterococci are,6,GvHD-paper.pdf,693,True
5fb0585b5d598332dbfa0df06c2d09af,"specifically enriched in enzymes of the tagatose-type galactose path- way for galactose-to-glucose degradation (24) (materials and methods and fig. S6, A and B). Enterococcal growth depends on lactose in vitro, as both E. faecalis and E. faecium strains cultured in brain-heart",6,GvHD-paper.pdf,694,True
7aec7f7e9a931198bd599848cf29dcfd,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019)",6,GvHD-paper.pdf,695,False
f40eea9163a0eafca1c765d2532619da,"infusion (BHI) broth depleted of lactose (by lactase; fig. S7A) did not grow (Fig. 3D). Growth was reinstated upon transfer to re- gular BHI, excluding antibacterial effects of lactase treatment (Fig. 3D). Enterococcal expansion after allo-HCT was accompanied by a loss of Clostridium spp. in the microbiota of allo-HCT patients (Fig. 3, A and F) and of mice with GVHD (fig. S8, A to C, and table S7). This may be important for allo-HCT patients, as high abundances of clostridia are associated with",6,GvHD-paper.pdf,696,True
83a84cf1c218335bbe5608707fd742dd,"better survival and low- er incidence of GVHD (12, 25). Commen- sal clostridia are known to produce large amounts of butyrate (26), which mitigates lethal GVHD in mice through protecting energy homeostasis of enterocytes (27). We observed that posttransplant enterococcal domination and a loss of clostridia were accompanied by a significant reduction in fecal butyrate in both allo-HCT patients and mice with GVHD (Fig. 3, E and G) (28). A loss of this key metabolite may contribute to the poor",6,GvHD-paper.pdf,697,True
206481ba15f1340438c11ac77753ac7f,outcomes in Enterococcus-dominated patients and mice.,6,GvHD-paper.pdf,698,False
b588c6e7e34cada90b753ddcecf6c937,"Given that the optimal growth of enterococci depends on lactose availability in vitro, we investigated whether enterococcal expansion can be mitigated by feeding mice lactose-free chow (fig. S7B and table S8). In the C57BL/ 6→BALB/c model, the absence of dietary lactose significantly reduced posttransplant Enterococcus bloom and mitigated GVHD (Fig. 4A and fig. S9B). Flow cytometric anal- ysis of donor T cells on day +14 revealed a reduction in the percentage of activated and proliferating CD4+",6,GvHD-paper.pdf,699,True
bbddbe11309e15be8746bc6e6d43c2f6,"T cells (CD4+CD69+; CD4+ Ki67+) as well as a reduction in the percent- age of CD4+Tbet+ (TH1) T cells (fig. S9). The effect of a lactose-free diet on enterococcal outgrowth and GVHD was replicated in the LP/J→C57BL/6 mouse model (Fig. 4B and table S9 for changes in non-enterococcal taxa). Intestinal mucosal damage by irradiation or allo-reactive T cells may affect the expres- sion of lactase, the enzyme found on small- intestine enterocytes that facilitates lactose absorption through",6,GvHD-paper.pdf,700,True
82449275e21b83a2772d56d81a11e386,"disaccharide cleavage. Duodenal lactase transcript abundance pro- gressively declined in BM+T recipients over the course of transplantation (fig. S9C), which may induce a lactose-intolerant–like state in mice, allowing nondigested lactose to reach the lower intestinal tract and serve as a car-",6,GvHD-paper.pdf,701,False
9580a38a6bd2010ce8455948bca92bea,"Next, we explored whether enterococci ex- pansion is associated with lactose tolerance in human allo-HCT patients by genotyping 602 patients from the MSKCC cohort with available pretransplant germline DNA sam- ples for the gene polymorphism rs4988235 (-13910*T). This single-nucleotide polymorphism (SNP) regulates lactase expression and pre- dicts lactose absorption and/or tolerance (C/T",6,GvHD-paper.pdf,702,True
5fa9f328d5e590d4b64f2731096f135e,29 November 2019,6,GvHD-paper.pdf,703,False
e5a71d616a1f5fa0cabb719adc207bb7,"or T/T alleles) and malabsorption (C/C alleles) in the upper gut (29). Although abundance of the genus Enterococcus increased comparably during exposure to broad-spectrum antibiotics in both lactose absorbers and malabsorbers, enterococcal domination was significantly prolonged in malabsorbers after cessation of antibiotics (Fig. 4D and fig. S10). This finding suggests that the maintenance of enterococ- cal domination and microbiota recovery after broad-spectrum antibiotic exposure is signif-",6,GvHD-paper.pdf,704,True
78830cec35677b5a6e4f50c5689ab0b4,icantly modulated by the luminal availability of lactose as a growth substrate.,6,GvHD-paper.pdf,705,False
b6a05d64d49450dd0c8ef03617fcb46d,"significant risk factor for the development of acute GVHD and for increased overall and GVHD-related mortality after allo-HCT. Our findings extend previous reports from smaller single-center analyses that posttransplant VRE bacteremia and fecal domination are associated with worse outcomes after allo-HCT (7, 8, 30). In gnotobiotic mouse models, enterococci exacerbate GVHD, consistent with previous reports of aggravated colitis in models of in- flammatory bowel disease (14) or systemic autoimmune",6,GvHD-paper.pdf,706,True
1c6bb1dfa8db30e79c638bec74376d1f,"responses (31). We previously identified Blautia abundance (a genus within class Clostridia) as a predictor of protection from lethal GVHD (12), whereas here we describe Enterococcus domination as a risk factor for GVHD. These two findings are noteworthy in light of our recent observa- tion that a B. producta strain can inhibit VRE growth via the production of a lantibiotic pro- tein (32). We identified a microbiota-intrinsic mechanism that is dependent on lactose uti- lization and favors the",6,GvHD-paper.pdf,707,True
cc33c91f1130a936ee46c6ae310e78a0,"expansion of enterococci. This process may be triggered through a loss of lactase produced by enterocytes damaged by conditioning or allo-reactive T cells. We validated this concept experimentally, by showing that depletion of lactose in vitro and in vivo inhibited enterococcal expan- sion and mitigated GVHD, and clinically, by showing that patients harboring a lactose- malabsorption allele experienced prolonged Enterococcus domination after antibiotic ex- posure. These observations in mice and",6,GvHD-paper.pdf,708,True
a3d4043417ac85988207774dac189cfc,"allo- HCT patients provide proof-of-concept for a novel, non–antibiotic-based therapeutic strategy, such as a lactose-free diet, to attenu- ate the outgrowth of pathobionts like enter- ococci and possibly improve clinical outcomes by modulating dietary sources of nutrients for",6,GvHD-paper.pdf,709,False
00a5825f57a05875cd0f7fc479113fab,REFERENCES AND NOTES,6,GvHD-paper.pdf,710,False
f39c62fdd3cd29e70f2d954d50009f4e,"1. Y. Litvak, M. X. Byndloss, A. J. Bäumler, Science 362, eaat9076 (2018).

2. M. S. Gilmore, F. Lebreton, W. van Schaik, Curr. Opin. Microbiol. 16, 10–16 (2013).

3. S. Schloissnig et al., Nature 493, 45–50 (2013).

4. F. Lebreton et al., Cell 169, 849–861.e13 (2017).

5. Y. Taur et al., Clin. Infect. Dis. 55, 905–914 (2012).

6. C. Ubeda et al., J. Clin. Invest. 120, 4332–4341 (2010).

7. E. Holler et al., Biol. Blood Marrow Transplant. 20, 640–645 (2014).",6,GvHD-paper.pdf,711,False
dd59080d8c938b601f17cba8b0974672,"6 of 7

o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",6,GvHD-paper.pdf,712,False
9d221ded558814e6317b4ba124b936b8,RES EARCH | R E P O R T,7,GvHD-paper.pdf,713,False
ecabee0112eaf7379ad6bd8a3d9b563b,"8. C. D. Ford et al., Biol. Blood Marrow Transplant. 23, 340–346 (2017).

9. H. J. Khoury et al., Haematologica 102 , 958–966 (2017).

10. Y. Shono et al., Sci. Transl. Med. 8, 339ra71 (2016).

11. Y. Taur et al., Blood 124, 1174–1182 (2014).

12. R. R. Jenq et al., Biol. Blood Marrow Transplant. 21, 1373–1383 (2015).

13. Y. Taur et al., Sci. Transl. Med. 10, eaap9489 (2018).

14. N. Steck et al., Gastroenterology 141, 959–971 (2011).

15. N. Geva-Zatorsky et al., Cell 168, 928–943.e11 (2017).",7,GvHD-paper.pdf,714,False
f98e448083fb8b012f78d194832d0af0,"16. K. Riesner, M. Kalupa, Y. Shi, S. Elezkurtaj, O. Penack, Bone Marrow Transplant. 51, 410–417 (2016).",7,GvHD-paper.pdf,715,False
2b1cefcfe11890ef7a98cb3eb3350980,"17. K. Dubin, E. G. Pamer, Microbiol. Spectr. doi:10.1128/ microbiolspec.BAD-0014-2016 (2014).

18. R. R. Jenq et al., J. Exp. Med. 209, 903–911 (2012).

19. S. Caballero et al., Cell Host Microbe 21, 592–602.e4 (2017).

20. N. W. Palm et al., Cell 158, 1000–1010 (2014).

21. K. Brandl et al., Nature 455, 804–807 (2008).

22. D. Zhao et al., J. Clin. Invest. 128, 4970–4979 (2018).

23. C. A. Lindemans et al., Nature 528, 560–564 (2015).",7,GvHD-paper.pdf,716,False
844f03a80df8824203382ac8a66b42ac,"24. K. H. Schleifer, A. Hartinger, F. Götz, FEMS Microbiol. Lett. 3, 9–11 (1978)

25. D. Weber et al., Biol. Blood Marrow Transplant. 23, 845–852 (2017).

26. P. A. Gill, M. C. van Zelm, J. G. Muir, P. R. Gibson, Aliment. Pharmacol. Ther. 48 , 15–34 (2018).

27. N. D. Mathewson et al., Nat. Immunol. 17, 505–513 (2016).

28. B. W. Haak et al., Blood 131, 2978–2986 (2018).",7,GvHD-paper.pdf,717,False
f6b98e530bc67dd68f8f5687a97a2932,"29. C. J. Ingram, C. A. Mulcare, Y. Itan, M. G. Thomas,",7,GvHD-paper.pdf,718,False
60b5e08e880db750dfac334ad240cf18,"D. M. Swallow, Hum. Genet. 124, 579–591 (2009).

30. J. Vydra et al., Clin. Infect. Dis. 55, 764–770 (2012).

31. S. Manfredo Vieira et al., Science 359, 1156–1161 (2018).

32. S. G. Kim et al., Nature 572, 665–669 (2019).",7,GvHD-paper.pdf,719,False
4a4fe6d4742a212bd8f1911839a25611,ACKN OW LEDG MEN TS,7,GvHD-paper.pdf,720,False
cd1abda4119c77820e44c5f6043b14ef,"We thank G. M. Dunny and J. Willett (Department of Microbiology, University of Minnesota) as well as R. Zbasnik and V. Schlegel (Department of Food Science, University of Nebraska) for helpful discussion and for providing materials for revision of the manuscript. Funding: This work was supported by a German Research Foundation (DFG) scholarship to",7,GvHD-paper.pdf,721,False
cc03def43a24e60552a9b5ad0569d094,"Bone Marrow Transplantation to C.K.S.-T.; partially supported by the DFG research consortium TR221 “GvH/GvL” (project B13) to E.H.; by NCI awards R01-CA228358 (M.R.M.v.d.B.), R01-CA228308 (M.R.M.v.d.B.), MSKCC Cancer Center Core Grant P30 CA008748, and Project 4 of P01-CA023766 (M.R.M.v.d.B.); NHLBI award R01-HL125571 (M.R.M.v.d.B.), R01-HL123340 (M.R.M.v.d.B.), and K08-HL143189 (J.U.P.); NIA National Institute of Aging award Project 2 of P01-AG052359 (M.R.M.v.d.B.); NIAID award U01 AI124275",7,GvHD-paper.pdf,722,False
5f489ce125e5317c2d466c67c9bcff5e,(M.R.M.v.d.B.); R01 AI032135 (E.G.P.); AI095706 (E.G.P.); U01 AI124275 (E.G.P. and J.B.X.); Tri-Institutional Stem Cell Initiative award 2016-013 (M.R.M.v.d.B.); the Lymphoma Foundation (M.R.M.v.d.B. and N.K.); the Susan and Peter Solomon Divisional Genomics Program (M.R.M.v.d.B.); the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center (M.R.M.v.d.B. and J.U.P.); the Sawiris Foundation (J.U.P.); the Society of Memorial Sloan Kettering Cancer Center (J.U.P.); MSKCC,7,GvHD-paper.pdf,723,False
334d94a329fb129325afc5bc3478c8b2,"Cancer Systems Immunology Pilot Grant (J.U.P.); Empire Clinical Research Investigator Program (J.U.P.); Seres Therapeutics (M.R.M.v.d.B., J.U.P., J.B.S., A.L.C.G., A.G.C., A.E.S., and A.D.S.); Japan Society for the Promotion of Science KAKENHI (17H04206 to T.T. and 17K09945 to D.H.); the Center of Innovation Program from Japan Science and Technology Agency (T.T.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (D.H.); R56 AI137269-01 (J.B.X.); Conquer Cancer Foundation Young",7,GvHD-paper.pdf,724,False
1871f55a7f0f2c529f132e462c348f1a,"Investigator Award/Gilead Sciences (N.K.); NIH KL2 TR001115-03 (NCATS CTSA to A.D.S.); NIA 2P30AG028716-11 (Claude D. Pepper Older Americans Independence Center to A.D.S.); NCI R01CA203950-01 (to N.J.C., A.D.S., L.B., M.L, and A.B.); NIH 1R01HL124112-01A (A.D.S. and R.R.J.); and NIA R21AG066388- 01 (A.D.S. and N.J.C.). Author contributions: C.K.S.-T., E.G.P., J.U.P, and M.R.M.v.d.B. conceptualized the project; C.K.S.-T., A.L.C.G., A.S., S.D., A.P., J.R.C., Y.T., R.R.J., J.B.X., E.R.L., and",7,GvHD-paper.pdf,725,True
27b96da7aaba4ffa978c81b0588369cb,"J.U.P. were involved in data curation and formal analyses; C.K.S.-T., K.B.N., A.L., M.D.D., A.E.S., J.B.S., A.G.C., G.A., Y.S., M.B.d.S., K.A.M., D.B., R.P., A.T., S.M., M.E.A., A.J.P., M.M., R.J.W., L.A.A., E.F., D.P., M.A.J., D.W., A.D.S., D.H., C.S., J.A.M., K.R., M.L., A.B., L.B., K.H., and Y.H. conducted",7,GvHD-paper.pdf,726,False
7ec483f2224a8f2392e0bc836fcea6c8,"and M.R.M.v.d.B.

the",7,GvHD-paper.pdf,727,False
098e8540f566a36f09c7ff336ae43224,"project and provided validation; and C.K.S.-T., J.U.P., A.L.C.G., and M.R.M.v.d.B. prepared data presentation and wrote the manuscript with contributions from all other authors. Competing interests: M.R.M.v.d.B has received research support from Seres Therapeutics; has consulted, received honorarium from, or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia",7,GvHD-paper.pdf,728,True
b85d8dc30fb90891dae4ff89521909cc,"Forum (ALF), and DKMS Medical Council (Board); and has IP Licensing with Seres Therapeutics and Juno Therapeutics and stock options from Smart Immune. J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics and consulting fees from Davolterra. A.D.S. received research support from Seres Therapeutics, Merck, and Novartis. E.G.P. has received speaker honoraria from Bristol-Myer Squibb, Celgene, Seres Therapeutics, MedImmune, Novartis, and",7,GvHD-paper.pdf,729,False
3ce3922fd862b683589b6308cb40b131,"Ferring Pharmaceuticals; is an inventor on patent application number WPO2015179437A1, entitled “Methods and compositions for reducing Clostridium difficile infection,” and patent number WPO2017091753A1, entitled “Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization”; and holds patents that receive royalties from Seres Therapeutics Inc. Other authors have no competing interests. Data and materials availability: All data are available in the manuscript",7,GvHD-paper.pdf,730,True
c5d7e17d22ae9815bc9276c1ae2e7731,or the supplementary materials. Sequencing data have been deposited into Sequence Read Archive under Bioproject number PRJNA545312.,7,GvHD-paper.pdf,731,False
b86b112b68e089e2ccc141d9bf134976,"SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/366/6469/1143/suppl/DC1 Materials and Methods",7,GvHD-paper.pdf,732,False
88c106e577df0ac4a12965f4ad81d4f7,"Table S1 to S10

Fig S1 to S10",7,GvHD-paper.pdf,733,False
c323fd5cf565794de8d5b347309531b5,References (33–53),7,GvHD-paper.pdf,734,False
6ed3e026ad2343dec4a659bb013686c3,"View/request a protocol for this paper from Bio-protocol.

18 March 2019; accepted 22 October 2019 10.1126/science.aax3760",7,GvHD-paper.pdf,735,False
3430d068bf0ac74e284767b7e1e129e3,"D o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",7,GvHD-paper.pdf,736,False
ac9c3055469a5127f3b82f8a6d66f516,"Stein-Thoeringer et al., Science 366, 1143–1149 (2019) 29 November 2019",7,GvHD-paper.pdf,737,False
f14dec2373fedbe6dff40a95eb608568,7 of 7,7,GvHD-paper.pdf,738,False
02099e1d2e387216ba2b8a68ac35519d,Science,8,GvHD-paper.pdf,739,False
95242abae2592d3655f378dd677c95b1,Lactose drives Enterococcus expansion to promote graft-versus-host disease,8,GvHD-paper.pdf,740,True
8734c737217262e9a8bc0594af3dcc4d,"C. K. Stein-Thoeringer, K. B. Nichols, A. Lazrak, M. D. Docampo, A. E. Slingerland, J. B. Slingerland, A. G. Clurman, G. Armijo, A. L. C. Gomes, Y. Shono, A. Staffas, M. Burgos da Silva, S. M. Devlin, K. A. Markey, D. Bajic, R. Pinedo, A. Tsakmaklis, E. R. Littmann, A. Pastore, Y. Taur, S. Monette, M. E. Arcila, A. J. Pickard, M. Maloy, R. J. Wright, L. A. Amoretti, E. Fontana, D. Pham, M. A. Jamal, D. Weber, A. D. Sung, D. Hashimoto, C. Scheid, J. B. Xavier, J. A. Messina, K. Romero, Lew, A.",8,GvHD-paper.pdf,741,False
0ee78abf427c8c727b361eeac860f7db,"Bush, L. Bohannon, K. Hayasaka, Y. Hasegawa, M. J. G. T. Vehreschild, J. R. Cross, D. M. Ponce, M. A. Perales, S. A. Giralt, R. R. Jenq, T. Teshima, E. Holler, N. J. Chao, E. G. Pamer, J. U. Peled and M. R. M. van den Brink M.",8,GvHD-paper.pdf,742,False
da8b6b9c96b5c1e95d953cec18703fee,"Science 366 (6469), 1143-1149. DOI: 10.1126/science.aax3760",8,GvHD-paper.pdf,743,False
6f807ca803e28e00e4b68668828e6ed1,Lactose can fuel GVHD,8,GvHD-paper.pdf,744,False
3a2aa0457adcaff586239378cb1d9d6e,"Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to",8,GvHD-paper.pdf,745,True
4b00abb7d1147c6075f334a2fe5f2f66,"provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models.",8,GvHD-paper.pdf,746,True
f9bf510acd31f4ac1aed82f7cca5e062,"Science , this issue p. 1143; see also p. 1077

ARTICLE TOOLS http://science.sciencemag.org/content/366/6469/1143 SUPPLEMENTARY MATERIALS http://science.sciencemag.org/content/suppl/2019/11/25/366.6469.1143.DC1 RELATED CONTENT http://science.sciencemag.org/content/sci/366/6469/1077.full REFERENCES This article cites 52 articles, 15 of which you can access for free http://science.sciencemag.org/content/366/6469/1143#BIBL PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions",8,GvHD-paper.pdf,747,False
6b10d0e8a86c5ba571d15af9275eae2e,"o w n l o a d e d f r o m h t t p : / / s c i e n c e . s c i e n c e m a g . o r g / o n N o v e m b e r 2 8 , 2 0 1 9",8,GvHD-paper.pdf,748,False
1fa82183f174a28e533c2a9cd205cd05,Use of this article is subject to the Terms of Service,8,GvHD-paper.pdf,749,False
c8e6b200448abed775db27c170ce4684,"Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title Science is a registered trademark of AAAS.",8,GvHD-paper.pdf,750,False
e04c640ef2eefc98b058908fb41e69b4,"Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works",8,GvHD-paper.pdf,751,False
>>>>>>> 5b6e3e1f6bb904635df1f05e870b8aeeed94cf1b
